Effect of Diet, Tobacco and Heredity on Lipid Metabolism and Hypertension by Mathew, Siji
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Mathew, Siji, 2007, “Effect of Diet, Tobacco and Heredity on Lipid Metabolism 
and Hypertension”,  thesis PhD, Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/id/eprint/520 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given.  
 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author 
 EFFECT OF DIET, TOBACCO 
 AND HEREDITY  
ON  
LIPID METABOLISM  
AND  
HYPERTENSION 
 
 
 
 
Thesis  
submitted to  
Saurashtra University 
Rajkot 
 
 
 
 
For 
The Degree of Doctor of Philosophy 
In 
Faculty of Science 
 
 
 
By 
Siji Mathew 
M.Sc. (Biochemistry) 
M.P. Shah Medical College 
Jamnagar 
October - 2007 
 
 
 
Jamnagar
Sd/-
Acknowledgement 
 
 
 
I have been indebted in the preparation of this thesis to my Ph.D guide, 
Dr. T.M. Chary, Professor and Head of Department of Biochemistry, M. P. Shah 
Medical College, Jamnagar, whose patience and kindness, as well as his 
academic experience, have been invaluable to me. It is difficult to overstate my 
gratitude for him. I could not have imagined having a better advisor and mentor 
for my Ph.D, and without his immense knowledge and perceptiveness I would 
never have achieved this goal. He provided me unflinching encouragement and 
support in various ways. His truly scientist intuition has made him as a constant 
oasis of ideas and passions in science, which exceptionally inspired and 
enriched my growth as a student and researcher. Throughout my thesis-writing 
period, he provided encouragement, sound advice, good teaching and lots of 
excellent ideas. I thank him for the systematic guidance and great effort he put 
into training me in the scientific field. Like a charm! I would have been lost 
without him. I am obliged to him more than he knows. 
 
 
Where would I be without my Parents? 
My parents deserve special mention for their inseparable and 
unconditional support and prayers. My parents have been a constant source of 
support- emotional, moral and of course financial during my years of existence; 
they bore me, raised me, supported me, taught me and loved me. I am forever 
indebted to my parents for their understanding, endless patience and 
encouragement when it was most required. Their inflinching courage and 
conviction will always inspire me. This thesis would certainly not have existed 
without them, It is thanks to my parents that I first became interested in pursuing 
research. I would also like to thank my parents for creating an environment in 
which following this path seemed so natural. ---  It is to my PARENTS that this 
thesis is dedicated.    
 
This thesis would not appear in its present form without the kind 
assistance and support of the following individuals and organizations. It is a 
pleasure to thank the many people who made this thesis possible and an 
unforgettable experience for me: 
 
Dr. Shilpa Jain, provided constructive comments during my research 
period as well as on the preliminary version of this thesis. I would like to thank 
her for her instinting commitment to helping me see this project through to its 
final completion, and her equally generous and wise guidance during its 
development. Her advice and willingness to share bright thoughts with me were 
very fruitful for shaping up my ideas and research. 
 
Dr. Hari Om Sharma, too in his own special way helped me in structuring 
the research work in its initial stages and thus I could glide smoothly throughout 
this study.  
 
Needless to say that, I am indebted to all the tutors and staff of 
Department of Biochemistry, M. P. Shah Medical College for being the surrogate 
family during the years, I have worked there.  
 
Dr. Dinesh Bhatt deserves a very special gratitude for providing me with 
the innumerable subjects for my study as with out them this study would have 
remained only a dream. I would also like to say a big ‘thank-you’ to all the people 
who agreed to be my subjects for this study and thus had to put up with my 
interviewing technique (or lack of it). 
 
Words fail me to express my appreciation for my husband whose 
dedication, love, patience and persistent confidence in me, has taken the load off 
my shoulder. I owe him for the constant support, understanding and lot of wise 
words that I received during the tough times of our lives. He has been my pillar, 
my joy and my guiding light. I would like particularly to acknowledge his 
contribution for, forever digging out papers related with my work.   
 
I wish to thank my entire extended family for providing a loving 
environment for me. My brother was always there for troubleshooting when I 
compiled my work on computer as it was the most difficult part of my thesis work. 
My sister always extended her help in doing the ‘running around’ errands in 
hours of dire needs. I thank my brother-in-law for helping me immensely in the 
typing of the thesis. The ‘little ones’ at home always with their entertaining 
company relieved me from my stress and tensed moments during my study. 
 
Thanks are due also to several researchers and staff at other 
organizations that I visited in the early stages of the study. The informal support 
and encouragement of many friends and relatives has been indispensable. 
 
Finally, I would like to thank everybody who was important to the 
successful realization of my thesis, as well as expressing my apology that I could 
not mention personally one by one. 
 
Last but not the least, I would like to glorify God Almighty for always 
showering His blessings on me and sending His angels to help me in utter times 
of disparity during the course of this thesis work.  
 
    
 
 
 
 
 
                              
 1
INDEX 
 
 
Sr. 
No. 
Contents Page 
No. 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
6. 
 
7. 
 
8. 
 
9. 
 
10. 
 
11. 
 
12. 
Index 
 
Abbreviations 
 
List of Figures 
 
List of Tables 
 
List of Graphs 
 
Introduction and Review of  Literature 
 
Aims and Objectives 
 
Methodology 
 
Results 
 
Discussions 
 
Summary and Conclusion 
 
Bibliography 
 
1 
 
2 
 
4 
 
5 
 
8 
 
10 
 
89 
 
91 
 
97 
 
169 
 
193 
 
197 
 
 
 
 
 
 
 
                              
 2
ABBREVIATIONS 
 
Sr. 
No. 
Abbreviations  
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
Acute Myocardial Infarction 
Arachidonic Acid 
American Heart Association 
ATP Binding Cassette Protein 1 
Anti-Oxidants 
Adults Treatment Panel III 
Angiotensin I Converting Enzyme 
Angiotensinogen 
Blood Pressure 
Body Mass Index 
Coronary Heart Disease  
Cardiovascular Disease 
Coronary Artery Disease 
Central Nervous System 
Chylomicrons 
Cholesteryl Esterase 
Cholesteryl Ester Transfer Protein  
Chronic Energy Deficiency 
Carbon monoxide 
C-Reactive Protein 
Chennai Urban Rural Epidemiology Study 
Disability Adjusted Life Years 
Diabetes Mellitus 
Diastolic Blood Pressure 
Dietary Approaches to Stop Hypertension 
Diet And Infarction Trial 
Docasohexaenoic Acid 
Eicosapentaenoic Acid 
Environmental Tobacco Smoke 
Free Fatty Acid 
Free Radicals 
Fatty Acid 
Fraction catabolic Rate 
Familial Hypercholesterolemia 
Hypertension  
High Density Lipoprotein-Cholesterol 
Hip Circumference 
Isolated Systolic Hyperstension 
Ischaemic Heart Disease 
Intermediate Density Lipoprotein-Cholesterol 
AMI 
AA 
AHA 
ABC 1 
AO 
ATP III 
ACE 
AGT 
BP 
BMI 
CHD 
CVD 
CAD 
CNS 
CM 
CE 
CETP 
CED 
CO 
CRP 
CURES 
DALY 
DM 
DSH 
DASH 
DART 
DHA 
EPA 
ETS 
FFA 
FR 
FA 
FCR 
FH 
HT 
HDL-C 
HC 
ISH 
IHD 
IDL-C 
 
                              
 3
   
Sr. 
No. 
Abbreviations  
41. 
42. 
43. 
 
44. 
45. 
46. 
47. 
48. 
49. 
50. 
51. 
52. 
53. 
54. 
55. 
56. 
57. 
58. 
59. 
60. 
61. 
62. 
63. 
64. 
65. 
66. 
67. 
68. 
69. 
70. 
71. 
72. 
73. 
74. 
75. 
76. 
77. 
78. 
79. 
Interleukin 
International Study of Electrolytes and BP 
Joint National Committee on prevention, detection, 
evaluation and treatment of high blood pressure 
Low Density Lipoprotein-Cholesterol 
Lipoprotein 
Lipoprotein (A) 
Lipoprotein Lipase 
Lecithin Cholesteryl Acyl Transferase 
Lipids Research Clinics 
Multiple Risk Factor Intervention Trial 
Myocardial Infarction 
Monounsaturated Fatty Acid 
Macrophage Colony Stimulating factor 
Medical Research Council Trial 
National Health And Nutrition Examination Survey 
Nitric Oxide 
National Cholesterol Education Program 
Nicotine Replacement Therapies 
Oxidized Low Density Lipoprotein 
Pulse Pressure 
Polyunsaturated Fatty Acid 
Prostaglandins 
Reactive Oxygen Species 
Recommended Dietary Allowances 
Renin Angiotensin System  
Systolic Blood Pressure 
Systolic Hyertension in the Elderly Program 
Sympathetic Nervous System 
Scavenger Receptors of Class B 
Saturated Fatty Acid 
Single Nucleotide Polymorphism 
Saturated Fat 
Total Cholesterol 
Triglyceride 
Therapeutic Lifestyle Changes 
Thomboxane A2 
Very Low Density Lipoprotein-Cholesterol 
Waist Circumference 
Waist-Hip Circumference 
 
IL 
INTERSALT
JNC 
 
LDL-C 
Lp 
Lp(A) 
LPL 
LCAT 
LRC 
MRFIT 
MI 
MUFA 
M-CSF 
MRC 
NHANES 
NO 
NCEP 
NRT 
Ox-LDL 
PP 
PUFA 
PG 
ROS 
RDA 
RAS 
SBP 
SHEP 
SNS 
SRCBI 
SFA 
SNP 
SF 
TC 
TG 
TLC 
TXA2 
VLDL-C 
WC 
WHR 
 
                              
 4
List of Figures 
 
Figure Contents Page 
No. 
 
1.1 
 
 
1.2 
 
 
2.1 
 
2.2 
 
2.3 
 
2.4 
 
2.5 
 
2.6 
 
2.7 
 
 
 
Role of autoregulation in the pathogenesis 
and progression of hypertension  
 
Role of rennin-angiotensin system in the 
pathogenesis of hypertension 
 
Structure of a Lipoprotein particle 
 
Compositions of Lipoproteins 
 
Metabolism of Chylomicrons 
 
Metabolism of very low density lipoproteins 
 
Low density lipoprotein metabolism 
 
High density lipoprotein metabolism 
 
The primary dysbetalipoproteinemia: sites of 
defects in metabolism 
 
 
 
 
 
 
18 
 
 
19 
 
 
25 
 
26 
 
28 
 
29 
 
30 
 
31 
 
33 
 
 
 
 
 
 
 
                              
 5
List of Tables 
 
Table 
No. 
Contents Page 
No. 
1.1 
 
1.2 
 
2.1 
 
2.2 
 
2.3 
 
 
2.4 
 
2.5 
 
2.6 
 
 
2.7 
 
 
2.8 
 
2.9 
 
 
2.10 
 
2.11 
 
3. 
 
 
3a. 
 
4. 
 
 
4a. 
 
 
Definitions and Classification of hypertension 
 
Lifestyle modification to manage hypertension 
 
Functions of Major Apolipoproteins 
 
Classification and characteristics of lipoproteins 
 
Causes of secondary hyperlipidaemia and 
dyslipoproteinemia 
 
Summary of the effects of lifestyle on HDL-C 
 
New Features of ATP III 
 
ATP III classification of LDL, TG, Total and HDL 
cholesterol 
 
Major Risk Factors (Exclusive of LDL-C) that modify 
LDL goals 
 
Three categories of risk that modify LDL-C goals 
 
LDL-C goals and cutpoints for TLC and Drug 
therapy in different risk categories 
 
Nutrient Composition of the TLC Diet 
 
Clinical Identification of the Metabolic Syndrome 
 
Effect of age on BP, Serum lipids and 
Anthropometric indices in Normotensive subjects 
 
Statistical Analysis of Table 3 
 
Effect of age on BP, Serum lipids and 
Antropometric indices in hypertensive patients 
 
Statistical analysis of Table 4 
 
 
13 
 
21 
 
26 
 
27 
 
34 
 
 
42 
 
44 
 
45 
 
 
46 
 
 
46 
 
48 
 
 
50 
 
51 
 
99 
 
 
99 
 
104 
 
 
104 
 
                              
 6
 
Table 
No. 
Contents Page 
No. 
5. 
 
 
5a. 
 
5b. 
 
6.1 
 
 
6.1a 
 
6.2 
 
 
6.2a 
 
6.3 
 
 
6.3a 
 
6.4 
 
 
6.4a 
 
6.5 
 
 
6.5a 
 
6.6 
 
 
6.6a 
Levels of Serum lipids and anthropometric indices 
with regard to levels of HT 
 
Statistical Analysis of Table 5 
 
Statistical Analysis of Table 5 (Contd) 
 
Effect of diet (calorie) on BP, Serum lipids and 
Anthropometric indices in Normotensive subjects 
 
Statistical Analysis of Table 6.1 
 
Effect of diet (fat) on BP, Serum lipids and 
Anthropometric indices in Normotensive patients 
 
Statistical analysis of Table 6.2 
 
Effect of diet (calorie) on BP, Serum lipids and 
Anthropometric indices in Hypertensive cases 
 
Statistical analysis of Table 6.3 
 
Effect of diet (fat) on BP, Serum lipids and 
Anthropometric indices in Hypertensive patients 
 
Statistical analysis of Table 6.4 
 
Effect of diet (calorie) on BP, Serum lipids,BMI and 
WHR in Normotensive and Hypertensive cases 
 
Statistical analysis of Table 6.5 
 
Effect of diet (fat) on BP, Serum lipids,BMI and 
WHR in Normotensive and Hypertensive cases 
 
Statistical analysis of Table 6.6 
 
 
109 
 
 
110 
 
111 
 
115 
 
 
115 
 
116 
 
 
116 
 
122 
 
 
122 
 
123 
 
 
123 
 
131 
 
 
131 
 
132 
 
 
132 
 
 
 
 
 
 
                              
 7
Table 
No. 
Contents Page 
No. 
 
 
 
 
7.1 
 
 
7.1a 
 
7.2 
 
 
7.2a 
 
7.3 
 
 
7.3a 
 
8.1 
 
 
8.1a 
 
8.2 
 
 
8.2a 
 
8.3 
 
 
8.3a 
 
 
 
 
 
 
Effect of tobacco on BP, Serum lipids and 
Anthropometric indices in Normotensive subjects 
 
Statistical Analysis of Table 7.1 
 
Effect of tobacco on BP, Serum lipids and 
Anthropometric indices in Hypertensive patients 
 
Statistical analysis of Table 7.2 
 
Effect of tobacco on BP, Serum lipids, BMI and 
WHR in Normotensive andHypertensive cases 
 
Statistical analysis of Table 7.3 
 
Effect of heredity on BP, Serum lipids, BMI and 
WHR in Normotensive cases 
 
Statistical analysis of Table 8.1 
 
Effect of heredity on BP, Serum lipids, BMI and 
WHR in Hypertensive cases 
 
Statistical analysis of Table 8.2 
 
Effect of heredity on BP, Serum lipids, BMI and 
WHR in Normotensive and Hypertensive cases 
 
Statistical analysis of Table 8.3 
 
 
 
 
 
 
142 
 
 
142 
 
146 
 
 
146 
 
151 
 
 
151 
 
155 
 
 
156 
 
160 
 
 
160 
 
164 
 
 
164 
 
 
 
 
                              
 8
List of Graphs 
 
 
Graph 
No. 
Contents Page 
No. 
 
1. 
 
 
2. 
 
 
3. 
 
 
4.1 
 
 
4.2 
 
 
4.3 
 
 
4.4 
 
 
4.5 
 
 
4.6 
 
Effect of age on BP, Serum lipids and 
Anthropometric indices in Normotensive cases 
 
Effect of age on BP, Serum lipids and 
Anthropometric indices in Hypertensive cases 
 
Levels of Serum lipids and Anthropometric indices 
with regard to levels of Hypertension 
 
Effect of diet (calorie) on BP, Serum lipids and 
Anthropometric indices in Normotensive cases 
 
Effect of diet (fat) on BP, Serum lipids and 
Anthropometric indices in Normotensive cases 
 
Effect of diet (calorie) on BP, Serum lipids and 
Anthropometric indices in Hypertensive cases 
 
Effect of diet (fat) on BP, Serum lipids and 
Anthropometric indices in Hypertensive cases 
 
Effect of diet (calorie) on BP, Serum lipids, BMI and 
WHR in Normotensive and Hypertensive cases 
 
Effect of diet (fat) on BP, Serum lipids, BMI and 
WHR in Normotensive and Hypertensive cases 
 
100 
 
 
105 
 
 
112 
 
 
117 
 
 
119 
 
 
125 
 
 
128 
 
 
134 
 
 
137 
 
 
 
 
 
 
 
 
 
                              
 9
Graph 
No. 
Contents Page 
No. 
 
 
5.1 
 
 
 
5.2 
 
 
 
5.3 
 
 
 
6.1 
 
 
 
6.2 
 
 
 
6.3 
 
 
Effect of tobacco on BP, Serum lipids and 
Anthropometric indices in Normotensive cases 
 
 
Effect of tobacco on BP, Serum lipids and 
Anthropometric indices in Hypertensive cases 
 
 
Effect of tobacco on BP, Serum lipids, BMI and 
WHR in Normotensive and Hypertensive cases 
 
 
Effect of heredity on BP, Serum lipids and 
Anthropometric indices in Normotensive cases 
 
 
Effect of heredity on BP, Serum lipids and 
Anthropometric indices in Hypertensive cases 
 
 
Effect of heredity on BP, Serum lipids, BMI and 
WHR in Normotensive and Hypertensive cases 
 
 
143 
 
 
 
148 
 
 
 
152 
 
 
 
157 
 
 
 
161 
 
 
 
165 
 
 
 
 
 
 
 
 
 
 
 
                              
 10
 
 
 
 
 
 
 
INTRODUCTION 
& 
REVIEW 
OF 
LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
                              
 11
INTRODUCTION & REVIEW OF LITERATURE 
 
 
Hypertension (HT) affects approximately 40million individuals in India [1] 
and approximately 1 billion worldwide. [2] It is estimated that 30-50% of the world 
population above 20 years of age is afflicted with HT. [1] As the population ages, 
the prevalence of HT will increase even further unless broad and effective 
preventive measures are implemented. 
 
 
Recent data from the Framingham Heart Study suggest that individuals 
who are normotensive at age 55 have a 90% lifetime risk for developing HT. [3]  
HT is a major health problem both in developed as well as in developing 
countries with a common end result of elevated blood pressure (BP) i.e. an 
epidemiological shift in the prevalence of HT in developing countries as 
compared to developed countries. [2,4] This is obvious from several Indian urban 
and rural studies. [5-9] The various studies estimated a prevalence rate of HT 
among urban population ranging from 1.24% in 1949 to 36.4% in 2003 and for 
rural people from 1.99% in 1958 to 21.2% in 1994. [4]  
 
 
Elevated BP is an important direct cause of cardiovascular morbidity and 
mortality in general and coronary heart disease (CHD) in particular. It is also a 
major risk factor for the development of cardiovascular disease (CVD). The 
higher the level of BP, the greater is the chance of various cardiovascular 
diseases like heart attack, heart failure, stroke and kidney disease to develop 
prematurely through acceleration of atherosclerosis, the pathological hallmark of 
uncontrolled hypertension. The relationship between blood pressure (BP) & risk 
of CVD events is continuous, consistent and independent of other risk factors.     
 
 
CVDs are the commonest cause of death globally and account for 
approximately 12 million deaths annually. The disability adjusted life years 
(DALY) attributed to CVD will rise to about 140-160 million with about 80% of this 
burden in developing countries. [10] This unexpected increase in CVD reflects the 
demographic economic and health transitions in these countries. In India, CVD is 
also the major contributor to the burden of premature mortality and morbidity and 
accounted for 85 million DALY’S in 1990. By the year 2020, CVD will still remain 
the leading cause of mortality and disability in India. [10] 
 
    
     HT has also been shown to be a major risk factor for cognitive impairment 
and dementia. [11] Also BP acts synergistically with other risk factors such as 
diabetes mellitus (DM), hypercholesterolemia and smoking and increases the risk 
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for CVD especially in the elderly. Apart from vascular risk factors, genetic factors 
are also known to play a role in the etiology of the CVD. [12] 
 
 
       Tracing the history of this malady it is interesting to note that HT has been 
described in Ayurvedic facts dating back to 1000 BC as Sira Kanchan and Rakta 
Poornta, where the tension of the blood rises from within due to the provocation 
and constriction of arterioles and venules.The role of mental affliction is 
provoking cardiac disorders and deaths is also highlighted in the Ayurvedic 
system of medicine. [1] 
 
 
     Till recent past control and prevention of communicable diseases was 
emphasized in India. Recently attention has shifted to control and prevention of 
non communicable diseases including stroke, HT, coronary artery disease (CAD) 
at the national level in view of the rising trend. Various hypothesis has been put 
forward to explain this rising trend and among these, consequences of 
urbanization such as changes in life style pattern, diet and stress has been 
implicated. The current urbanization rate in India is 35% as compared to 15% in 
the 1950. [13] With growing urbanization socio-developmental changes having 
taken place over last 40-50 years. Dramatic changes in lifestyle from traditional 
to modern have lead to physical inactivity due to technological advances. Rising 
affluence has modified the dietary pattern characterized by increased 
consumption of diets rich in fat, sugar and calories. 
 
      
Thus seeing the rising trend of hypertensives there is an urgent need for 
primary prevention of HT. So in order to successfully treat a disease it is 
necessary to remove or reduce its cause rather than its manifestations or 
markers. 
 
 
 
 
I. Hypertension: 
 
 
The recommendation of the Seventh Joint National Committee (JNC) on 
the Definition and Classification of HTN are shown in table 1.1. [2] 
 
 
A new category designated prehypertension has been introduced in the 
JNC VII criteria. Patients with prehypertension are at increased risk for 
progression to HT; those in the 130-139/80-89 mmHg BP range are at twice the 
risk to develop HT as those with lower values. [14] Recent data from the 
Framingham Heart Study suggest that individuals who are normotensive at age 
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55 have a 90% life time risk for developing HT. [3] For individuals 40-70 years of 
age, each increment of 20mmHg in systolic BP (SBP) or 10mmHg in diastolic BP 
(DBP) doubles the risk of CVD across the entire BP range from 115/75 to 
185/115mmHg. [15] 
 
 
 
 
 
Table 1.1 
Definitions and Classification of Hypertension 
 
BP classification SBP 
mmHg 
DBP 
mmHg 
Normal < 120 and  < 80 
Prehypertension 120-139 or 80- 89 
Stage I 
Hypertension 
140-159 or 90- 99 
Stage II 
Hypertension 
≥ 160 or  ≥100 
 
     
 
  
    Health dangers from BP may vary among different age groups and 
depending on whether systolic or diastolic (or both) is elevated. A third 
measurement, pulse pressure is becoming important as an indicator of severity.  
 
 
 
● High systolic BP appears to be a significant indicator for heart complications 
including death in all ages, but especially in middle aged and elderly people. 
Infact, elevated SBP may pose a significant danger for heart events and stroke 
events even when diastolic is normal, a condition called isolated systolic 
hypertension (ISH).The wider the spread between the systolic and diastolic 
measurements the greater the danger. ISH is the most common form of HT in 
people older than fifty. 
 
 
● High diastolic pressure is a strong predictor of heart attack and stroke in young 
adults and in people of any age with essential hypertension. 
 
 
● Pulse pressure is the difference between the systolic and diastolic numbers. It 
appears to be an indicator of stiffness and inflammation in the blood vessel walls. 
The greater the difference between systolic and diastolic numbers, the stiffer and 
more injured the vessels are thought to be. Although not yet used by physician to 
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determine treatment, evidence is suggesting that it may prove to be a strong 
predictor of heart problems, particularly in older adults. Some studies suggest 
that in people over 45 years old, every 10mmHg increase in pulse pressure, the 
risk for stroke increases by 11%, cardiovascular disease by 10% and overall 
mortality by 16%. 
 
 
 
 
1. Hypertension Categories: 
 
 
 
 ● Primary Hypertension: Primary HT is also known as essential or idiopathic HT. 
The causes of essential HT are unknown. The primary determinant of essential 
HT, which represents 95% of the hypertensive population, have not been 
elucidated in spite of numerous investigations undertaken to clarify the various 
mechanisms involved in the regulation of BP, but yet it is believed to be a result 
from the interplay of multiple genetic and environmental determinants. [16] 
Essential HT is being increasingly recognized as part of a complex multifaceted 
disorder which may include other abnormalities including dyslipidaemia, central 
obesity, glucose intolerance and hyperinsulinaemia, all of which may increase 
the risk of coronary heat disease (CHD). [17] Essential HT tends to cluster in 
families and represents a collection of genetically based disease and/or 
syndromes with a number of underlying inherited biomechanical abnormalities. 
[18,19] 
 
 
 ● Secondary Hypertension: Secondary hypertension comprises about 5% of 
high BP cases; wherein the cause of this HT is identified. It is important to 
recognize these because they can often be improved or cured by surgery or 
specific medical therapy. Certain clues related to age, history, physical 
examination and laboratory results point to the possibility of secondary HT. For 
e.g.: when HT develops before 30 or after age 50, a secondary cause should be 
considered. Younger patients might have renal artery stenosis or coarctation of 
the aorta. In an older patient, the most likely cause is renovascular disease 
associated with atherosclerosis. Unexplained hypokalemia, hypercalcemia or 
hyperglycaemia may be the cause associated with secondary HT. 
 
 
● Isolated Systolic HT: Systolic HT is a particular problem in the elderly and 
contributes significantly to cardiovascular and cerebrovascular risk. Isolated 
systolic HT (ISH) is defined as a sustained SBP above 140mmHg with normal 
DBP of less than 90mmHg.HT occurs in 50% of those over 60 years of age 
regardless of race.  
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Increased rates of ISH (>160/<90mmHg) among older individuals were 
observed in the 1970s. [20] Both the third National Health and Nutrition 
Examination Survey (NHANES III) and Framingham data have shown that SBP 
rises with age, contrasting a seemingly age-related decline in DBP beginning 
between the age of 50 -60 years. [21,22] 
 
 
 Systolic hypertension has been recognized as a risk factor for CVD for 
more than 30 yrs. [23] Garland et al. [24] observed an increased risk of stroke 
related mortality in association with an ISH of ≥160/90 mm Hg. In Finland, ISH of 
165/95 mmHg  in men and women aged 30 to 59 yrs was associated with 
increased risk of acute myocardial infarction (MI), stroke and death. [25] The 
Framingham studies provided the earliest data suggesting that SBP affects risk 
more than DBP. [26,27] Among the men screened for inclusion in the Multiple Risk 
Factor Intervention Trial (MRFIT) SBP was a better predictor of CHD and all 
cause mortality than DBP. [28] Data from the National High Blood Pressure 
Education Programme revealed that for all levels of DBP, SBP confers increased 
cardiovascular risk and reduced life expectancy. [29] 
 
 
ISH in the elderly contributes to the following cardiovascular and 
cerebrovascular risk. 
1. Three-fold increase of stroke 
2. Increased risk of overall mortality 
3. Increased risk of cardiovascular mortality 
4. Increased risk of congestive heart failure  
 
 
 
As the pendulum of interest once swung from DBP to SBP, today there is 
increasing interest in pulse pressure (PP), the difference between SBP & DBP. 
PP has been associated with risk of congestive heart failure, [30] coronary artery 
disease, [31] and stroke. [32] In a meta-analysis of data from 3 trials enrolling 
patients older than 60 years with systolic HT (the European Working Party on 
High Blood Pressure in the Elderly trial, the Systolic Hypertension in Europe 
[Syst-Eur] trial, and the Systolic Hypertension in China [syst-China] trial), each 
10-mmHg increment in PP conferred a 20% increased risk of cardiovascular 
mortality. [33] More importantly, analysis from the Systolic Hypertension in the 
Elderly Programme (SHEP) [32] and the Established Populations for the 
Epidemiologic study of the Elderly [34] established PP as a risk factor for all cause 
mortality. Numerous studies have documented the importance of PP as a risk 
factor for adverse clinical outcomes in the general population [30,35] and in various 
selected cohorts with or without prevalent CVD. [32,36] 
 
 
             In patients > 60 yrs old, DBP is inversely related to adverse coronary 
events because increasing PP, which conveys increased risk is associated with 
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both higher SBP and lower DBP. [37] Also as demonstrated in the Systolic 
Hypertension in the Elderly Programme (SHEP) Study, the benefits of treating 
SBP in this high risk group are substantial, with, marked reductions in the rates of 
stroke, myocardial infarction, and heart failure. [37] Since SHEP, two other large 
studies have demonstrated that treatment of SBP leads to reductions in 
cardiovascular events. [38,39] Domanski et al [40] concluded, “Any combination of 2 
of the 3 BP measures (i.e., SBP, DBP, PP) provided more information about 
CVD risk than any single measure.” Each component of BP obtained by routine 
measurement has potential clinical utility in the aging vasculature, risk prediction 
progresses such that DBP is supplanted by SBP, which subsequently is eclipsed 
by PP. [41] 
 
 
 
 
2. PATHOPHYSIOLOGICAL MECHANISMS OF 
HYPERTENSION 
 
 
 
   The cause of HT is unknown in most cases, but it seems that 
multifactorial events participate in the development of this pathology. The 
pathophysiological hallmark of HT is a rise in peripheral vascular resistance but 
no single or specific cause of essential HT has been firmly established. 
Haemodynamic studies revealed that while the cardiac output may be elevated 
during the developmental phases of HT, ultimately it declines progressively. Thus 
in the basic equation, BP= cardiac output x peripheral vascular resistance, the 
establishment of HT is frequently associated with a normal cardiac output and 
elevated vascular resistance. What causes the resistance to go up is not fully 
understood. [42] 
 
 
Excessive sodium retention by the kidney may play a major initial role. A 
resetting of the pressure-natriuresis relationship wherein a rise in systemic BP 
evokes further sodium retention has been proposed as a possible renal 
mechanism. [42] Prostaglandins are important in maintaining renal and other 
regional circulations regulating sodium and water excretion, suppressing 
cardiovascular responses to pressure stimuli and potentiating the responses to 
kinins and other vasodepressor substances. [43] The products of prostaglandins 
namely PGE2 and PGI2 along with the kinins form the main axis of vasodilatory 
influence and their deficiency; particularly in kidney was considered a 
contributing factor in the causation of HT. 
 
 
 Kidney plays an important role in maintaining intravascular volume and 
BP. [44] In essential HT the kidney requires a higher than normal blood pressure 
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to maintain normal extra cellular fluid volume. Robert [45] reviewed the evidence 
that essential HT results from an inherited renal tendency towards excess 
vasoconstriction or an inability to appropriately increase renal blood flow. This 
would be especially important in certain environmental situations involving a high 
dietary intake of NaCl or stress with central nervous system (CNS), sympathetic 
nervous system (SNS) and renal vascular consequences. In addition, kidneys 
subjected to elevated blood pressure, over time, develop structural changes due 
to arteriosclerosis that limit its ability to excrete sodium and water in response to 
increase in pressure. Thus, defect in excretion of salt and water may play a 
central role in pathogenesis of essential HT. [45]  
 
 
In some hypertensive patient, it has been suggested that hyperfunction of 
the cardiac sympathetic nerves leads to increased cardiac output and systolic 
hypertension. Eventually, protective peripheral arteriolar constriction i.e. auto 
regulation results in diastolic hypertension. [46] The SNS directly or indirectly 
dictates the state of cardiac output and systemic vascular resistance. Thus, 
inappropriate or excessive activity of SNS may increase the BP (Fig 1.1). Stero 
Julius [47] also showed strong evidence for increased sympathetic drive in the 
early phase of hypertensive process in prehypertensive and stage 1 i.e. these 
subjects have increase cardiac beta adrenergic and vascular alpha adrenergic 
drive. In addition to high plasma nor epinephrine values, their cardiac output and 
heart rate are also elevated. This hyperkinetic state is a stage in the evolution of 
established HT. Tecumsch-Michigen population based study showed that 
hyperkinetic state is very frequent and is seen in 37% of all prehypertensive 
middle aged men. The hyperkinetic subjects show higher BP readings since 
childhood and have strong background of parental HT. [47]  
 
 
Salt dependent rat model of essential HT showed that provision of 
increased intake of the amino acid arginine prevents HT and nephrosclerosis on 
high salt intake. Arginine is the substrate for the enzyme nitric oxide synthetase 
which produces nitric oxide (NO) one of the potent endothelium derived 
vasodilators. NO also functions as a physiological regulator of basal vasomotor 
tone, this regulation may be abnormal in essential HT. NO also inhibits smooth 
muscle cell and mesangial cell mitogenesis. [45] Endothelial dysfunctions 
characterized by reduced production of NO and/or by increased generation of 
endothelien-1 may play a pathogenetic role. [42] 
 
 
Specific molecular defects in cell membrane system such as Na+/ K+ 
ATPase co-transport have been described in hypertensive subject and related to 
the pathogenesis of hypertension. Several abnormalities like excessive passive 
entry of Na+, increased maximal rate of Na+/ Li+ exchange, and decreased 
apparent affinity of the Na+/K+ pump for internal Na+ have been found in red 
blood cells of human hypertensive. The consequence of these abnormal 
alterations in cellular handling of Na+ is an increase in intracellular Na+  
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concentration which results in an increased intracellular free Ca++ concentration. 
[44] 
 
 
Inappropriate release of renin culminating in the formation of angiotensin II 
which causes vasoconstriction is also a possible mechanism (Fig 1.2) 
Sympathetic overactivity may also augment renin release. [42] The inherited 
abnormalities in renin-angiotensin aldosterone system, perhaps including 
alterations in sympathetic nervous drive to renin release and/or an intrinsic defect 
in the ability of the kidney to handle volume overload, may contribute to the 
pathogenesis of essential hypertension. 
 
 
  
 
 
 
Insulin resistance and hyperinsulinaemia are associated with hypertension. 
While the cause of insulin resistance is not known, it results in a failure of 
vasodilation, thus ensuring a rise in systematic blood pressure. [42] Many yet 
undetermined local hormones may participate in the pathogenesis of 
hypertension by causing vasoconstriction or by preventing vasodilation. 
 
 
       Thus in short pathophysiological factors for HT include increased 
sympathetic activity, overproduction of unidentified sodium retaining hormones, 
Fig 
1.2 
       Role of renin-angiotensin system in the pathogenesis of 
hypertension. Note the effect of drugs at various steps in the pathway 
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chronic high sodium intake, inadequate dietary intakes of K+ and Ca++, increased 
or inappropriate renin secretion, deficiencies of vasodilators such as 
prostaglandins, congenital abnormalities of the resistance vessels, diabetes 
mellitus, insulin resistance, obesity, increased activity of vascular growth factors 
and altered cellular ion transport. [44]           
 
 
 
 
3. Management:  
 
 
 
     The ultimate public health goal of antihypertensive therapy is the 
reduction of cardiovascular and renal morbidity and mortality. In clinical trials, 
antihypertensive therapy has been associated with reductions in stroke incidence 
averaging 35-40%; myocardial infarction 20-25% and heart failure, more than 
50%. [48] In a recent Cochrane review examining long term use of 
antihypertensive medication in the elderly, cardiovascular morbidity and mortality 
was reduced by 29%, from 177 to 126 events per 1000 people. [49] It is estimated 
that in patients with stage1 hypertension (SBP 140-159mmHg and or DBP 90-
99mmHg) and additional cardiovascular risk factors achieving a sustained 
12mmHg reduction in SBP over 10 years will prevent 1 death for every 11 patient 
treated. In the presence of CVD or target organ damage only 9 patients would 
require such BP reduction to prevent a death. [50] Since most persons with HT, 
especially those age >50 years, will reach the DBP goal once SBP is at goal, the 
primary focus should be on achieving the SBP goal. Treating SBP and DBP to 
targets that are <140/90mmHg is associated with a decrease in CVD 
complications [2] 
 
 
 
 
4. Lifestyle Modifications: 
 
 
 
     Adoption of healthy lifestyles by all persons is critical for the prevention of 
high BP and is an independent part of the management of those with 
hypertension. Major lifestyle modifications shown to lower BP include weight 
reduction in those individuals who are overweight or obese [51], adoption of the 
dietary approaches to stop hypertension (DASH) eating plan [52] which is rich in 
potassium and calcium [53], physical activity [54] and moderation of alcohol 
consumption. [55] (Table 1.8) Lifestyle modification reduces BP, enhance 
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antihypertensive drug efficacy and decrease cardiovascular risk. Combinations of 
two or more lifestyle modifications can achieve even better results. 
 
 
 
 
 
 
  
 
 
 
 
Table 1.2
Lifestyle modifications to manage hypertension 
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Despite the clear benefits of pharmacological managing HT ,only approx 
31% of all hypertension patients have their BP under effective control 
(<140/90mmHg) [56] Furthermore, only 10% of hypertensive men aged 18 to 74 
years have their BP under control. [57] Although awareness and treatment of BP 
have increased over the past several decades, levels of control of BP especially 
systolic BP (SBP), have plateaued or even fallen in recent years [2,58] Also, most 
poor control is because of failure to attain SBP targets. There is an epidemic of 
uncontrolled systolic hypertension which may stem in part, from prior beliefs that 
elevated SBP is a normal accompaniment of aging that is tolerable so long as 
DBP is controlled. Recent studies on the importance of elevated SBP and 
especially PP have clearly shown that this approach is no longer tenable. [32] 
  
 
In the traditional view of HT case, the major barrier to BP control is patient 
non adherence to prescribed therapies. For example the 1988 report of the JNC 
on Detection, Evaluation and treatment of high blood pressure states that poor 
adherence is the “major reason for inadequate control of high blood pressure” 
and physicians cite failure to make lifestyle changes and take medications as 
instructed as the two most common factors impeding effective treatment. [59,60] 
Rates of BP control in the US are consistent with world wide rates, which range 
from 6% to 40%. [58] Abundant evidence shows that effective BP control lowers 
the risk of CVD. [49,61,62] Therefore achieving adequate BP control is important for 
reducing the burden of HT related CVD. 
 
 
HT is a cardinal risk factor for coronary artery disease and the risk of CAD 
further increases in presence of dyslipidemia. [63] Both HT and dyslipidemia 
coexist more often than by a chance alone. [64-66] Although a common metabolic 
abnormality may underlie both disorders another possibility is that one may be 
implicated in the development of the other. A few studies in Western populations 
have established the relationship between HT and hyperlipidaemia. [66,67]  
 
  
     Indian data on the co-existence of this risk factor is scanty. Epidemiologic 
studies in India have found more on the prevalence of either HT or CHD in 
various communities [68,69] the correlations of various risk factors with CHD. [70] 
Recently two studies have been published which show a high prevalence of lipid 
and glucose abnormalities in Indian hypertensive patients. [71,72] Another study [17] 
showed that with increasing severity of HT there was a steady and significant rise 
in the proportion of patients having borderline or high TC, LDL-C and low HDL-C. 
Various epidemiological studies in the world have shown a positive relationship 
between plasma cholesterol, LDL, VLDL, TG and the incidence of CHD. [73-75] In 
some countries as in India, the role of TC in the occurrence of MI have been 
found to be not significant. [76] The controversy regarding the lipid hypothesis for 
antherogenesis and the role of cholesterol in CHD continues. 
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     In tropical countries [77] like India and Africa the last 2 to 3 decades have 
seen a marked increase in the incidences of cardiac diseases. The socio-
economic development of under privileged and the rapid sophistication of life 
style have made diseases such as Ischemic Heart disease (IHD) and HT 
common in these countries. Deaths due to cardiac diseases in under developed 
countries like Mexico, Philippines are 17.6 and 14.8% respectively. In Asia and 
Africa, CHD accounts for 8 to 20% of all medical admissions to hospitals. [77] 
 
 
     In India, HT and atheromatosis are the most important CVD entities which 
have caused stroke, renal diseases, cardiac hypertrophy (due to HT) and CAD 
due to atheromatosis in this century. There has been progressive increase in the 
reported incidence of mortality due to CHD and this trend has yet not leveled off. 
[78] 
 
 
     A prospective autopsy study [79] showed a linear correlation between the 
concentration of plasma cholesterol and severity of atherosclerosis. This 
conclusion was further strengthened by the predominance of cholesterol as 
cholesteryl ester among the lipids in the atherosclerotic plaques and the fact that 
experimental manipulation of the serum cholesterol content induces or 
diminishes lesions [80]. The findings of Coronary Drug Project [79] strongly and 
significantly related serum cholesterol to focus end points viz mortality from all 
causes, mortality from CHD, sudden death due to CHD and incidence of nonfatal 
myocardial infarction. Simons [81] analyzed epidemiological data from 19 
countries and found that in men 45% of inter population difference in CAD 
mortality could be accounted for by the variation in serum cholesterol level. Peto 
[82] also noted that in societies in which average TC levels are under 150mg/dl 
and LDL-C levels are low the risk for atherosclerosis and CAD were greatly 
reduced. 
 
     
      Thus hypercholesterolemia is a major risk factor in the development of 
CHD and in the progression of atherosclerosis. [83] CHD morbidity and mortality is 
positively related to LDL-C concentration and inversely related to HDL-C 
concentration. [84] Not only does lowering TC and LDL-C in asymptomatic 
individuals with hypercholesterolemia reduce CHD death and nonfatal coronary 
events [85] but lowering TC reduces risk of subsequent CHD events in people with 
established CHD [86] and may actually slow the progression of CHD. [87] 
 
 
    During the past decade, there has been tremendous progress in 
identifying novel risk factors and precisely delineating the role of traditional risk 
factors associated with CHD, with substantial research advances related to the 
role of lipoproteins (Lps) and lipid metabolism.  Before dealing with the role of 
lipids and lipid metabolism, a study of lipids, lipoproteins and lipid metabolism is 
necessary. 
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II. LIPIDS:  
 
 
   
      ‘Lipid’ is the term used to describe a number of substances of diverse 
chemical structure which bear little functional relationship to each other but which 
have in common the property of being (1) relatively insoluble in water and (2) 
soluble in nonpolar solvents. They can be broadly classified as fatty acids, 
triglycerides, cholesterol and phospholipids. 
 
 
 As lipids are not water-soluble they are transported in the plasma in 
association with proteins. Albumin is the principal carrier of free fatty acids (FFA) 
while the other lipids circulate in complexes known as lipoproteins. [88] 
 
 
 
 
 
1. Lipoproteins:  
 
 
 
The lipoproteins are macromolecular complexes of lipid (cholesterol, 
triglyceride, phospholipids) and protein(apolipoproteins, enzymes). All have the 
same basic structure, triglycerides and cholesteryl esters form a hydrophobic 
core surrounded by a layer of amphipathic phospholipids and protein known as 
apolipoproteins fig.[2.1]. [88] A small proportion of lipoprotein cholesterol is 
unesterified and located on the surface. The latter (apolipoprotein) are important 
both structurally and in the metabolism of lipoproteins. {fig. [2.2]} [88] The 
apolipoprotein governs the lipoprotein interaction with enzymes, lipid transport 
proteins and cell surface receptors. 
 
 
 
 
a) Classification of lipoproteins: 
 
 
 
             Lipoproteins are classified on the basis of their densities as 
demonstrated by their ultracentrifugal separation. Density increases from 
chylomicrons (CM), of lowest density through lipoproteins of very low density 
(VLDL), intermediate density (IDL), low density (LDL), to high density lipoproteins 
(HDL). HDL can be separated, on the basis of density, into two metabolically 
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distinct subtypes, HDL 2 (density1.064-1.125) and HDL 3(density 1.126-1.210). 
Distinct subtypes of LDL are also recognized. IDL are normally present in the 
blood stream in only small amounts but can accumulate in pathological 
disturbances of lipoprotein metabolism. This approximate lipid and apo content is 
illustrated in fig.2.2 and the classification in table 2.2. However it is important to 
appreciate that the composition of the circulatory lipoproteins is not static. They 
are in dynamic state with continous exchange of components between the 
various types. The principal functions of these lipoproteins are summarized in 
table 2.2. 
 
 
 
 
 
 
 
      
2.1
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Fig 2.2 
Composition of lipoproteins although composition in each 
class is similar, the particles are heterogeneous so the 
percentage given are approximate. Figure shown for HDL are 
for HDL3; HDL2 contains protein and more lipid. Only the 
principal apoproteins are shown 
Table 2.1
                              
 27
 
 
 
 
 
 
 
 
 
 
 
   Table 2.2
Classification and Characteristics of Lipoproteins 
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b) Lipoprotein Metabolism: 
 
 
? Chylomicrons (CM): 
 
 
  CM (fig 2.3) is formed from dietary fat (principally triglyceride but also 
cholesterol) in enterocytes; they enter the lymphatics and reach the systemic 
circulation via the thoracic duct. CMs are the major transport form of exogenous 
(dietary) fat. TGs contribute about 90% of the lipid. 
 
 
 
Fig 2.3 
Chylomicrons (CM) 
 
 
 
 
Fig 2.3 
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? Very low density lipoprotein (VLDL): 
 
 
 
                VLDL (fig 2.4) are formed from triglyceride synthesized in the liver 
either denovo or by the reesterification of FFA. VLDL also contain some 
cholesterol, apoB, apoC and apoE, the apoE and some of the apoC is 
transferred from circulating HDL. VLDL are the principal transport form of 
endogenous TG and initially share a similar fate to chylomicrons triglyceride 
being stripped of by the action of LDL. 
 
 
 
Fig 2.4 
Very low density lipoproteins 
 
 
Fig 2.4 
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? Low density lipoprotein (LDL): 
 
 
 
                 LDL is the principal carrier of cholesterol, mainly in the form of 
cholesteryl ester. They are formed from VLDL via IDL (fig 2.5). LDL can pass 
through the junctions between capillary endothelial cells and attach to LDL 
receptors on cell membranes that recognize apoB100. LDL receptors are 
saturable and subject to down regulation by an increase in intracellular 
cholesterol. Macrophages derived from circulating monocytes can take up LDL 
via scavenger receptors. This process occurs at normal LDL concentration but is 
enhanced when LDL concentrations are increased and by modification, e.g. 
oxidation of LDL. LDL concentration increases during childhood and reach adult 
levels after puberty. 
 
 
                                        Fig 2.5 
                             Low Density Lipoprotein Metabolism 
 
 
Fig 2.5 
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? High density lipoproteins (HDL): 
 
 
 
                 HDL is the smallest lipoprotein and contains the least lipid. It has a 
core of CE and TG and a PL coat containing apoAI and apoII. [89] HDL (fig 2.6) is 
synthesized primarily in the liver and to a lesser extent in small intestinal cells as 
a precursor (nascent HDL) comprising PL, cholesterol, apoE and apoA. Apo A1 
like HDL is produced by both the liver and intestine while Apo AII is synthesized 
by the liver only. [90] 
 
 
 
 
 
Fig 2.6 
Fig 2.6 
High Density Lipoprotein Metabolism 
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Thus HDL has two important functions: it is a source of apoproteins for 
CMs and VLDL and it mediates reverse cholesterol transport taking up 
cholesterol from senescent cells and other lipoproteins and transferring it to 
remnant particles which are taken up by the liver. Cholesterol is excreted by the 
liver in the bile, both as cholesterol and after metabolism to bile acids. 
 
 
 
2. Disorders of lipid metabolism: 
 
          There are several rare, inherited metabolic diseases associated with the 
accumulation of lipids in tissues and others in which plasma lipoprotein 
concentration are reduced. By far, the commonest disorders however are the 
Dyslipidaemias. [88]  
 
 
           Dyslipidaemia has numerous forms mainly hypercholesterolemia, 
hypoalphalipoproteinemia and hypertriglyceridemia. The term itself simply refers 
to an abnormal metabolism of plasma lipids which can be caused by genetic, 
dietary and secondary disease factors. For the safe cholesterol transport, 
cholesterol concentration in plasma must be kept sufficiently low and its tendency 
to escape from the bloodstream must be controlled. [91] 
 
 
             Hyperlipidaemia refers to an increased concentration of either 
cholesterol or TG or both these lipids in serum and results from an increase in 
one or other class of plasma lipoproteins. The terms hyperlipidaemia or 
hyperlipoproteinemia imply an increase above a defined upper limit. When 
hyperlipidaemia is defined in terms of a class or classes of elevated plasma 
lipoproteins the term hyperlipoproteinemia is used. 
 
 
             Three categories of causation, however has been identified viz (1) 
genetic (2) secondary to other diseases and (3) dietary. A deficiency of an 
enzyme on a single gene defect may result in an abnormal lipoprotein. However 
in many cases the underlying mechanism or the basic defect is not known or fully 
understood. Thus hyperlipoproteinemia due to genetic defect or due to 
unidentified cause or due to imbalance in dietary practice is known as primary 
hyperlipoproteinemia. 
 
 
        A primary dyslipoprotenemia is an inherited disorder of lipoprotein 
metabolism which may manifest as hyperlipidaemia, hypolipidaemia or 
normolipidaemia associated with lipoproteins of abnormal composition or an 
abnormal distribution of the normal lipoprotein classes. [92] Finally, a significant 
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increase in production or an increase in removal of lipoproteins can lead to a 
marked reduction in lipid and lipoprotein concentrations [93]  (fig 2.9).  [92] 
 
 
 
 
Fig 2.7 
The primary dysbetalipoproteinemia: sites of defects in 
metabolism. 
 
                        
Key 1.Abetalipoproteinemia                           12.Remnant Hyperlipoproteinemia                 
2.Chylomicronemia retention disease             13.Hepatic TG lipase deficiency 
3.Familial hypobetalipoproteinaemia             14.Familial hypercholesterolemia 
4.Normotriglyceridemic abetalipoproteinemia 
5.Hypobetalipoproteinemia with truncated apo B100 
6.Familial defecative apo B100 
7.Familial combined hyperlipidemia/hyperapobetalipoproteinemia 
8.Familial hypertriglyceridemia 
9.Lipoprotein lipase deficiency 
10.Apolipoprotein CII deficiency 
11.Familial lipoprotein lipase inhibitor   
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On diagnosing hyperlipidaemia in a given patient the hyperlipidaemic 
status should be evaluated to determine whether it is primary lipoprotein disorder 
or secondary to any of a variety of metabolic diseases. The diagnosis of primary 
hyperlipidaemia is made after secondary causes have been ruled out. The 
causes of secondary hyperlipoproteinemia are listed in table 2.3. [94] 
 
 
 Table 2.3 
   Causes of Secondary Hyperlipidaemia and Dyslipoproteinemia 
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The acquired hyperlipidaemia or secondary dyslipoproteinemia results 
from some under lying disorder that leads to alternations in plasma lipid and 
lipoprotein metabolism. They manifest as an increase in plasma TC and plasma 
TG levels, or both cholesterol and TG with or without a decrease in the 
circulating levels of HDL. Treatment of underlying disorder, when possible or 
discontinuation of the offending drug usually results in improvement in the 
hyperlipidaemia. [95] 
 
 
 
             The major atherogenic lipoprotein, the LDL acts for 60% to 70% of the 
total cholesterol while HDL usually represents some 20 to 30% of the TC and 
their levels are ½ correlated with the risk for CHD. The VLDL which are largely 
composed of TG accounts for 10 to 15% of the TC. [96]  
 
  
 
a) Hypertriglyceridaemia: 
 
 
          Epidemiologically prospective and case controlled studies have shown that 
serum TG levels associated positively with the risks for CAD. [97,98] Semi 
quantitative techniques of meta-analysis on some population based prospective 
studies [99-102] of TG and CVD showed a relative risk of 1.32 in men and 1.76 in 
women indicating a 32% and 76% increase in disease risk associated with 
increased TG. Also, there is growing evidence that hypertriglyceridaemia is a 
marker for increased risk for CAD; in fact it can serve as a marker for several 
atherogenic factors. [103] The association between a high TG level and other 
atherogenic factors theoretically could exist at three levels: 
 
  
• First, a high TG level would be a marker for raised concentration of 
atherogenic TG rich lipoproteins (Lps). TG rich lipoproteins include several 
species of Lps belonging to the classes of CMs and VLDL. Both classes include 
newly secreted Lps as well as Lps modified in the circulation. Modified and 
partially catabolized TG rich Lps are called remnants. Remnant Lp are product 
through the interaction of newly secreted Lps with several factors,  most notably 
Lp lipase. During the catabolism of TG rich Lps they are increased in size and 
modified in composition. The concentration of TG rich Lps are diminished in TG 
content but have a gain in cholesteryl esters. Apolipoprotein composition also 
changes, in rare instances, when the primary structure of apolipoproptein E is 
genetically abnormal, catabolism and clearance of remnants is severely 
impaired. [104] Because of their delayed clearance, remnants become highly 
enriched with cholesteryl ester and apolipoprotein E. These cholesterol enriched 
remnants are named β-VLDL. Normal remnants contain more TG and less 
cholesterol than β-VLDL. All CM remnants are removed by the liver. In contrast, 
VLDL remnant can have 2 fates; about half normally are removed directly by the 
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liver, whereas the other half are converted to LDL. [103] Animal studies show that 
the atherogenecity of TG rich LPs increases as LP particles become more 
enriched in cholesteryl esters. [105] 
 
 
• Second, an elevated serum TG could be a marker for other Lp abnormalities 
with which they frequently coexist, namely abnormally small particles of LDL and 
low concentration of HDL. The combination of high TG level, small LDL particles 
and decrease HDL chol levels has been named the atherogenic Lp phenotype 
[106] or simply the Lipid Triad. 
 
 
        Lipid Triad i.e. raised TG levels, small LDL particles and low HDL chol, the 
latter two abnormalities frequently occurs because of an increase in the TG 
component of TG rich Lps. [107] Exchange of TG in TG rich Lp for cholesteryl 
ester in LDL and HDL decreases the cholesteryl ester content of the latter, 
hydrolysis of the newly acquired TG in LDL and HDL in turn decrease the size of 
HDL and LDL particles. These changes manifest clinically as smaller LDL 
particles and low HDL cholesterol levels. Also recent prospective epidemiologic 
studies [86,108] have also shown that plasma TG and LDL particle size predict 
subsequent CAD in Caucasian populations. These small LDL particles are more 
atherogenic than normal sized LDL. Small LDL particles filter more rapidly into 
the arterial wall than do normal sized LDL, also they could be unusually 
susceptible to retention in the extra cellular matrix. Both properties would 
promote atherogenesis, moreover small LDL appears to be more particularly 
susceptible to oxidation [109]; this too could enhance their atherogenecity. Also an 
elevated serum TG may increase the risk for CAD by inducing a pro coagulant 
state. [110] Although an elevation in serum TG commonly causes small LDL 
particles and low HDL-C levels, there are other causes too.  
 
 
• Third, since increased TG levels also commonly associate with HT, insulin 
resistance (with or without glucose intolerance) and a pro thrombotic state, they 
could be a marker for these non lipid risk factors. The clustering of these non lipid 
risk factors along with the lipid triad has been called the metabolic syndrome. [111] 
 
 
 
The metabolic syndrome is defined as the presence of three or more of the 
following: [112]  
 
1) Central obesity [waist circumference more than 40 inch in men and more 
than 35 inch in women] 
2) A fasting TG levels of 150mg/dl or more  
3) An HDL-C level of less than 40mg/dl in men or less than 50mg/dl in women 
4) Blood pressure of 130/85 or higher and 
5) A fasting glucose level of more than 110mg/dl 
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Multiple factors, which are common in our society, combine to cause the 
metabolic syndrome. These factors are obesity, physical inactivity, certain 
nutrient excesses and genetics. The syndrome also occurs more frequently with 
advancing age and it is more common in men than women. The higher frequency 
in men may be associated with truncal obesity, which seems to enhance the 
severity of the syndrome. 
 
   
 
b) LDL modification and its consequences: 
 
 
Because most of the cholesterol in the serum is found in the LDL (60to 70%) 
[96], the concentration of total cholesterol is closely correlated with the 
concentration of LDL-C. In clinical lipidology the concentration of LDL-C is the 
time-honored “gold standard” for estimating the plasma Lp-related risk of 
individuals for complications of atherosclerotic vascular disease. In several 
animal models, high levels of serum LDL rapidly induce atherosclerosis. [113] 
Likewise in patients who have high LDL levels on a genetic basis, premature 
CAD frequently occurs even in the absence of other risk factors. [114] Several 
studies have convincingly demonstrated that lowering of raised plasma 
cholesterol can retard progression, even induce regression and reduce the risk of 
coronary events in patients with atherosclerotic coronary artery disease. The fact 
that there is a wide diversity in the expression of clinical disease even in subjects 
with marked hypercholesterolemia reflects a complex multifactorial chronology of 
events and shows that factors other than raised LDL concentrations are involved 
in the process of atherogenesis and its clinical sequelae. One of the factors that 
go “beyond cholesterol” [115] is the “oxidation hypothesis”. 
 
 
     The so-called “oxidation hypothesis” [116] states that the oxidative modification 
of LDL is important and possibly obligatory in the pathogenesis of the 
atherosclerotic lesion. It was shown that LDL would be taken up faster by 
macrophages as it is oxidized by the endothelial cells [117] All major types within 
the atherosclerotic lesions- endothelial cells, smooth muscle cells, macrophages 
and lymphocyte can oxidize LDL [118], but macrophages appear to be the most 
active. 
 
 
• Susceptibility of LDL to oxidation: 
 
Oxidative modification of LDL is believed to be caused by free radicals (FR), 
substances with unpaired electrons which tend to be highly reactive. The nature 
of these free radicals and their sources within the cells are controversial. It is still 
not known whether cells oxidize LDL by releasing simple oxidizing agents such 
as super oxide or hydrogen peroxide which then attack LDL, or by releasing lipid 
peroxidation products formed by the oxidation of the cells own lipids. Lipid 
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peroxidation presumably starts in the polyunsaturated fatty acids (PUFA) in LDL-
surface, resulting in oxidation modification not only of the PUFA, but also of the 
cholesterol moiety itself and of phospholipids. [119] The oxidized PUFA in LDL is 
converted into lipid hydroperoxide. These fragment into aldehyde which are 
believed to combine covalently with lysine and may be other as in apoB-100 the 
protein moiety of LDL. [115] The modified apoB-100 then becomes recognized by 
scavenger receptors on macrophages. 
 
 
• Oxidized LDL and Atherosclerosis: 
 
There are several mechanisms by which oxidatively modified LDL promotes 
atherosclerosis: 
 
1) Chemotactic activity which facilitates the recruitment of blood monocytes. 
2) Inhibition of migration of macrophages from the arterial wall back to plasma. 
3) Enhanced uptake of LDL by macrophages via scavenger receptors, resulting 
in the formation of foam cells. 
4) Direct cytotoxicity to endothelial cells which may facilitate the entry of LDL 
and monocytes in the arterial wall in the early stages of the disease process. 
[117] 
 
 
Oxidized LDL (Ox-LDL) may contribute to the atherogenesis process 
above and beyond that of simple deposition of cholesterol within the arterial 
wall. It leads to enhanced uptake by macrophages and yields many modified 
molecules with diverse effects. [119] Ox-LDL or its products can profoundly 
impair the nitric-oxide mediated vasorelaxation of coronary arteries in 
response to agents such as acetylcholine. Hypercholesterolemia by 
generation of more Ox-LDL in the intima or by creation of a pro-oxidant 
environment that stimulates endothelial cells to release more superoxide 
anion, may contribute importantly to vasospasm even in the absence of 
significant lesions. Certain products of Ox-LDL as oxysterols are highly toxic 
to endothelial cells and could initiate breaks in endothelial integrity. Other 
products may stimulate tissue factor release and initiate coagulation. 
Irreversible damage occurs when too much Ox-LDL accumulates with 
resulting cell death and release of oxidized and insoluble lipid protein adducts 
leading to atheroma formation. Any process that interferes with uptake of Ox-
LDL could be counter productive. 
 
 
 
• Role of antioxidants in the prevention of CAD: 
 
 
          Formation of FR in humans in diseases like CAD is controlled by various 
antioxidants (AO) protective mechanisms. [120] These include primary enzymatic 
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defenses such as super oxide dismutase and glutathione peroxidase, which 
depend functionally on minerals like manganese, copper, zinc and selenium and 
stabilizing substances such as vitamin E, vitamin C, beta-carotene and vitamin A. 
When FR are present in excess they can attack DNA, disrupt the function of vital 
enzymes and lead to peroxidation of polyunsaturated fats in cell membranes. 
Therefore antioxidants nutrients which protect tissues against attack by free 
oxygen radicals play an important role. [117] The most abundant natural 
antioxidant in LDL is alpha tocopherol [121] and supplementation of the diet with 
vitamin E can increase the vitamin E content of LDL and lead to enhanced 
protection of such LDL from in vitro oxidation. β-carotene is the next common 
antioxidant in LDL. [122] A diet low in saturated fat and cholesterol and enriched in 
fruits, vegetables and natural antioxidants are recommended for antioxidants 
vitamins. 
 
 
 
c) Importance of HDL-C levels: 
 
 
Current guidelines for the prevention of coronary heart diseases (CHD) 
focus on lowering LDL-C as the primary target of lipid-modifying therapy. [123] 
However there is increasing interest in HDL-C as a secondary target of therapy. 
Raising HDL-C levels with therapeutic lifestyle changes & pharmacologic 
intervention might afford opportunities to further reduce the risk of CHD beyond 
LDL-C lowering. Although lowering LDL-C remains the primary target of lipid 
modifying therapy, dyslipidaemia therapies that are efficacious for both LDL-C 
reduction and causing HDL-C might offer further improvements in CHD risk 
reduction. In observational studies, plasma levels of HDL-C and its major protein, 
apo A-1, have been shown consistently to be inversely correlated with CHD risk.  
[124] Thus person with low HDL-C levels are at increased risk of CHD, [125] 
restenosis after angioplasty [126] and death from cardiovascular causes, 
especially if such persons are male [127] or have diabetes. [128] Also often persons 
with low HDL-C levels have other CV risk factors such as diabetes, HT or both 
which further increase risk. [129] Epidemiologic studies and studies in animals 
suggest that raising the levels of HDL-C may retard the development of 
atherosclerosis. [129] Studies in animals have shown that over expression of the 
apo AI gene prevents the development of progression of atherosclerosis. [130]  
 
 
    Recently a working group reporting on low levels of HDL-C as a risk factor 
for CHD concluded that HDL-C is a national target for cardiovascular therapy. 
[131]  In regard to HDL-C, strong evidence from the Framingham Heart Study [132] 
supports the premise that low level of HDL-C predicts an increased incidence of 
CAD, independent of other CAD risk factors, including LDL-C levels. Infact, 
across all levels of LDL-C e.g. 100-200mg/dl, the level of HDL-C influence the 
risk of developing CAD. [132] Two primary prevention trials of LDL lowering – the 
Lipid Research Clinics Primary Prevention Trial using cholestyramine [133] and 
                              
 40
the Helsinki Heart Study [134] using gemfibrozil - both demonstrated that 
increasing HDL-C levels lowered CAD events, independent of the effect of LDL 
lowering. In recent years, there has been more interest in non-pharmacological 
approaches to increased HDL-C levels. This has been prompted by the 
recognition of HDL-C as an independent risk factor for CHD [135], the difficulty in 
manipulating HDL-C levels through pharmacological means [136] and the recent 
change in the American (ATP III) definition of low HDL-C from < 35 mg/dl to 40 
mg/ dl. [123] Whereas LDL and VLDL are considered atherogenic, HDL and HDL-
C have been shown to be protective factors against atherosclerosis resulting in 
decreased occurrence of CHD. HDL-C has also been found to be the single most 
important lipid risk factor having an inverse association with the incidence of 
CHD in the Framingham study. [137] In humans, each increase in baseline HDL-C 
of 1 mg/dl is associated with a 6% decrease in the risk of death from coronary 
disease or of MI. [138] National Cholesterol Education Program (NCEP) guidelines 
do not identify HDL-C as a treatment target but do, nevertheless, state that a 
level of HDL-C < 40 gm/dl constitutes a risk factor for CHD, whereas level ≥60 
mg/dl is considered protective.  [123] Thus persons with HDL-C levels below 35 
mg/ dl have a CHD incidence rate of  more than 8 times, compared to persons 
with HDL-C levels greater than 65 mg/dl or above. [137] 
 
 
The publication of a paper be Miller & Miller, [139] postulating that the 
reduction of plasma HDL-C may accelerate the development of atherosclerosis 
by impairing the clearance of cholesterol from peripheral tissue including the 
arterial wall to the liver, has created a lot of interest in the study of the role of 
HDL and HDL-C in CHD and other forms of atherosclerotic disease. [137,139] 
 
 
 
• Role of HDL-C 
 
 
i. Reverse Cholesterol Transport: 
 
 
The main mechanism by which HDL is thought to be antiatherogenic is in 
the transport of cholesterol from peripheral tissues to the liver in the process of 
increased cholesterol transport. [140] Nascent HDL is able to facilitate removal of 
free cholesterol from peripheral cells, such as macrophages, thus the action of 
ATP binding cassette protein 1 (ABC 1). [141] Mature HDL particles form the 
esterification of cholesterol by lecithin cholesteryl acyl transferase (LCAT) which 
is activated by Apo A1, CE can be selectively taken up by the scavenger 
receptors of class B, type II (SRCBI) on the liver. [142] The CE can be excreted as 
bile acids or free cholesterol in the bile. Alternatively the CE of mature HDL can 
be transferred to Apo B containing lipoproteins, such as VLDL and LDL, by 
cholesteryl ester transfer protein (CETP) [143] with eventual uptake of LDL by the 
liver and excretion via the bile. [144]  
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ii. HDL-C and atherogenesis: 
 
 
There are several mechanisms through which HDL-C may attenuate the 
formation and progression of atherosclerotic lesions, including its role in 
mediating reverse cholesterol transport. Additional HDL-C properties 
demonstrated that might protect against atherosclerosis include AO effects, 
attenuation of endothelial dysfunction and anti-inflammatory effects. [145] Particles 
of HDL like apo AI, platelet activating factor acetylhydrolase and paraoxanase 
provide AO protection to LDL particles by scavenging ROS (reactive oxygen 
species). [146] Plasma from transgenic mice that are led to express the human 
apo AI gene increase the oxidation of LDL in vitro to a significantly greater extent 
than plasma from control mice. Platelet activating factor acetyl hydrolase 
prevents oxidative modification of LDL and paraoxanase also increase LDL 
oxidation. [147] Oxidized LDL contributes to the development of atherosclerotic 
lesions in several ways, including accumulation in macrophages to form foam 
cells and modulation of various pro-inflammatory pathways. [146] HDL abolishes 
the transmigration of monocyte induced by modified LDL in co-culture of human 
aortic wall cells. [148] By preventing LDL oxidation, HDL-C may also prevent the 
associated increase of endothelial nitric oxide synthase. [149] Additionally HDL-C 
may improve endothelial function by stimulating the release of prostacyclin, a 
vasoactive prostaglandin synthesized by vascular endothelial and smooth muscle 
cells. [150] In terms of antinflammatory effects, HDL-C might reduce cytokine-
mediated upregulation of cell adhesion molecules and block the nuclear factors- 
KB signaling cascade. [151] Thus the postulated role of HDL in attenuating 
formation of oxidized LDL may promote endothelial vasodilation; HDL may also 
stimulate fibrinolysis [152] effects that would tend to retard the evolution of 
atherosclerotic CAD. 
 
 
 
• Interventions to raise HDL-C: 
 
 
           A number of interventions are currently available for improving HDL-C 
profiles and thereby potentially reducing cardiac risk (Table 2.4) (Summary of the 
effects of lifestyle on HDL-C). 
 
           These include lifestyles changes and pharmacologic intervention with 
statins or fibrates as monotherapy or statins in combination with niacin. Lifestyle 
changes recommended to reduce the likelihood of CHD include smoking 
cessation, weight loss, exercise and diet, some of which have an effect on HDL-
C levels. [123] Elevated HDL-C levels are associated with other factors including 
estrogens, which may explain why women tend to have higher levels than men 
and exhibit lower incidence of CAD before the age of 50; a diet high in saturated 
fat which also elevates LDL-C in; regular exercise (≥ 4, 200 KJ/ week); alcohol 
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consumption and cessation of cigarette smoking which can lead to a 3-4 mg/dl 
increase in HDL-C. [153] Smoking ≥ 20 cigarettes/day was shown to decrease  
 
 
Table 2.4 
Summary of the effects of Lifestyle on HDL- C 
Interven
tion 
Study  reference Details Effects on HDL-C 
Alcohol 
intake 
Rimm et al 1999 
 
 
 
Hata & Nakajima 
2000  
Meta analysis of 36 data records 
including 886 adults from 25 
studies(duration 1 week to 3months) 
Meta- analysis of 24 publication 
including 26 712 men( all Japanese) 
 
Increase of 8.3% in an 
average individual 
consuming 30 g alcohol 
per day 
Increase of 0.06 
mmoL/L (3.9-9.5%) for 
every 23 g alcohol per 
day 
Exercise  Leon & Sanchez 
2001a and2001b  
 
 
 
 
Halbert et al 1999 
Meta- analysis of 51 (including 28 
randomized controlled trail)moderate 
intensity exercise training trials(>12-
weeks duration)including 4700 
participants 
Meta-analysis of 31 studies including 
1833 normo-and hyperlipidemic  
subjects 
Average increase 4.6 % 
 
 
 
 
 
Increase of 0.05mmol/L 
(3.3-6%) with aerobic 
and resistance exercise 
Weight 
loss 
Datillo et al 1992  
 
 
 
Yu-Poth et al 1999  
Meta analysis of 70 studies involving 
diet-induced weight loss and lipid 
parameters 
 
Meta-analysis of 37 dietary 
intervention studies (9276 subjects in 
intervention groups and 2310 subjects 
in control groups) 
For every 1 kg decrease 
in body weight HDL 
increases by 
0.009mmol/L (0.58-
1.08%) 
For every 1 kg decrease 
in body weight HDL-C 
increased by-1% 
 
 
Smoking 
cessation 
Maeda et  al 2003  
 
 
Craig et al 1989     
Meta-analysis of 29 cohorts from 24 
studies (4476 patients) 
 
Meta-analysis of 54 published cross-
sectional studies. 
Increase of 3.0-5.6% 
following  smoking 
cessation 
HDL-C levels are 5.7% 
higher in non smokers 
compared with smokers. 
 
HDL-C levels by 11-14% in a dose dependent manner. [154] Heredity also 
appears to play a role. A gene condition termed familial 
hypoalphalipoproteinemia is expressed primarily by low levels of HDL-C. The 
fundamental defect in most patients with hypoalphalipoproteinemia is not known. 
In the other hand in hyperalphalipoproteinemia, another genetic condition, levels 
of apo AI and HDL-C are quite high. The prevalence of CAD is higher in hypo 
alpha and lower in hyper alpha, compared with those who have average levels of 
HDL-C. Humans who consume high-fat diets often have increased HDL-C levels. 
One possibility is that a high fat diet suppresses LDL receptors in the liver, 
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increasing LDL-C production (by decreasing VLDL remnant uptake by LDL 
receptors and converting more VLDL remnants into LDL) leading to more LDL-C 
uptake by the extra hepatic tissues. [155] A study also reported an inverse 
relationship between BMI and HDL-C with levels of  patients in the 10th percentile 
for BMI being 6-7 mg/dl higher than for those in the 90th percentile [156], and a 
direct relationship between exercise and HDL-C was also observed. [157] Multiple 
regression analysis demonstrated an increase in HDL-C of approximately 2 mg/dl 
of every 4.5 kg weight reduction. [158] 
 
 
 
 
3. Management of dyslipoproteinemia: 
 
 
 
CVD is the major cause of death in our society. The ability to prevent the 
development of atherosclerosis or alternatively, to decrease established 
atherosclerotic plaques, often referred to as regression, has major implication for 
public health. Whereas the incidence of CAD was halved in the past 30 yrs, the 
rates doubled in India with no signs of downturn. It appears that the CAD 
epidemic would explode in parallel with affluence and urbanization in rural 
villages unless the gravity and magnitude of the problem is recognized and 
immediate action is taken. [159] Research from experimental animals, laboratory 
investigation, epidemiology and genetic forms of hypercholesterolemia indicate 
that the elevated LDL-C is a major cause of CHD. In addition, recent clinical trials 
robust show that LDL-lowering therapy reduces risk for CHD. For these reasons 
the Third report of the Expert Panel on Detection, Evaluation and Treatment of 
High Blood Cholesterol in Adults (Adults Treatment Panel III or ATP III) [160] 
continues to identify elevated LDL-C as the primary goals of therapy. As a result 
the primary goals of therapy and the cut points for initiating treatment are stated 
in terms of LDL. [123] The features of ATP III are shown in (Table 2.5). [123] 
 
 
 
a) Risk-Assessment: First step in Risk Management  
 
 
A basic principle of preventions that the intensity of risk-reduction therapy 
should be adjusted to a person’s absolute risk. Hence the first step in selection of 
LDL-lowering therapy is to assess a person risk status. Risk assessment requires 
measurement of LDL-C as part of the lipoprotein analysis and identification of 
accompanying risk determinants. In all adults aged 20 yrs or older fasting lipid 
profile (TC, HDL-C, LDL-C and TG) should be obtained once every 5 years. The 
relationship between LDL-C levels and CHD risk continues over a broad range of  
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Table 2.5 
New features of ATP III 
 
? Focus on Multiple Risk factors 
 
● Raises person with diabetes without CHD, most of whom have multiple 
risk factors, to the risk levels of CHD risk equivalent 
 
● Uses Framingham projections of 10-year absolute CHD risk (i.e., the 
percent of probability of having a  CHD event in 10 years) to identify certain 
patients with multiple (2+) risk factors for more intensive treatment 
 
● Identifies persons with multiple metabolic risk factors(metabolic 
syndrome) as candidates for intensified therapeutic lifestyle changes 
 
? Modifications of Lipid and Lipoprotein Classification 
 
● Identifies LDL cholesterol < 100 mg/dl as optimal 
 
● Raises categorical low HDL cholesterol from < 35 mg/dL to < 40 mg/ dL 
because the latter is a better measure of a depressed HDL 
 
● Lowers the triglyceride classification cut points to give more attention to 
moderate elevations 
 
? Support for Implementation 
 
● Recommends a complete lipoprotein profile (total, LDL and HDL 
cholesterol and triglyceride) as the preferred initial test, rather than 
screening for total cholesterol and HDL alone. 
 
●Encourages use of plant stanols/sterols and viscous (soluble) fiber as 
therapeutic dietary options to enhance lowering of LDL cholesterol. 
 
● Presents strategies for promoting adherence to therapeutic lifestyle 
changes and drug therapies 
 
● Recommends treatment beyond LDL lowering for persons with 
triglycerides ≥ 200 mg/dL 
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LDL levels from low to high. Therefore, ATP III adopts the classification of LDL-C 
levels shown in Table 2.6 [123], which also shows the classification of total HDL 
cholesterol and TG levels. 
 
 
  Risk determinants in addition to LDL-C include the presence or absence of 
CHD, other clinical forms of atherosclerotic disease, and the major risk factors 
other than LDL (table 2.7). [123] Based on these other risk determinants, ATP III 
identifies three categories of risk that modify the goals and modalities of LDL 
lowering therapy. Table 2.8 [123] defines these categories of risk and shows 
corresponding LDL-C goal. 
 
 
 
Table – 2.6 
   ATP III Classification of LDL, TG, Total and HDL Cholesterol (mg/ dl)  
 
LDL Cholesterol 
<100 Optimal 
100- 129 Near or above optimal 
130-159 Borderline high 
190 Very High 
Total Cholesterol 
<200 Desirable 
200-239 Borderline High 
≥ 240 High 
HDL Cholesterol 
< 40 Low 
≥60 High 
Triglyceride (TG)  
< 150 Normal 
150- 199 Borderline high 
200- 499 High 
≥ 500 Very High 
 
 
 
The category of highest risk consists of CHD and CHD risk equivalents .The 
later carry a risk for major coronary events equal to that of established CHD, 
i.e.>20% per 10 years(i.e. more than 20 of 100 such individuals will develop CHD 
event within 10 years). CHD risk equivalents comprise: 
 
 
1) Other clinical forms of atherosclerotic disease (peripheral arterial 
disease, abdominal aortic aneurysm and symptomatic carotid artery 
disease. 
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2) Diabetes 
3) Multiple risk factors that confer a 10 years risk for CHD >20% 
 
Persons with CHD or CHD risk equivalents have the lowest LDL-C 
goal (<100 mg/dl). 
 
 
 
 
Table – 2.7 
Major Risk Factors (Exclusive of 
LDL Cholesterol) that Modify LDL Goals* 
 
●  Cigarette smoking 
●  Hypertension (blood pressure ≥140/ 90 mm Hg 
or on antihypertensive medication) 
●  Low HDL cholesterol (<40 mg/dl) 
●  Family history of premature CHD (CHD in male) 
first degree relative 
first degree relative  < 65 years 
●  Age (men- 45 years; women; > 55 years 
* Diabetes is regarded as a coronary heart disease (CHD) risk 
equivalent. LDL indicates low-density lipoprotein; 
HDL, high density lipoprotein. 
HDL cholesterol ≥ 60 mg/dl counts as a “negative” risk factor; its 
presence removes 1 risk factor from the total count. 
 
 
 
Table – 2.8 
Three Categories of Risk that modify LDL Cholesterol Goals 
 
 
 
Risk category                                                              LDL Goal 
                                                                                       (mg/dL) 
 
CHD and CHD risk equivalents 
 
<100 
 
Multiple (2+) risk factors* 
 
 
0-1 risk factor 
 
<160 
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The second category consists of persons with multiple (2+) risk factors in 
which 10 years risk for CHD is ≤20%. Risk is estimated from Framingham risk 
scores. [123] The major risk factors, exclusive of elevated LDL-C are used to 
define the presence of multiple risk factors that modify the goals and cutpoints for 
LDL lowering treatment and these are listed in Table 2.7.The LDL-C goal for 
persons with multiple (2+) risk factors is <130mg/dl. 
 
 
The third category consists of persons having 0-1 risk factors with few 
exceptions, persons in this category have a 10 year risk <10%.Their LDL-C goal 
is 160mg/dl. 
 
 
 
 
b) Primary prevention with LDL lowering therapy: 
 
 
 
The clinical approach to primary prevention is founded on the public health 
approach that calls for life style changes including (1) reduced intakes of 
saturated fat and cholesterol (2) increased physical activity and (3) weight control 
to lower population cholesterol levels and reduce CHD risk, but the clinical 
approach intensifies preventive strategies for higher risk persons. One aim of 
primary prevention is to reduce long term risk (>10 years) as well as short term 
risk (≤10 years). LDL goals is primary prevention depend on a persons absolute 
risk for CHD (i.e. the probability of having a CHD event in the shot term or the 
long term) - the higher the risk, the lower the goal. Therapeutic lifestyle changes 
are the foundation of clinical primary prevention. Nonetheless, some persons at 
higher risk because of high or very high LDL-C levels or because of multiple risk 
factors are candidates for LDL lowering drugs. Recent primary prevention trials 
show that LDL-lowering drugs reduce risk for major coronary events and 
coronary death even in the short term. 
 
 
 
? LDL lowering therapy in three risk categories: 
 
 
The two major modalities of LDL lowering therapy are therapeutic lifestyle 
changes (TLC) and drug therapy. The cut points for initiating lifestyle and drug 
therapies are shown in table 2.9. [123] 
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Table – 2.9 
LDL Cholesterol Goals and Cut points for Therapeutic Lifestyle 
Changes (TLC) and Drug Therapy in Different Risk Categories* 
  
Risk Category LDL Goal
(mg/ dl) 
LDL Level at which 
to initiate 
Therapeutic 
Lifestyle Changes 
  (mg/dl) 
LDL Level at which 
to consider Drug 
Therapy (mg/dl) 
CHD or CHD 
risk equivalents 
(10 year risk < 
20 % 
< 100 > 100 ≥ 130 
(100- 129; drug 
optional) 
2+  Risk factors 
(10 year risk ≤ 
20 %) 
< 130 ≥ 130 10 year risk 10% - 
20% : ≥130 
0-1 Risk factor < 160 > 160 > 190 
(160- 189: LDL 
lowering 
 drug optional) 
 
 
 
1) CHD and CHD risk equivalents: 
 
 
If baseline LDL-C is ≥130mg/dl intensive lifestyle therapy and maximal control 
of other risk factors should be started. Moreover for more patients an LDL 
lowering drug will be regarded to achieve an LDL-C level of <100mg/dl thus an 
LDL-C lowering drug can be started simultaneously with TLC to attain the goal of 
therapy. 
 
If LDL-C levels are 100-129mgldl, either the baseline or an LDL lowering 
therapy several therapeutic approaches are available: 
 
● Initiate or intensify lifestyle and/or drug therapy specifically to lower LDL. 
● Emphasize weight reduction and increased physical activity in person with the 
metabolic syndrome. 
● Delay use or intensification of LDL lowering therapies and institute treatment of 
other lipid or non lipid risk factors. 
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 If baseline LDL-C is <100mgldl further LDL lowering therapy is not 
regarded. Patients should nonetheless be advised to follow the TLC on their own 
to help keep the LDL level optimal. 
2) Multiple (2+) risk factors and 10 year risk of ≤20% : 
 
 
For persons with multiple (2+) risk factors and 10 year risk ≤20% intensity of 
therapy is adjusted according to 10 year risk and LDL-C levels  
 
 
3) 0-1 risk factor : 
 
 
Most persons with 0-1 risk factor have a 10 year <10%. They are managed 
according to Table-2.9.The goal for LDL-C in this risk category is <160mgldl. The 
primary aim of therapy is to reduce long term risk. First-line therapy is TLC. If 
after 3 months of TLC the LDL-C is <160mgldl, TLC is continued. However if 
LDL-C is 160-169mgldl, after an adequate trial of TLC, drug therapy is optional 
depending on clinical judgment. 
 
 
 
? Therapeutic lifestyle changes in LDL lowering therapy: 
 
 
ATP III recommends multifaceted lifestyle approach to reduce risk for CHD. This 
approach is designated therapeutic lifestyle changes (TLC). Its essential features 
are: 
 
● Reduced intake of saturated fat (<7% of total calories) and cholesterol 
(<200mgldl) see table 2.10 [123] for overall composition of the TLC diet. 
● Therapeutic options for enhancing LDL lowering such as plant stanols/sterols 
(2g/d) and increased viscous (soluble) fiber (10-25g/d) 
● Weight reduction 
● Increased physical activity 
 
 
 
? Benefit beyond LDL lowering:  
 
 
The Metabolic Syndrome as a Secondary Target of Therapy: 
 
 
Evidence is accumulating that risk for CAD can be reduced beyond LDL lowering 
therapy by modification of other risk factors. The potential secondary target of 
therapy is the metabolic syndrome which represents the constellation of lipid and 
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non lipid risk factors of metabolic origin. This syndrome is closely linked to 
generalized metabolic disorder called insulin resistance in which the normal 
action of insulin are impaired. Excess body fat (particularly abdominal obesity) 
and physical inactivity promote the development of insulin resistance but some 
individuals also are genetically predisposed to insulin resistance 
 
 
 
 
Table – 2.10 
      Nutrient Composition of the Therapeutic Lifestyle Changes (TLC) Diet 
 
Nutrient Recommended Intake 
Saturated fat < 7% of total intake 
Polyunsaturated fat Up to 10% of total calories 
Monounsaturated fat Up to 20% of total calories 
Total fat 25%-35% of total calories 
Carbohydrates 50%- 60% of total calories 
Fiber 20-30 g/d 
Cholesterol <200 mg/d 
Total calories Balance energy intake and expenditure 
to maintain desirable body weight 
/prevent weight gain 
 
●  Trans fatty acids are another LDL raising fat that should be kept at a 
low intake 
● Carbohydrates should be derived predominantly from foods rich in 
carbohydrates including grains, especially whole grams, fruits and 
vegetables. 
●  Daily energy expenditure should include at least moderate physical 
activity(contributing approximately 200 kcal/d) 
 
 
 
The risk factors of the metabolic syndrome are highly concordant; in 
aggregate they enhance the risk of CHD at any given LDL-C level. For purpose 
of ATP III the diagnosis of the metabolic syndrome is made when three or more 
of the risk determinants shown in Table 2.11 are present. These determinants 
include a combination of categorical and borderline risk factors that can be 
readily measured in clinical practice. 
 
  
Management of the metabolic syndrome has a 2 fold objective, (1) to reduce 
underlying causes (i.e. obesity and physical inactivity) and (2) to treat associated 
non lipid and lipid risk factors. 
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There is no doubt that abnormal BP and cholesterol levels cause major 
morbidity and mortality and that aggressive treatment saves lives. Careful 
management of hypertension and lipid disorders in adults with or at risk for CHD 
is an essential component of quality cardiovascular cause. Thus it is very clear 
that to prevent, manage or reduce the rate of hypertension and lipid disorders, 
the factors that influence these have to be dealt with. It is shown earlier that 
factor like smoking, diet, obesity, physical inactivity, DM acts synergistically with 
BP and lipid disorders. [123,129,153,154,156-158] Apart from vascular factors genetic 
factors are also known to play a role in the etiology of these disorders. [161] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.11 
Clinical Identification of the Metabolic Syndrome 
Risk factor Defining Level  
✦ Abdominal obesity* 
 (waist circumference)# 
  Men > 102 cm (>40 in) 
  Women > 88 cm (> 35 in) 
✦ Triglycerides ≥ 150 mg/dL  
✦ High-density lipoprotein  
 Cholesterol  
  Men <40 mg/dL 
  Women < 50 mg/dL 
✦ Blood pressure ≥ 130/≥85 mm Hg 
✦ Fasting glucose  ≥ 110 mg/dL 
 
* Overweight and obesity are associated with insulin resistance and the 
metabolic syndrome. However, the presence of abdominal obesity is more 
highly correlated with the metabolic risk factor than is an elevated body 
mass index (BMI). Therefore, the simple measure of waist circumference 
is recommended to identify the body weight component of the metabolic 
syndrome. 
 
# Some male patients can develop multiple metabolic risk factors when the 
waist circumference is only marginally increased, eg. 94-102 cm (34-40 in). 
Such patients may have strong genetic contribution to insulin resistance and 
they should benefit from changes in life habits, similarly to men with 
categorical increases in waist circumference.    
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DIET 
 
 
 
 CVD is one of the leading causes of death in the Western world and is the 
third cause of mortality in developing countries, accounting for ≈25% of all 
deaths. [162] Many risk factors for CVD, including high blood cholesterol, HT, 
obesity, and diabetes are substantially influenced by dietary factors. Because 
these risk factors are modifiable, primary preventive efforts hold much promise. 
[163] Despite the documented decrease in LDL-C and TC universally as a result of 
many preventive efforts, obesity and diabetes have continued to increase 
progressively, primarily because of a marked decrease in physical activity and 
exercise as well as an increase in caloric intake in the population. Nutritional 
status within a given population is subject to great variation, based on affluence, 
habit, religion and geography, compared to various CHD risk factors like 
behaviors or traits, diet appears to have a pivotal role. [164] In diet especially fat 
plays an important role in the development of heart diseases. It also influences 
serum TC, TG and Lps. [165] Current dietary advice aimed at reducing the 
incidence of CHD encourages reduction in the proportion of daily energy intake 
derived from fat. [168] Thus modification in the dietary practices can significantly 
improve the Lp profile and ameliorate hyperlipidaemia to some extent. 
 
 
 Several population studies [167,168] correlated severity of atherosclerosis, 
serum cholesterol level and dietary fats. Countries like Finland, Netherlands and 
US had the highest intake of saturated fats when compared to South European 
countries and Japan. The Finns were actually the least sedentary of the group 
studied but they were also the most hypercholesterolemic and had the highest 
rates of CHD. [167] In Ni-Hon-San study [169] of Japanese with the same genetic 
background residing in Japan, San Francisco and Hawaii had high degree of 
variation in their dietary habits. An increased rate of CHD seen in the above 
group residing in Hawaii and San Francisco paralleled the increases seen in 
dietary saturated fat and serum TC. The dietary composition leading to 
hypercholesterolemia rather than genetic make up seemed to play a key role in 
the increase in CHD. 
 
 
 A significant reduction of 28% in coronary events but no improvement in 
the survival was reported in the Oslo trial [170] through dietary modification. In 
another trial- the diet and infarction trial (DART) - it was only when intake of n-3 
fatty acids (fish oil) was increased that mortality was reduced. [171] Except for the 
DART trial no other previous dietary secondary prevention trials were successful. 
[170,172] Even in primary prevention, the only trial successful in preventing 
coronary death was the Hjerman trial. [173] Several insights have been gained 
from observing vegetarians, consuming a high carbohydrate and low fat diet, had 
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low serum cholesterol, LDL-C and LDL/HDL cholesterol when compared to non-
vegetarians. Even lacto-ovo vegetarians had 24% higher LDL-C and 7% higher 
HDL-C than that of strict vegetarian. Serum cholesterol levels in lacto-ovo 
vegetarian, vegetarian and normal American omnivorous group were 6.62, 5.33, 
and 7.53 mmols/lit, respectively as reported by Hardinge and Stare et al.  [164] 
 
 
In Seventh-Day Adventists study [174] it was observed that meat, eggs and 
dairy products were the major sources of saturated FFA and cholesterol and the 
same are the generally recognized risk factor of CHD. Dietary cholesterol is 
entirely derived from animal food like beef, pork, sea foods eggs and milk 
products. In people who ingest considerable amount of meat, eggs, and dairy 
products, dietary cholesterol can be as high as 1000 mg/day, whereas strict 
vegetarian can ingest almost none. [164]  
 
 
The Seven Countries Study by Keys et al in the 1960s showed a relation 
between saturated fat intake, fasting blood cholesterol concentration and CHD 
mortality in various populations [175], which suggests the protective effect of 
traditional Mediterranean – type diets. A Mediterranean α-linolenic acid – rich diet 
had a markedly reduced rate of recurrence, other cardiac events and overall 
mortality. Even more recently some cohort studies in Spain and Greece have 
provided data supporting a cardiovascular protective effect of Mediterranean 
diets. [176,177] These studies, together with other reliable epidemiologic studies 
[178] provide the basis for the well known traditional Mediterranean diet pyramid 
and healthy eating model. [178] Moreover the Indo-Mediterranean Diet Heart 
Study [179] showed that a Mediterranean type diet ( rich in α-linolenic acid from 
fruit, vegetables and nuts ) was also of benefit for secondary prevention of CHD 
in non-Mediterranean populations. The Medi-RIVAGE intervention study [180] 
provides support to early [175] or recent [176] observation studies linking adherence 
to the traditional Mediterranean diet and reduced CVD mortality and reinforces 
the notion of its efficacy in primary as well as secondary prevention. 
 
 
 
 
1. FATS:  
 
 
 
Quality and Quantity of dietary fat have greater effect on blood cholesterol 
and predominant type of fatty acids present in diet play a key role in the control of 
serum lipids. [182] Current dietary guidelines from the American Heart Association 
(AHA) [183] and NCEP [184] recommend restricting consumption of fat to an upper 
limit of 30% of daily caloric intake. This limit translates into 67g of fat for small or 
sedentary individuals who need 2000 cal/day and 100g of fat for large or more 
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active individuals who need 3000 cal/day. Step I diet [containing 28.1% cal as fat 
(8.7% saturated, 11.5% monounsaturated, 7.9% polyunsaturated and 
76mg/1000kcal cholesterol), 13.9% protein and 58.0% carbohydrate] and Step II 
diet [containing 23.7% cal as fat (6.2% saturated, 9.7% monounsaturated, 7.8% 
polyunsaturated and 63mg/1000kcal cholesterol ), 14.4% protein and 61.8% 
carbohydrate] are effective in lowering blood cholesterol levels [185] and 
consequently are advocated as the primary dietary strategy for reducing 
cardiovascular risk. [186] 
 
 
Population studies show that low fat diets are associated with lower LDL-C 
levels but also lower HDL-C levels. Similarly clinical studies involving low fat diets 
also showed equal percent of reduction in both HDL-C and LDL-C. Low fat diets 
alone do not appear to reduce CAD events. [187] Changes in fat composition, 
rather than quantity appear to be key to reduction in CAD events. For e.g. in the 
Lyon Heart Study the experiment group that experienced less CAD events 
consumed less lipid, saturated fat, linoleic acid and cholesterol but more oleic 
and linolenic acids. [188] Replacing saturated fat with monounsaturated is as 
efficient on LDL-C reduction as reducing total fat intakes with a smaller reduction 
in HDL-C levels. [187] 
 
 
 Dietary saturated fatty acids (SFAs) have been implicated as an important 
factor in the production of high levels of plasma cholesterol in populations at high 
risk for CHD. [189]  SFAs are found typically in animal products such as beef, pork 
fats and lamb, dairy products such as milk, ghee, butter and cheese. Vegetable 
oil sources like coconut oil, palm oil, palm-kernel oil, hydrogenated oil and lard 
also contain saturated fats. [190] Although these FAs vary in chain length from 4 to 
18 carbon (C) atoms, they are generally all considered plasma-cholesterol raising 
FAs. This may not be justified. For e.g. FAs with chain lengths of 4 to 10 C atoms 
have been claimed not to increase the cholesterol levels. [191] Likewise, stearic 
acid (18 C atoms, no double bonds [18:0] ) has been reported not to raise 
plasma cholesterol  levels. [192-194] The principal piece of evidence supporting 
this latter claim is that cocoa butter, which is rich in stearic acid, apparently does 
not increase cholesterol concentration as much as do fats that are high in lauric 
acid (12:0), myristic acid (14:0) or palmitic acid (16:0). [193] Later Keys and 
coworkers [194] confirmed these finding and proposed that stearic acid does not 
raise the plasma cholesterol levels. At the same time Hegsted et al [193]  obtained 
similar results and also concluded that stearic acid does not increase cholesterol 
levels. Finally data obtained in studies in laboratory animals were consistent with 
this conclusion. [195,196] This all SFAs do not have the same cholesterol-raising 
potential. Margarines and shortenings high in stearic acid would provide texture 
in foods (as saturated fats do), without raising plasma-cholesterol levels. 
 
 PUFA are those, containing omega-3 and omega-6 fatty acids. Oils such 
as corn oil, safflower oil, rapeseed oil, soybean oil are rich sources of omega-6 
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PUFA. Marine products like seal, salmon, shellfish etc are rich sources of omega 
3- FA like eicosapentaenoic acids, docosahexanoic acids and linolenic acids. 
The ratio of PUFA and SFA in a given fat or oil is designated as P/S value. Fats 
with a high P/S value of 2.1 and above are generally recognized to be 
hypocholesterolemic. A dietary P/S value of more than 1, even if association with 
a decrease in plasma cholesterol, enhanced platelet aggregation to adenine 
diphosphate. [197] High platelet aggregation is associated with MI [198] and closely 
predicts coronary events. [199] In addition a high concentration of linoleic acid 
could be associated with increased lipid peroxidation [200] and platelet induced 
aggregation. [197] The Cretan Mediterranean diet induced a high intake of α-
linolenic acid (the precursor of n-3 long chain FAs), known for its beneficial effect 
on platelet reactivity. [201] Being rich in vegetable and fruits, the diet also supplies 
a high intake of antioxidants. 
 
 
In a recent trial [188], a reduction in coronary events and cardiac deaths of 
close to 70% was achieved without a reduction of serum cholesterol, TG or an 
increase in HDL compared to controls using the α-rich linolenic Mediterranean 
diet. Compared with the DART trial [171] the protective effect observed was 
associated with dietary supply of the n-3 long chain FA precursors (α linolenic 
acid) instead eicosapentaenoic acid and extended to non fatal MI. The two 
populations with the lower CHD mortality in the world have a high intake of α 
linolenic acid; the Japanese in the form of canola and soybean oils, the Cretans, 
possibly through the consumption of purslanc [202] and walnuts. The increase in 
intake of oleic acid less susceptible to peroxidation [200] and in natural 
antioxidants, probably also play a protective part. Recent observations, of a lower 
risk of CHD with a high intake of Vit E [203] and higher concentration of β-carotene 
in adipose tissue [204] is observed. Also a low fat vegetarian diet containing nuts 
(some rich in α linolenic acid) reduced the rate of coronary events within 6 weeks 
was observed in a study. [205] 
 
 
 
 
2. CALORIE: 
 
 
 
 Excessive calorie intake from sources like fats, carbohydrates, proteins or 
alchohol promotes hyperlipidaemia. Recommendations for energy intake have 
been reduced in recent years. This is because of the undoubted reduction in 
physical activity arising from the increasing mechanization of industry and also to 
the more widespread use of mechanical transport. Energy output has been 
determined for people undertaking various activities. Sedentary work requires 
about 2000 to 2500 kcal/day, light work 2500 to 3000 kcal, while heavy work 
such as felling trees, may need 4000 kcal or even more. Carbohydrate rich diet 
increases serum lipids in persons having higher baseline serum lipid levels than 
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in those with low or normal serum lipids. In a high carbohydrate, low fat low 
calorie diet: 1200 to 1500 kcal/day for women and 1500 to 1800 kcal/day for 
men, with approximately 60% of calories from carbohydrate, 25% from fat, and 
15% from protein were present. [206] High sucrose diet provides empty calories 
and increases serum lipids in type III, type IV, type V than for type II HLP 
patients. The age and sex of the subjects may influence the response to changes 
in diet. [164] With increase in age, a reduction in the intake of cereals, pulses and 
legumes were observed in both the genders. This could be attributed to dental 
problems and also digestive problems commonly associated with aging. The 
energy intakes tended to decrease with increase in age in both the sexes, which 
is attributable to the decreased cereals intake. It is mentioned that the RDA for 
energy among the elderly are based on the actual body weights, physical activity 
and sex. The median intake of all the nutrients was relatively low among the 
elderly of both the genders compared to their adult counterparts. The prevalence 
of chronic energy deficiency (CED) (BMI<18.5) was marginally higher among 
males (53.5%) than the female (49.4%). 
 
 
 The use of large quantities of PUFA in vegetable oil in diet causes  serious 
problems because fat is the most calorically dense food. Body responds to an 
excessive consumption of calories by converting food stuffs to fat and by 
depositing fat in adipose tissue which in turn stimulates the liver to synthesize 
more triglycerides and to secrete increased amounts of VLDL and increased 
fasting triglyceride concentration. Enlarged adipose tissue cells may have a 
reduced capacity to remove circulating TG from the plasma, and also because of 
their decreased sensitivity to circulating insulin which activates LPL. [207] Breads, 
cereals, pasta, rice, dried peas and beans are rich in carbohydrate and proteins 
and most have low fat content. Therefore they can be increased in the diet as 
substitutes for fatty foods. However they too contain calories and cannot be 
eaten in excess. 
 
 
 
 
3. DIET AND BLOOD PRESSURE: 
 
 
 
 Diet has an important role in the primary prevention of HT. [208] Several 
epidemiologic studies have reported reduced BP linked to Mediterranean dietary 
pattern (a-linolenic acid rich diet). [209,210] Also vegetarians have relatively low BP 
levels and consume less protein than do non-vegetarians and there have been 
suggestions that certain proteins may raise BP. 
 
 
 Omega-3FAs viz eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) administered in low doses (<3g/d) has shown a BP lowering effect in 
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subjects with type 2 DM. [211] There are few studies showing similar results of ω-
3FA therapy in patients of essential HT at a higher dose (>5g/d) of omega 3FA 
[212,213], attributable to platelet enrichment with EPA, which competes with 
arachidonic acid (AA)[ an omega-6FA] as a potential substrate for the enzyme 
cyclooxygenase. While the predominant product of AA in the platelets 
thromboxane A2 (TXA2) is a potent vasoconstrictor the corresponding product of 
EPA is thromboxane A3, which is virtually biologically inert. In contrast both 
prostaglandins I3 (PGI3) derived from AA and PGI3 derived from EPA; are potent 
vasodilators. Thus alterations of the ω-6FA/ω-3FA ratio in diet to near normal 
(8:1) with dietary  modification and supplementation of ω-3FA, results in a shift of 
the net balance between PGI2/PGI3 and TXA2/TXA3 in the body to a more 
vasodilator state. [214] Beneficial effects of ω-3FA even in low doses have been 
seen on serum lipid profile of 935 NIDDM/IGT patients with 
hypertriglyceridaemia. A study by Wander et al [215] using better technique of 
measuring oxidized LDL and low dose of omega-3FA have shown decreased 
oxidative susceptibility. 
 
 
 Omega-3FA substitution result in reduction of SBP by 16.4% and DBP by 
25%; which is probably attributable to reduction in insulin levels as well as 
production of vasodilatory eicosanoids from ω-3FA in platelet membranes by 
cyclooxygenase. In a study by Singer et al [216] on 12 patients with mild essential 
HT, substitution of ω-3FA in the dose of 5g/day for 8 week resulted in lowering of 
SBP by 9 mmHg and DBP by 11mmHg. When the patients were followed up with 
1.2g/d for 8 months (period 8), the BP still remained significantly lower. A study 
showed beneficial role of ω-3FA on TC, serumTG, LDL and HDL also. [217] These 
beneficial effects of ω-3FA on serum lipid profile of hypertensive patients are 
probably due to blunting of the stimulating action of insulin on hepatic 
lipogenesis. [218] Thus any dose of ω-3FA, as long as omega6:omega3FA ratio in 
diet is maintained at 8:1. Omega-3-FA substitution in low dose and normalization 
of ratio of omega6:omega3-FA in diet to 8:1 resulted not only in improvement of 
BP (SBP and DBP) in patients with mild to moderate essential HT, but also in a 
significant decline in plasma insulin levels and favorable alterations in serum lipid 
profile of the patients, which are desirable for comprehensive management of 
essential HT. Thus it may be concluded that low dose of ω-3FA substitution 
along with dietary curtailment of ω-6FA may be used as an adjunctive measure 
in patients with essential HT. 
 
 
 The Dietary Approaches to Stop HT(DASH) trial has shown that a dietary 
pattern rich in fruit, vegetables and low fat dairy products and with reduced total 
and saturated fat (the DASH diet) can be effective in the prevention of HT. [52,219] 
This pattern was more effective than a diet rich in fruit and vegetables in which 
diary consumption was low. Substantial epidemiologic and clinical data exist that 
show that a long term high consumption of fruit and vegetable, one of the main 
components of the DASH diet, is inversely associated with BP levels, 
independent of other dietary factor. [210,220] Some prospective studies have found 
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a beneficial relation between diary consumption and the incidence of HT or a 
change in BP, but this association was only evidenced in young adults [221] and in 
children. [222] On the other hand dairy consumption has been associated with a 
higher CVD mortality risk in postmenopausal women [223], whereas the nutritional 
intervention in the Oslo study which was mainly focused on reducing whole fat 
dairy consumption was associated with a lower risk of coronary events. [224] 
 
 
 In the Mediterranean Cohort, low fat dairy intake was associated with a 
lower risk of incidence of HT, even after control for several potential confounders 
such as age, sex physical activity, BMI and major dietary factors related to HT. 
The observed risk reduction was high. Two reasons however support that a 
substantial protective association actually exists. First, the reported results are 
consistent with the findings of the coronary artery risk development in young 
adults study [221] and with the findings of clinical trials that included low fat dairy 
products in the intervention diet. [219] For instance in the DASH trial [219], SBP and 
DBP reduction were -5.5 and -3.0mmHg respectively, for the combination 
(DASH) diet, whereas respective decrease of only -2.8 and -1.1mmHg were 
observed with the fruit and vegetable diet. These results also represent an 
important difference in the magnitude of the effect of each diet , which had clear 
cut difference in the amount of low fat dairy products provided. (2.0 servings/day 
in the combination diet compared with 0 serving/day in the fruit and vegetable 
diet). This is the first study that showed an inverse association between the 
consumption of low fat dairy products and incident HT independent of other 
dietary factors in a perspective follow-up population, which included subjects 
aged > 40 years. Thus some cross sectional studies have shown a beneficial 
association between dairy consumption and BP. [210,225] Calcium could partly 
account for the observed inverse association between dairy consumption and the 
risk of HT. Also it could be that other components that occur in low fat dairy 
products or an interaction between some different nutrients may have caused the 
observed reduction in the risk of HT. For e.g.:- milk proteins- both caseins and 
whey proteins are a rich source of angiotensin converting enzyme inhibitory 
peptides. In animal models, these proteins (casokinins and lactokinins) have 
been shown to significantly reduce BP. [226] It is plausible that SF in whole fat 
dairy products somehow neutralize the beneficial effect of dairy consumption. 
The capacity of Ca to form soaps is much higher when fat intake is increased. 
Therefore foods that are high in fat such as whole fat dairy foods might hinder Ca 
absorption, thereby reducing the bioavailability of calcium. [227] Also more 
recently, the WELL trial found that a diet rich in low fat dairy products resulted in 
a greater decrease in BP than did a low fat comparison diet, which supports the 
beneficial effect of low fat dairy consumption for the prevention of HT. 
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4. DIET AND LIPID METABOLISM: 
 
 
 
 A number of studies have revealed the central role of elevated blood 
cholesterol [especially increased LDL-C] in the pathogenesis of CAD, it is clear 
that one of the biggest challenges facing public health authorities and medical 
practitioners is the control of the blood cholesterol in individual patients and at 
the population level. [228] A low fat diet is generally recommended for patients 
with CHD. [229] Numerous studies have shown that a low fat diet decreases 
plasma total, HDL and LDL cholesterol, apoA-I and apoB concentration and also 
increase triglyceride concentration. [230,231] An important health concern of 
consuming unrestricted amounts of SF is the potential to increase the LDL-C 
concentration, which is an established risk factor for CHD. Plasma LDL-C and 
HDL-C levels decline with reductions in the intake of dietary fat. The recomitant 
decrease of LDL-C that occurs with a diet low in SF may override the effects 
associated with the decline in HDL-C. [232] Reducing the fat content of the diet 
from 35 to 40% of energy to 15% to 20% of energy reduces total cholesterol and 
LDL-C levels by 10 to 20%. [233,234] Thus response is likely attributable primarily 
to decrease in the SF content of the diet rather than the increase in CHD content. 
[235] 
 
 
 In a recent study the co-administration of garlic pearls with fish oil was 
found to be more effective than placebo in the management of dyslipidaemia. 
Studies with fish oil supplementation [n-3 fatty acid containing eicosapentenoic 
acid (EPA) and docosahexaenoic acid (DHA)] in hypocholesterolemic subjects 
have shown significant reductions in the serum TG and VLDL concentrations, 
whereas there was a significant increase in the serum LDL concentration which 
plays a major role in the development of atherosclerotic CAD. [236,237] Griffin [238] 
has reported that n-3 fatty acid shift LDL away from harmful small dense particles 
to larger, lighter less pathogenic ones. The Framingham Heart study and the 4-S 
study have reported that TG levels >100 mg/dl and HDL-C <40 are indicators of 
the presence of harmful small dense LDL-C particles. [239] Garlic or (allium 
sativum) has been used as both food and medicine in many parts of the world. 
[240] Garlic contains an active substance called ‘allicin’ and sulphur compounds 
like diallyl disulphide and allyl propyl disulphide which are responsible for the 
therapeutic properties of garlic. [241] Supplementation with garlic alone has been 
found to significantly lower LDL and TC concentrations. [240] Also TG levels 
consistently increase in response to short term consumption of a very low fat 
diet. [242,243] A very low fat diet is defined as one in which ≤ 15% of total calories 
are derived from fat (33 gm for a 2000 calories diet, 50 gm for a 3000 calorie 
diet) with fat calories distributed approximately equally, among saturated MUFAs 
and PUFAs. Also approximately 15% of total daily calories consumed should be 
derived from protein and ≥ 70% from carbohydrates. Higher TGs levels are 
frequently accompanied by lower HDL-C levels and higher TC/HDL-C ratios 
[243,244] as well as increased levels of small dense LDL particles. [245] Very low fat 
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diets increase TG levels regardless of whether the diet is high in simple or 
complex carbohydrates [235] but the increase may be attenuated by higher dietary 
fiber intake or weight loss. [244] Weight loss attenuates the HDL-C lowering effect 
of very low fat diets and is related in part to blunting the increase in TG levels. 
[243,244] 
 
 
 Epidemiological studies have shown that the majority of heart attacks 
occur in normolipidaemic individuals with low HDL-C (≤ 40 mg/dl). [125,246] Among 
normolipidaemic subjects HDL-C vary greatly. [247] About 15-20% of the male 
population has low HDL-C (≤40mg/dl). Data from the Framingham study [246] as 
well as data by Assmann et al [248] showed that the incidence of CHD increased 
in subjects with low HDL-C despite normal TC(<200mg/dl) or LDL-C (<135mg/dl). 
The major protein constituent of HDL is apoA-I. ApoA-I concentration can be 
influenced by genetic and environmental factors, diet and exercise. [249] A high fat 
diet increases apoA-I concentration by increasing production rate and decreasing 
fraction catabolic rate (FCR) without altering apoA-I mRNA levels; [250] the major 
regulations of apoA-I levels occur post transcriptionally. 
 
 
  HDL is not homogenous; they contain several subpopulations. [251] The 
largest size (alpha1) is an apoA-I only particle corresponding approximately to 
the HDL2 fraction. [252] Smaller alpha2 and alpha3 particles correspond to HDL3. 
On an average American diet (AAD), healthy normolipidaemic low HDL-C 
subjects have different concentration of HDL sub populations compared to 
normal HDL-C individuals. It was observed in a recent study that the HDL alpha1 
subpopulation is lower and HDL alpha3 is higher in low HDL-C subjects 
compared to normal HDL-C individuals. [253] Also increased CETP activity has 
been shown in subjects with low HDL-C. [254] In a particular study the response to 
low fat diets of subjects with low and normal HDL-C were compared. Low fat 
diets resulted in a significant decrease in HDL-C both on step1 and step2 diets in 
subjects with normal HDL-C. The atherosclerotic index LDL-C/HDL-C did not 
change in individuals with normal HDL-C; while in low HDL-C subjects, it 
decreased significantly from 3.92 to 3.49 (11%). Also in an earlier study, 
[255],HDL-C levels in school boys who consumed different habitual diets were 
compared wherein; HDL-C levels were strongly and inversely related to 
carbohydrate intake. Diets rich in n-3 PUFAs have high HDL-C levels. [256] 
Although diet high in MUFA does not elicit a significant change in HDL-C levels, 
[257] the dietary glycemic load (which represents the equivalent elevating effect on 
BP levels of 1 gm of pure glucose or white bread) is negatively correlated with 
HDL-C levels. [258] Thus a diet rich in n-3 PUFA sources include oils (olive, 
canola, soya,  flaxseed), nuts (almonds, peanuts, walnuts, pecans), coldwater 
fish (salmon, mackerel) and shellfish with limited carbohydrates that contribute a 
high glycemic load (such as those found in ready to eat cereals, potatoes, white 
bread and snack foods) can be recommended to increase serum HDL-C levels. 
                              
 61
Clinical trials and epidemiological studies suggest an increase of 1mgldl 
HDL-C results in a 2-3% decrease in coronary risk while an increase of 1mgl/dl 
LDL-C results in a 1% increase in the risk of CHD. Thus every mg/dl change in 
HDL-C concentration provides a 3 fold greater contribution to the production of 
CHD than does a 1mg/dl change of LDL-C. [125,229] 
 
 
          The result of a controlled metabolic study have suggested that dietary fatty 
acids containing at least 1 double bond in the transconfiguration (transFAs) have 
a detrimental effect on serum lipid levels relative to FAs containing only double 
bonds in the cis configuration or in some cases SFAs. [259] Adverse effects of 
dietary transFAs on the risk of the development of CVD have also been reported 
in some studies of large cohorts. [260,261] TransFAs are naturally present at low 
levels in meat and dairy products as a result of bacterial fermentation in ruminant 
animals. They are also formed in varying amounts during the hydrogenation of 
oil, a process used to transform oil from a liquid to a semisolid or solid state. 
Recent studies consistently demonstrate a positive relation between the level of 
intake of trans fatty acids and LDL-C levels. [262,263] Soybean oil and semi liquid 
margarine has the lowest levels of transFAs of the various fats that are studied 
and they are also low in saturated fat. In the use of soyabean oil or semi liquid 
margarine results in the most FAV total and LDL-C levels and ratios of TC/HDL-
C, whereas the use of stick margarine or butter results in the opposite effects. 
The fats with intermediate levels of trans and SFAs resulted in intermediate 
values. In addition, from a practical perspective they provide a sound basis on 
which to make strong recommendation to the general public and food 
manufacturers to emphasize the use of vegetable oils in their natural state and 
minimal hydrogenation. 
 
 
 It is known that unrestricted amount of saturated fats have the potential to 
increase the LDL-C concentration, but in a particular study it was shown that the 
diet high in stearic acid significantly reduced plasma levels of TC and LDL-C, as 
compared with the diet rich in palmitic acid. [264] The high stearic acid diet 
reduced both the total and LDL-C levels as much as the high oleic acid diet. Also 
neither the high stearic acid nor the high oleic acid diet increased plasma TGs or 
reduced HDL-C, as compared with the high palmitic acid diet. Stearic acid is a 
saturated FA and we may speculate about why it does not increase plasma 
cholesterol levels as much as palmitic acid does. One possible mechanism for 
the cholesterol lowering action of stearic acid, as compared with palmitic acid, 
may be that stearic acid but not palmitic acid, is rapidly converted to oleic acid. 
 
 
 The Mediterranean and α-linolenic Enriched Groningen Dietary 
intervention (margarine) study, [265] a primary prevention study in 
hypocholesterolemic subjects showed the benefit of the alpha-linolenic acid 
contained in a Mediterranean diet. Also the Lyon Heart Study for secondary 
prevention of CHD [188] showed that the positive effect of a Mediterranean type 
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diet enriched with alpha-linolenic acid (mainly in the form of margarine), the 
survival rate after a first MI increasing markedly compared with that for the 
control group [low fat diet]. The Mediterranean diet provides greater intakes of 
soluble fibres (from fruit, vegetable, legumes and cereals) and MUFA (oleic acid 
from olive oil) which are known independently to have cholesterol and LDL-C 
lowering effects. [231,266] Fibre rich diets [266] and a high consumption of fruit and 
vegetable have been related to a reduced occurrence of CHD. [176,177] The 
reduction in plasma TG (mainly in the form of TRLs) observed only in the 
Mediterranean group may have been due mainly to a high intake of fish and long 
chain of n-3 FAs. [267] In line with most recent theories on optimal eating patterns 
for prevention of CHD [268] and according to Law’s concept, [269] the observed 
lowering in plasma cholesterol actually indicates a reduction in CV risk of 19% 
with the low fat diet and 15% with the Mediterranean diet. 
 
 
 
 
5. CURRENT GUIDELINE FOR DIET: 
 
 
 
 Current American Heart Association (AHA) recommendations regarding 
diet and related lifestyle practices for the general population are based on 
evidence indicating that modification of specific risk factors will decrease 
incidence of CHD. [229] These risk factors include cigarette smoking; elevated 
levels of plasma cholesterol, particularly LDL-C, low levels of HDL-C; increased 
BP; DM; obesity especially visceral adiposity and physical inactivity. To reduce 
the impact of these risk factors on the occurrence of CHD in the general 
population, in 1996, the AHA recommended the following population wide dietary 
and lifestyle goals. 
 
 
 
a) Eat a variety of foods: 
 
 
 Dietary recommendations should enable individuals to adopt eating 
patterns consistent with their own lifestyles and that will supply the calories, 
proteins, EPAs, carbohydrate, vitamins, minerals and fiber needed for good 
health. This is achieved by eating foods from all the food groups including fruits 
and vegetables; non fat and low fat diary products; whole grain bread, cereals, 
pasta, starchy vegetable and beans; and lean meat, skinless poultry and fish. 
The AHA recommends that healthy individuals obtain an adequate nutrient intake 
from foods eaten in variety, balance and moderation. Excessive intake of 
calories, sugar and salt should be avoided. 
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b) Balance food intake with physical activity and maintain or 
reduce weight: 
 
 
 Loss of excess weight and long term maintenance of a healthy weight can 
improve blood lipid levels and blood pressure and reduce risk for heart disease, 
the most common form of diabetes, stroke and certain cancers. [270] In many 
individuals with increased abdominal or visceral fat, even modest weight 
reduction may result in improvement in many metabolic CHD risk factors, 
particularly those associated with insulin resistance, including low HDL level, 
elevated TG levels and small dense LDL. [271] Successful long term maintenance 
of a healthy body weight can be promoted by regular physical activity in 
conjunction with a diet that is limited in calories particularly those derived from fat 
and relatively rich in complex carbohydrates and fiber. [272] 
 
 
c) Choose a diet low in fat, saturated fatty acids and 
cholesterol: 
 
 
 
 The AHA’s population wide recommendation to consume no more than 
30% of total calories as fat is aimed at reducing saturated fatty acid intake and 
maintaining a healthy body weight. The AHA emphasizes restriction of saturated 
fatty acid intake because this is the strongest dietary determinant of plasma LDL-
C levels. [193] Total plasma and LDL-C levels are mainly affected by lauric (12 C 
atoms), myristic (14) and palmitic (16) acids. Reduced intake of these C raising 
saturated fatty acids has resulted in a reduction in plasma LDL-C levels in well 
controlled dietary studies. Short chain (less than 10 carbon atoms) fatty acids 
and stearic acid (18) have little effect on cholesterol levels. [273]  
 
 
Currently AHA recommendation is less than 10% of total calories come 
from saturated fatty acids. Controlled clinical studies indicate that reducing 
saturated fat intake from the current average intake of 12% to 14% [194,274] of 
calories can lead to an average reduction of 3% to 5% in CHD risk in the 
population as a whole. There is, however, inter individual variation in plasma 
LDL-C response to reduced intake of saturated fatty acids, partially influenced by 
genetic factors. [275] 
 
 
 To reduce lipid and lipoprotein levels while maintaining caloric intake, 
SFAs in the diet can be replaced by either PUFAs or MUFAs, carbohydrates [276] 
or protein, [277]  all of which have differing effects on plasma serum lipids and 
lipoproteins. The AHA currently recommends that intake of Ω-6 fatty acids be no 
more than 10% of total calories.Ω-3 PUFA, derived primarily from fish, can also 
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be substituted for dietary saturated fatty acids and may have beneficial effects 
beyond those associated with lowering LDL-C levels. [278]  
 
 
MUFA suitable replacement for SFAs, although, net effect on serum lipids 
and lipoproteins is not much different from that of PUFAs, they may have some 
advantages. Unlike polyunsaturates, monounsaturates are not as susceptible to 
oxidation, which may play a role in atherogenesis. The AHA therefore 
recommends a MUFA intake in the range of 10 to 15% of total calories. [279] 
Dietary cholesterol [280] can increase plasma and an LDL-C level in 
epidemiological studies [281,282] has been shown to be related to CHD risk 
independent of its effects on blood cholesterol levels. Currently the AHA 
recommends that dietary cholesterol intake be less than 300mg /day. 
 
 
 
 
d) Choose a diet with plenty of vegetables, fruits and whole 
grain products: 
 
 
 
 These foods should contribute the majority of daily energy intake between 
55 and 60% of total calories. Fruits, vegetables, whole grains and legumes 
provide important vitamins, minerals, fiber and complex carbohydrates as part of 
a diet moderate in total fat and low in saturated fat content. Diets high in 
unrefined carbohydrates also tend to be high in both soluble and insoluble fiber. 
Foods rich in soluble fiber, including oats, barley, beans, Soya products, guar 
gum and protein found in apples, cranberries, currants and goose berries can 
help maximize a reduction  in plasma total and LDL-C levels as part of a fat 
modified diet. [283] Total dietary fiber intake of 25 to 30 g/d from foods, not 
supplements, will help ensure an eating pattern high in complex carbohydrates 
and low in fat. 
   
 
 
e) Choose a diet moderate in sugar: 
 
 
 
 Sugar intake has not been directly related to risk for CVD, but diets high in 
refined carbohydrates are often high in calories and low in complex 
carbohydrates, fiber and essential vitamins and minerals. 
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f) Use salt and sodium in moderation: 
 
 
 
 The AHA recommends that the general public consumes no more than 6 
gms of sodium chloride (NaCl) per day. This recommendation is based on the 
evidence for an association between dietary NaCl intake and BP derived from a 
couple of epidemiological observations [284,285] and clinical trials of salt restriction. 
Results of therapeutic trials of NaCl restriction in hypertensive individuals also 
documents modest but significant reductions in BP. [286,287] The AHA has elected 
to limit NaCl intake to 6g/day. However slightly higher intake (6 to 7.5g/ day) 
have not been demonstrated to increase CV risk or raise BP in normotensive 
persons without other CV risk factors.  
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III. TOBACCO AND SMOKING 
 
 
Smoking and tobacco habits have a more firmly established pernicious 
influence on cardiovascular mortality and morbidity. More than 1.1 million 
individuals are affected by myocardial infarction (MI) each year in North America 
and >20% of these individuals are habitual smokers. [288] Cigarette smoking 
promotes atherosclerosis & is associated with an increased risk of sudden death, 
angina, MI, peripheral vascular disease and stroke. [289,290] It is observed that 
men who smoke cut their lives short by 13.2 years while women who smoke lose 
14.5 years of life. In 1934, Howard first proposed such an association after 
observing that the increased incidence of CAD in Europe after World War I 
coincided with a sharp rise in the number of smokers during the war. In 1964 the 
US Surgeon General’s report noted that the causative role of smoking was not 
proved but was strongly enough suspected to warrant counter measure. In 1979, 
the Surgeon General’s report contained much stronger, wording referring to a 
definite association between smoking and CAD, with the report of an increase of 
2 to 3 fold risk of CAD with smoking [291] 
 
 
 In the Framingham study the relative risk of sudden coronary death was 
about 10 times higher in men and 4.5 times higher in women when compared to 
their non-smoking counter parts. [292] Also a multiple regression analysis of the 
Framingham offspring study showed that smoking was significantly associated 
with lower HDL-C levels of 4mg/dl in men and 6mg/dl in women. [293] Other 
studies have shown a 7-20% reduction in HDL-C levels in smokers. [294,295] Thus 
there is a linear dose dependent effect between the number of cigarettes smoked 
per year and HDL-C levels. Continuous smoking of large number of cigarettes 
disturbs the lipid metabolic balance and liver functions. It was observed that 
effect of smoking on lipid metabolism and liver functions depend on the number 
and regularity of smoking. Pooling project research group study [296] and Key’s 
Minnesota business and professional men study [297] showed that an increase in 
CHD risk is associated with an increase in the number of cigarettes smoked. 
 
 
 
 
1. Increased risk of CHD: 
 
 
Cigarette smoking increases the risk of CHD by itself. When it acts with other 
factors, it generally increases the risk. 
 Smoking: 
I) increases blood pressure 
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ii) Decreases exercise tolerance and  
iii) Increases the tendency for blood to clot 
 
 
Smoking also increases the risk of recurrent CHD after bypass surgery. 
Cigarette smoking is the most important risk factor for young men and women. It 
produces a greater relative risk in persons under age 50 than in those over 50. 
Cigarette smoking combined with a family history of heart disease also seems to 
greatly increase the risk. In subjects, smoking 10 to 15 cigarettes daily a 
tendency of high TC and TG and low HDL-C is found but no change in LDL and 
VLDL is seen. 
 
 
 
 
2. Pathophysiology: 
 
 
 
Cigarette smoking has a major impact on the cardiovascular system. Smoking 
is a leading contributing factor to aortic aneurysm, atherosclerosis, IHD, MI, 
peripheral vascular disease and stroke. [289,290] There are four principal 
mechanisms that contribute to acute cardiac events that are due to smoking: 
induction of a hypercoagulable state, reduction of oxygen delivery because of 
carbon monoxide (CO), coronary vasoconstriction and nicotine mediated 
heamodynamic effects. 
 
 
 
a) Induction hypercoagulable state: 
 
 
Smoking affects both coagulation factors and platelet function. Smoking 
increases factor VII, which is involved in the initiation of coagulation and 
contributes to blood coagulability. [298] Changes in red cell deformability and 
plasma viscosity associated with smoking, increases the thrombus formation. 
After cigarette smoking there is reduced platelet survival time [299] and increased 
circulating platelet aggregates release of platelet specific proteins. [298] Platelet 
aggregation is increased due to the reduction in production of endothelial cell 
prostacyclin, an inhibitor of platelet aggregation, by tobacco smoke. Short ended 
platelet survival is found in smokers and is considered an indirect indicator of 
platelet activation. This could explain the increase in thrombus formation in vivo. 
Smoking causes acute and chronic inhibition of cyclooxygenase which inhibits 
prostacyclin and increases the biosynthesis of the thromboxane A2, an 
eicosanoid releases by activated platelets, which supports the notion that 
smoking activates platelets. [298] It is also a potent vasoconstrictor and platelet 
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agonist with a half life of approx 30 seconds at physiological pH. Smokers have 
higher levels of fibrinogen and factor VII and are decreased after smoking 
cessation, although this decrease may take several years. Increased levels of 
factor VII and fibrinogen are associated with an increased risk for CAD. [298] 
 
 
 
b) Reduction of oxygen delivery because of CO: 
 
 
Smokers inhale CO and their carboxy hemoglobin levels average 
approximately 5% per packs smoked per day. These levels compare with levels 
of 1% to 3% in non smokers. [300] Smoking acutely increases myocardial O2 
demand by raising peripheral resistance, blood pressure, heart rate and possibly 
coronary artery flow and reduce O2 carrying capacity of hemoglobin due to CO. 
CO binds to hemoglobin available to carry oxygen and allostericaly inhibiting 
hemoglobin mediated oxygen release. [300] Cardiac patients exposed to CO 
during exercise experience an increase in both ventricular dysfunction and 
number and complexity of ventricular arrhythmias. [289] Thus a reduction in 
oxygen delivery because of CO inhalation can lead to events such as arrhythmia 
and MI. 
 
 
 
c) Coronary vasoconstriction: 
 
 
Smoking causes constriction of the coronary arteries and has been observed 
to produce acute vasospasm during angiography. [301] Coronary vasoconstriction 
is a result of α-adrenergicallly mediated increases in coronary artery tone. [302] 
Intracoronary Doppler measurements have demonstrated that cigarette smoking 
conducts both epicardial arteries and coronary resistance vessels and also 
increases total coronary vascular resistance. [301] In smoking with CAD, 
vasoconstriction decreases coronary blood flow despite the increase in O2 
demand associated with smoking. [301] The resulting reduction in myocardial 
blood supply can produce arrhythmias, ischemia and MI. 
 
 
 
 
 
d) Nicotine mediated heamodynamic effects: 
 
 
Rapid absorption of the nicotine in cigarette smoke leads to arterial plasma 
concentration in body organs 6 to 10 times higher than venous plasma conc. [289] 
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This rapid delivery of high conc. of nicotine can lead to intense immediate 
cardiovascular effects because there is minimal time for development of 
tolerance. [289] The nicotine mediated heamodynamic effects of smoking include 
an increase in heart rate and BP, which increases myocardial work. Nicotine also 
increases O2 demand and causes arterial constriction, which impairs blood flow 
to the heart. [301] Furthermore nicotine increases both heart rate and myocardial 
hypoperfusion in cardiac patients. [289] The introduction of nicotine into healthy 
non smokers has been shown to blunt the increase in coronary blood flow that 
occurs with a nicotine-induced increase in heart rate. This finding suggests that 
low doses of nicotine are capable of constricting coronary arteries. [289] For high 
risk cardiac patients, eliminating nicotine induced coronary constriction is 
important in the prevention of MI. 
 
 
 
 
3. Atherosclerosis: 
 
 
 
Smoking accelerates endothelial atherosclerosis through damage to the 
endothelium and increased fibrinogen levels. [303] Over time inhaled CO from 
cigarette smoke damages the endothelium and accelerates the process of 
atherosclerosis. [304] Approx 25% to 50% of the relation of cigarette smoking to 
the occurrence of CAD is attributable to the effect of smoking on increased 
fibrinogen levels in the blood. [303] High fibrinogen levels enhance the tendency 
for thrombosis, leading to occlusive clinical events. [303] 
 
 
 
 
4. Metabolic Effect of tobacco Use: 
 
 
 
Nicotine administration and cigarette can lead to an increase in fatty acids in 
serum as first observed by Kershbaum et al. [305] The increase is mediated by 
catecholamine release. There is no change in concentration of serum total 
cholesterol and phospholipids. Smoking has an additional indirect effect on lipid 
metabolism by affecting LPL which is an important enzyme in the metabolism of 
cholesterol and triglycerides. Smoking elevates VLDL-C and reduces HDL-C and 
thus increases atherogenic property. Cigarette smoking is also associated with 
reduced LCAT activity, [306] CETP activity [307] and HDL-C. [128] The combination 
of these metabolic effects may promote endothelial cell injury and reduce efficacy 
of vascular repair mechanisms. Smoking affects cardiovascular system adversely 
by increasing plasma free fatty acids, growth hormone, ADH, cortisol and 
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glucose. Cigarette smoking in women is associated with earlier menopause, 
which is considered an important risk factor of CVD. Smoking increases 
metabolic clearance rate of estradiol in liver [308] and is responsible for lower level 
of estrogen. In postmenopausal women, smoking increases bone loss. 
 
 
 
5. Pro inflammatory and Pro coagulant markers in CAD: 
 
 
 
Experimental studies have shown that tobacco glucoprotein products, induce 
the release of interleukin (IL)-6 and macrophage colony stimulating factor (M-
CSF) from alveolar epithelial cells [309] and from pulmonary macrophages. [310] 
Smoking renders LDL more susceptible to per oxidative modification by 
macrophages and smooth muscle cells. [311] Oxidized LDL can induce expression 
of M-CSF by endothelial cells. [312] In circulation, M-CSF released by vascular 
macrophages and injured endothelium [410] induces monocyte/macrophages 
activation, [313] facilitates platelet monocyte adhesion and activation [313] and this 
leads to release of platelet thromboxane A2 (TXA2). [314] M-CSF also promotes 
tissue factor expression [315] and release of IL-6 by vascular cells [316] leading to 
c-reactive protein (CRP) production. [317] Smoking status has been also 
associated with enhanced TXA2 released by platelets, [314] elevated IL-6 and CRP 
plasma levels in healthy [318] and increased tissue factor expression in human 
atherosclerotic plaques. [319] Cigarette smoking appears to be a triggering factor 
for M-CSF and CRP production in patients with coronary atherosclerosis. Rohde 
et al have also shown a relation between smoking status, increased CRP levels 
and risk to develop CAD in apparently healthy subjects. [318] And alternative 
pathway for CRP production by liver involves the generation of oxidized LDL [320] 
which may be significantly enhanced by smoking. M-CSF increases cholesterol 
uptake by macrophages [321] and mediates the monocyte induced apoptosis of 
the vascular smooth muscle cells [322] resulting in foam cell formation, [323] the 
hall- mark of atherogenesis. 
 
 
In a prospective study of patients with chronic CAD, cigarette smokers had 
approximately three fold levels of M-CSF and two fold CRP levels compared with 
non smokers and healthy control. Also a two fold levels of 11 – dehydro TXB2 in 
smokers than non smokers and healthy control in agreement with another study 
in healthy volunteers was seen. Thus this prospective study links cigarette 
smoking to the circulatory levels of a major atherogenic cytokine namely, M-CSF 
of a pro-coagulant and inflammatory protein namely, CRP in addition to 
thromoboxane A2 production in patients with chronic CAD. [324] 
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6. Nicotine dependence: 
 
 
 
Tobacco dependence is driven by nicotine addiction which perpetuates 
itself by controlling the release of several neuro transmitters (dopamine, γ amino 
butyric acid, nor epinephrine, serotonin). [325] The immediate release of 
neurotransmitter produces sensation of stimulation and pleasure with prolonged 
exposure to nicotine, tolerance to these effects develops and the presence of 
nicotine in the brain becomes necessary to maintain normal function. When 
tobacco use ceases, there are subnormal levels of dopamine, norepinephrine 
and serotonin in the brain, with associated withdrawal symptoms. [290] Although 
motivated patients may have high initial quit rates (up to 60 % within the first six 
months), the relapse rates at one year increase dramatically because of patients’  
strong addiction to nicotine. [289] In addition, a large no of individuals who initially 
stops smoking but relapse after one year do so because of the withdrawal 
symptoms. Withdrawal symptoms range from anxiety, depressive symptoms or 
dysphoria to intense cravings and hunger. [290] 
 
 
 
 
7. Smoking cessation: 
 
 
 
Smokes from cigarettes contains from .5 to 3 mg of nicotine depending on 
different brands when smoke is inhaled, practically all the nicotine is absorbed 
and the plasma nicotine levels may increase up to 40 to 50 mg per ml of the 
plasma. CO also constitutes 3 to 6 % of cigarette smoke. COs high affinity for 
binding to hemoglobin elevates carboxy hemoglobin level and reduce the oxygen 
carrying capacity of the blood. Thus more than 500,000 people each year die of 
smoking in North America, making smoking the leading preventable cause of 
premature death. [326] Approximately 70% of the 50 million North American 
smokers want to quit smoking but only 2.5% per year actually succeed in quitting. 
Both pharmacological and behavioral smoking cessation aids have been 
developed to improve the chances of overcoming nicotine dependence. These 
aids can be classified into two groups: Nicotine Replacement Therapies (NRTs) 
and non –NRTs. NRTs including the nicotine patches, gum and inhalers supply 
the user with nicotine  while avoiding the toxic chemicals ingested from 
cigarettes. The two non NRTs are bupropion and behavioral therapy. 
 
 
Cessation of smoking is related to a marked decrease in CVD, including 
reduced cardiac arrest, coronary death and MI. A substantial decrease in CHD, 
mortality for former smokers compared with continuing smokers. This decrease 
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in risk occurs relatively soon after cessation of smoking and increasing interval 
since the last cigarette smoked are associated with progressively lower mortality 
rates from CHD. Gordon and Kannel, [327] reported 20- 60% reduction in risk of 
heart attacks in moderate (20 cigarettes per day) and heavy (40 cigarettes per 
day) smokers, two years after cessation of smoking. Rosenberg [328] in his study 
of 3285 women, showed that within 4 years of stopping  smoking, the risk of CHD 
decline to a level approximately that for women who had never smoked. HDL-C 
level will rise to the levels of non smokers after smoking cessation for 30 to 60 
days with the elevation sustained at one year. [294] Its elevation by a mean of 4 
mg/dl is more so in women than in men and in persons with elevated baseline 
HDL-C levels (47 mg/dl). [329] Also person with diagnosed CHD experience as 
much as a 50% reduction in risk of re-infarction, sudden cardiac death and total 
mortality if they quit smoking after the initial infarction. Smoking cessation results 
in decreased fibrinogen level, reduces oxidative damage from CO and also 
increases the ratio of HDL/LDL-C. [303] These changes help reduce the risk of 
CAD and MI caused by arthrosclerosis. [330] Smoking cessation decreases 
mortality caused by atherosclerotic diseases by 50% within five years in both 
men and women. [331] Thus there is overwhelming evidence demonstrating both 
the cardiovascular hazards of smoking and the prompt benefit that occurs with 
smoking cessation. 
 
 
But it is no longer enough simply not to smoke. Non smokers have to be alert 
to the presence of environmental smoke produced by others. Environmental 
tobacco smoke (ETS) is a mixture of more than 4000 compounds over 50 of 
which are known to cause cancer. ETS consists of two different kinds of smoke. 
Approximately 85% is side stream smoke, the smoke emitted from the burning of 
cigarettes, cigar or pipe between puffs. The remainder is the main stream smoke 
exhaled by the smoker. Although both smoke are chemically very similar, 
undiluted side stream smoke burns at a lower temperature and therefore 
contains high concentration many of the toxic elements in tobacco smoke 
including nicotine, CO, Benzene, ammonia, 4-amino-biphenyl and benzo [a] 
pyrene. ETS also affects heart diseases. Byrd et al [332] concluded that 37,000 
CHD deaths occur per year in USA due to ETS exposure accounting for seventy 
percent of all deaths due to the same. Passive smoking has also been shown to 
lower HDL-C level with a significant relationship between the HDL-C level of 
children and adolescents and passive smoking by adult smokers in the home. 
[333] Therefore passive smoking is an important risk factor for heart disease 
morbidity and mortality. 
 
 
 Cigarette smoking is as widespread and significant as a risk factor and is 
the leading preventable cause of disease and death worldwide. A comprehensive 
approach to smoking cessation involving pharmacotherapy, nicotine replacement 
therapy and counseling should be recommended. [334] 
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IV. HERIDITARY 
 
 
 
 
Over the past few years research in HT and CVD has focused on different 
biochemical variables such as positive family history, lipid levels, smoking, 
alcohol etc. However all these are useful only when the patient is in the 
advanced stage of the disease. One would definitely like to prevent the 
occurrence of these diseases much earlier than this and in an individualized 
manner. The advances in the field of genetics and genomics have enabled us to 
understand the role of genes and its minor variations in the pathogenesis of 
different diseases. With the “Human Genome Project” completed and the rapid 
technological advances in the field of biotechnology and molecular biology, new 
candidate genes are continuously emerging for various aspects of cell biology, 
for modulating HT and CVDs .Also the human gene sequence would give us a 
better correlation between genotype-phenotype and may also help us identify 
individuals at an increased risk for the above mentioned diseases. Medical 
genetics is predicted on the concept of genetic variation resulting in disease and 
has traditionally focused on diseases that can be tracked through families. 
Classical genetics uses pedigree analysis of families and is able to use statistical 
methods to couple genes with disease through what is termed linkage analysis. 
The reason for the strength of linkage analysis is that individuals are well 
matched for genetic background. The most common variations in the human 
genome are single base changes called single nucleotide polymorphisms 
(SNPs). Although human beings are 99% genetically identical that 0.1% of the 3 
billion base pairs in the human genome has 3 million base pairs of difference 
between individuals. One of the major advances from studying various 
polymorphisms including SNPs of multitude of genes which are involved in the 
pathogenesis of HT and CVD is the possibility of predicting the development of 
these diseases and their probable outcomes. 
 
 
Since the discovery of DNA in 1950s and elucidation of this molecule as the 
information keeper of the cell, explosive knowledge and development of 
technologies have taken place in the field of molecular biology. Various 
techniques like cell transformation, gene transduction, reverse copying of mRNA 
to cDNA, cutting DNA at desired places using restriction enzymes, ability to join 
the desired fragments with multitude of DNA and RNA ligating enzymes, 
discovery of PCR technology etc have resulted in understanding the detailed 
mechanisms of gene control by environmental factors, the process of cell 
division, apoptosis, angiogenesis, vasculogenesis and several other cellular 
events within our body. In order to understand better how different genes 
ultimately translate into differences in various disease conditions and survival, it 
is essential to be able to read the whole human genome. These considerations 
led to “Human Genome Project” in 1990s which has now been completed 
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successfully and thus are in a position to look ahead and see how this knowledge 
can be helpful in understanding and managing CVD and HT. 
 
 
 
 
1. Facts in relation to Heredity: 
 
 
 
Although a positive family history is widely accepted as an independent 
risk factor for CHD there is little published evidence to support this view. It is also 
observed that a positive family history is not an independent primary risk factor of 
the same magnitude as HT, hyperlipidaemia, DM, obesity or smoking but showed 
that in younger patients the positive family history of premature CHD is 
consistent with an inherited susceptibility to the action of coronary risk factors. 
[335] Asian Indians who have settled overseas and those in urban India have 
increased CHD mortality rates as compared to most other ethnic groups. [336] 
Numerous studies in the last four decades have confirmed this observation. 
[337,338] Reasons for this increased risk are thought to be genetic but are yet 
unclear. 
 
 
 
 
2. Heredity and Blood Pressure: 
 
Activation of the renin angiotensin system (RAS) that regulates 
cardiovascular homeostasis has been proposed a very important step in the 
pathogenesis of HT and atherosclerosis. In the Angiotensin I converting enzyme 
(ACE), the effective molecule of RAS system which convert angiotensin I to 
angiotensin II, a 287bp deletion(D) polymorphism was identified with increased 
ACE level, [339] and as a potential risk factor for myocardial infarction. [340] In 
Indian population, the D allele of the ACE gene conferred no appreciable 
increase in the risk of CHD, MI [341] or in HT. [342] However D allele was 
significantly associated with an early onset of HT rather than late onset of HT and 
although non-significant the D allele form was highest in subjects with family 
history of CHD. [342] 
 
 
 Also Angiotensin II carries out its action through angiotensin II type 
receptor (AGTRI).The AGTRI geneA/C166 polymorphism was very first identified 
by Bonnardeaux et al [343] and was shown to be significantly associated with 
essential HT. Again a strong linkage was demonstrated between the primary 
substrate of this system angiotensinogen (AGT) gene and essential hypertension 
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in Utah and French Caucasians and also associations of  two molecular variants 
in exon 2, M235T and T174M with BP. [344] 
  
Previously the role of apoE polymorphism in causing atherosclerotic 
events have been reported. [345,346] ApoE is an exchangeable protein which acts 
as an ligand for LDL receptors. It also has a repair function in response to tissue 
injury. It plays an essential role in lipid metabolism specially in the removal of 
atherogenic remnants of TG-rich lipoproteins [347] and by reversing cholesterol 
transport in plasma and intercellular lipid transport within tissues. These common 
isoforms of apo E including E2, E3, E4 [348] have been identified. It is well known 
that the E4 isoform is associated with increased levels of TC and β-lipoprotein 
[349] and increased susceptibility to CVD. [350] Some studies have suggested that 
high BP may be associated with the presence of the E4 allele [351,352] while others 
have found its association with E2 allele. [353] Mechanisms of apoE such as 
increased rigidity and decreased elasticity of the aorta and other large vessels 
[354] may contribute to the development of HBP and thus explain the lack of 
association in the elderly subject. 
 
 
There is convincing evidence that the relationship between apo E 
genotype and plasma Lp lipid levels is context dependent being significantly 
influenced by age [355] and sex. [356] Recent evidence [357] also indicated that the 
responses of plasma lipoprotein lipid levels to different lipid lowering 
interventions may be affected by an individual apoE genotype indicating the 
significance of gene environment interactions. These changes in lipid parameter 
indicate a delayed degradation of the administered fatty load. The most 
significant changes were evident in the subgroup of apoE4 carriers reflecting 
their higher fasting lipid levels. This abnormal lipid metabolism is similar in 
character as observed in patients with confirmed IHD and is another 
manifestation of an increased atherogenic risk of HT patients. 
 
 
 Thus significant association of E4 allele is observed with HT in addition to 
other well known risk factors and positive family history. These observations 
emphasize the need to monitor HT and lipid metabolism especially in middle 
aged males and those with a positive family history to reduce the susceptibility to 
CAD. 
 
 
 
3. Heredity and Lipid Metabolism: 
 
 
 
It is pronounced that “In India approximately four people die of heart attack 
every minute because Indians are genetically predisposed to the disease. One 
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of the best understood inborn error of metabolism determining elevated levels of 
plasma cholesterol and LDL-C is the autosomal dominant disorder of familial 
hypercholesterolemia (FH). FH is caused by mutations in the LDL receptor gene 
located on chromosome 19 and containing 18 exons. Though certain isolated 
populations show the presence of common mutations due to founder gene effect, 
[358] there exists mutational heterogeneity in the LDL-R gene with over 800 
mutation identified across the entire length of the gene. No common mutation 
has been yet identified in FH cases from India. [359] A few point mutations, 
however have been reported in Indian families residing in South Africa, which 
suggest a high frequency of FH in the Indian subcontinent. [360] Recently a 
missense mutation in exon 9(E387K) and a polymorphism (C1617T) in exon 11 
in a Gujarati family from Mumbai have been observed. [361] The E387K mutation 
of exon 9 has been previously identified in an Asian Indian of Gujarat origin 
residing in the UK, French and in America. [358] Considering the fact that there 
exist various distinct communities in India which has remained segregated from 
each other for over centuries, due to various religions, cultural or geographical 
reasons, it is likely that there might exist some common community based 
mutations. The E387K mutation identified could be one such mutation among 
Gujarati community in India. 
 
 
 In recent times new markers like the apo E polymorphism (seen above in 
case of BP regulation) have been found associated with CHD and are being 
extensively studied. [347] The apoE4 isoform is associated with increased 
cholesterol level and thus an increased risk of CHD. [362] A small study from the 
Southern parts of rural India in tribal communities suggested that the low 
frequency of the apo E4 allele was a contributing factor for the low prevalence of 
CHD in this community. [363] 
 
 
 Apo C3 (chromosome 11q23), important in the regulation of plasma TG 
concentration is major component of TG rich Lps-CM and VLDL and as minor 
component of HDL. It is a noncompetitive inhibitor of lipoprotein lipase (LPL) and 
thereby plays a role in reducing hydrolysis of TRL. Ito et al [364]  have reported 
that over expression of apo C3 resulted in hyperglyceridemia with positive linear 
relation between apoC3, TG, and reduce HDL-C levels. This action of apo C3 is 
prevented by insulin. [365] Several forms of hypertriglyceridemia in humans 
originate from genetic abnormalities. In human hypertriglyceridemia, the 
composition and particle size of TG rich Lps appears to determine their 
atherogenecity. For e.g., with genetic deficiency of LPL, newly secreted CMs 
accumulate in serum, these CM are large TG enriched Lps. Patients having 
chylomicronemia because of genetic difference of LPL rarely develop CAD, [366] 
presumably CM are not atherogenic. Another disorder, familial 
hypertriglyceridemia is characterized by large TG enriched VLDL. The incidence 
of CAD in patients with familial hypertriglyceridemia likewise appears to be 
relatively low. [367] In yet another condition, familial combined hyperlipidaemia, 
VLDL are smaller and more enriched in cholesterol than in familial 
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hypertriglyceridemia. [367] Finally, patients with familial dysbetalipoproteinemia 
have elevated to β-VLDL, this disorder definitely predisposes to premature CAD. 
[368] Genetic forms of hypertriglyceridemia thus strongly imply that TG rich Lps 
are potentially atherogenic and that atherogenecity of TG rich lipoproteins 
increases Lps become smaller and more enriched in cholesterol. 
 
 
 Faster [369] found significantly shortened platelet survival half life of 89+/-
1.98 hours in patients having symptomatic CAD, when compared with the platelet 
survival half life in the controls (3103+/-2.8 hours). Increased platelet 
consumption at the sites of lesion of coronary atherosclerosis and the same in 
young persons indicates accelerated atherosclerotic process. The normal healthy 
people with strong positive family history of CAD also showed shortened platelet 
survival time which might represent sub clinical disease. 
 
 
 In a study of coronary artery disease among Indians showed that only 
14% of Asian Indian men and 5% of women had optimal HDL-C level. [370] Thus 
decreased HDL-C is one of the common feature observed among Asian Indians. 
Also patients with positive family history of CAD showed raised serum apo B 
levels than those having negative family history. A positive coefficient of 
correlation was observed between serum apo B and LDL levels suggesting that 
more the number of apo B particles more will be the synthesis of atherogenic 
LDL particles. Thus elevated serum apo B levels turn out be a genetic factor 
responsible for causation of CAD. [371] 
 
 
 Recently a condition termed SyndromeX that predisposes Indians to a 
whole repertoire of biochemical bullets blasting the heart is increasingly seen by 
experts as the prime culprit for the alarming rise in heart disease in the country. 
The understanding of its potential for mischief came from a recently concluded 
10 year study of 4500 patients by the Coronary Artery Disease Institute (CADI) in 
Lisle, Illinois, that found the Indian Community had much higher levels of a 
deadly genetic factor called Lp(A) than other ethnic groups. It is 10 times deadlier 
in causing clogged arteries that lead to heart attacks than bad cholesterol LDL. 
[372] 
 
 
 
 
4. Genetic Aspects of CVDs: 
 
 
 
Despite high contribution of factors such as hypercholesterolemia, 
systemic HT, smoking, and diabetes in development of CAD, evidence from 
family studies show that genetic factors also contribute significantly to the 
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predisposition to CAD. Knowledge of genetic risk factors will help define the 
mechanisms of the disease and could ultimately assist in the rational design of 
selective prophylaxis or therapy. Many single genes have been identified as the 
basis for different CVDs. However unlike other genetic disorders, CVDs are not 
solely due to to a single gene mutation/polymorphism. It has a multifunctional 
etiology and is termed as a complex disease caused by variety of genes as well 
as environmental factors. 
 
 
 The major genetic causes for CVDs are (i) chromosomal disorders and 
single gene disorders (8%), (ii) environmental teratogens (2%) and (iii) 
multifactorial disorders, which means both genetic and environmental factors 
interact (90%). Arterial HT, glucose intolerance and mild forms of 
hyperlipoproteinemia are likely to have polygenic inheritability influence and each 
could be solely responsible for most of the observed aggregation of CAD. [373] 
Thus three ways in which a positive family, history might be related to the 
development of CHD are (i) as an index of the inheritance of risk factors 
(elevated BP, serum total cholesterol, smoking, obesity, impaired glucose 
intolerance) which tend to cluster within families, (ii) as a truly independent risk 
factor and (iii)as a vulnerability factor potentiating the action of risk factors. [335] 
Clinical studies have shown that CVDs are associated with strong genetic 
components with difference types of inheritance. [374,375] Apart from possible 
therapeutic developments, once the abnormalities in the gene leading to disease 
in family is identified, it may be possible to assign the risk to the other members 
of the family who have not yet developed the disease or to offer prenatal 
diagnosis. 
 
 
 
 
5. Shared genes in blood relatives: 
 
 
 
It is acknowledged that family history is an important risk factor for CVDs 
and HT. The following is the information to determine whether or not a person is 
at higher risk of CVDs and HT due to genetics i.e. family history or not. 
 
 
? First degree relatives are person’s children, parents or brothers and sisters. 
The subject shares 50% of the genes with these family members. 
 
? Second degree relatives are the subject’s aunt, uncle, grandparents, half 
siblings, nieces and nephews. The subject share 25% of the genes with these 
family members. 
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? Third degree relatives are cousins and great grandparents. They share 12.5% 
genes with these family members. 
 
 
 Obviously, the subject’s risk of genetically linked illness is four times 
higher if that illness is in a first degree family member, as it is in a third degree 
family member as the subject share four times more genes with the first degree 
relative as you do with the third degree relative. 
  
 
Once it is known that a person is at a higher risk to develop an illness on 
basis of his family history, the subject should concentrate on the lifestyle. Genes 
alone don’t explain the sudden spurt in heart disease among the young. The 
answer is lifestyle- smoking, obesity, physical inactivity, high serum cholesterol, 
diabetes. Through genetics or nature genes are present in a subject, but these 
genes are nurtured by unhealthy lifestyle associated with rising affluence, rapid 
urbanization and mechanization. In a nutshell “Genetics load the gun, lifestyle 
pulls the trigger”. 
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V. OVERWEIGHT & OBESITY 
 
 
 
 
Hippocrates wrote “Corpulence is not a disease itself, but the harbinger of 
others”, recognizing that obesity is a medical disorder that also leads to many 
comorbidities. Overweight is associated with a host of adverse health outcomes 
and places severe burden on the world health care system. [376] WHO [377] 
describes obesity as one of the most blatantly visible, yet most neglected, public-
health problems that threatens to overburden both, more and less developed 
countries. The risk increases with increasing adiposity and there is excess 
mortality at any age. The problems of overweight and obesity have achieved 
global recognition only during the past 10 years, in contrast to underweight, 
malnutrition and infectious disease which have always dominated thinking. 
 
 
Excess bodyweight is the sixth most important risk factor contributing to 
the overall burden of disease worldwide. [378] The International Obesity Task 
Force estimates that at present at least 1.1 billion adults are overweight, 
including 312 million who are obese. Also 10% of these are children classified as 
overweight or obese.  
 
 
In males at 18 years of age, approximately 15 to 18% of body weight is 
fat, while in women it is 20 to 25%. This percentage tends to increase with age 
which may not be desirable. Obesity has been defined as a body fat content 
greater than 25% of total body weight for men and more than 30% for women. 
[379] On the otherhand, overweight has been defined as a relative weight greater 
than 120% of what is ideal. Relative weight itself involves dividing a patient’s 
weight by a standard weight that is based on the patient’s height. [380] 
 
 
Risk from overweight and obesity predispose to many disease conditions 
like diabetes, HT, coronary and vascular disease. The importance of overweight 
and obesity in association with CAD has been well known. Obesity at an early 
age is thought to have a greater influence on CVD than late onset obesity. The 
excess body fat associated with obesity is considered a risk factor for many 
chronic diseases and predisposes to premature CVD. Even in healthy young 
people who are obese, some degree of myocardial dysfunction has been 
demonstrated echocardiographically which tends to be reversible with weight 
loss. [381]  
 
 
A recent report described associations between overweight and obesity 
and the prevalence of chronic conditions including high BP and high blood 
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cholesterol levels in National Health and Nutrition Examination Surveys 
(NHANES) III data. [382] Additional association of adiposity at baseline and 
incidence of HT and Dyslipidaemia have been shown in men and women and in 
diverse race or ethnic groups in large prospective cohort studies. [383-386] Also 
clinical trials have shown the effect of weight loss on lowering BPs and lowering 
lipid values. [158,387,388] The science base for concluding that higher levels of body 
mass are causally related to higher levels of BP and total cholesterol and lower 
levels of HDL-C is substantial and convincing. 
 
 
It has been suggested that central, particularly visceral fat is a more 
important contributor to cardiovascular risk than total body fat. Also it has 
become obvious that metabolic complications of obesity are associated with 
upper body segment or abdominal obesity. [389] Increase risk of CVD has been 
found in individuals presenting with distribution of excess fat in the abdominal 
region. [390] 
 
 
Several factors seem to participate in the pathogenesis of obesity and 
atherosclerosis viz: excess intake of dietary calories, over and above the daily 
requirement (most important factor in the development of obesity), sedentary 
lifestyle, addiction like smoking, heavy alcoholism and increased mental stress in 
day-to-day life. Inspite of continued upliftment in health consciousness, there is 
an upsurge in the incidence of CAD (the most devastating slow global pandemic) 
and obesity. [391]  Primordial and secondary preventive measures like restriction 
of dietary calories and SFAs, [392] adoption of vegetarian diet, relaxation exercise 
etc has failed to prevent the increase to an appreciable extent. Thus the 
prevalence of overweight and obesity is increasing and obesity is now estimated 
to be the second leading cause of preventable death after cigarette smoking in 
the US. [393,394] Therefore obesity, with its array of comorbidities, necessitates 
careful clinical assessment to identify underlying factors and to allow coherent 
management. 
 
 
 
1. Determining Obesity: 
 
 
 
Criteria for identifying an individual as overweight or obese are now 
available through a number of techniques, yet anthropometry is the simplest and 
most practical technique. Among them body mass index (BMI), as a measure of 
obesity is proved useful and easily applicable clinically to give a reasonable 
estimation of adiposity and is also claimed to represent the degree of body fat 
content. BMI is a relative weight index that shows highest correlation with 
independent measures of body fat. It is one of the most accurate ways to 
determine when extra pounds translate into health risks. It is also a measure 
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which takes into account a person’s weight and height to gauge total body fat in 
adults. BMI is calculated by dividing the weight in kilograms by the square of 
height in metres. (kg/m2) 
 
 
A recent review supports the use of BMI in clinical practice to define 
overweight and obesity. [387] WHO now accepts a BMI of 25 kg/m2 or higher as 
abnormal; the overweight category is classified as obese when the BMI is 30 
kg/m2 or more. The risks of diabetes, HT and dyslipidaemia increase from a BMI 
of about 21 kg/m2, thereby reducing life expectancy and greatly increasing the 
health and societal economic burden. [395] The standard criteria used to define 
obesity in the western literature is a BMI greater than 27.8 for men and greater 
than 27.3 for women. [393] But the distribution of BMI in the western population 
differs considerably from that of Indians. [396] Thus the desirable upper limit of 
BMI in Indian population is <23. [392] 
 
 
Someone with a BMI of 26 to 27 is about 20% overweight, which is 
generally believed to carry moderate health risks. The higher the BMI, the greater 
the risk of developing additional health problems. There are numerous reports 
suggesting that BMI values greater than 2.6 for women are associated with 
increased risk of fatal and non-fatal CHD, NIDDM and a rise in all cause mortality 
rates. [384,397] Other studies also show that BMI and the pattern of body fat 
distribution affect morbidity and mortality from CVD. [398,399] MI, sudden death and 
coronary insufficiency are all associated with a high BMI. [400] 
 
 
Measures of regional adiposity such as waist circumference (WC), hip 
circumference (HC), waist-hip ratio (WHR) and subscapular to triceps skin fold 
thickness correlate highly with other measures of overweight such as BMI and 
may be even more strongly correlated with lipoprotein cholesterol fractions. [401] 
Central adiposity is a predictor of CVD independently of major risk factors, 
including BMI. [402] Part of the relationship between central adiposity and CVD is 
mediated by a modification of the metabolism of insulin and lipids. [403] 
Dyslipidaemic individuals are more frequently “centrally obese”. (E.g. with a high 
WHR) [404] These observations have been made in a variety of populations from 
developed [405,406] and less developed countries. [406]  
 
 
The WHR has been found to be of value in identifying people with 
abnormal distribution of body fat and it is now believed that excessive body fat 
around the abdomen in contrast to that around the hip would be a clinical as well 
as epidemiological marker in predisposing, towards CAD. [398] WHR ≥0.9 for men 
and WHR ≥0.8 for women are coded as high WHR by gender. [407] BMI and WHR 
are routinely employed because they are directly related to clinical entities (i.e. 
peripheral overweight, central obesity, etc.) High BMI [386] and high WHR [408] are 
associated with higher incidence of CAD. 
                              
 83
WC reflects the proportion of body fat located intra-abdominally and is the 
best indicator of changes in Intra-abdominal fat (IAF) during weight loss. [409] The 
WC relates closely to BMI and is also the dominant measure in the WHR. 
Studies by Pouliot et al [410] suggest that WC is superior to WHR in providing 
assessment of abdominal obesity and related metabolic complications. Optimum 
WCs are lower for Asians: 90cm for men and 80 cm for women, [411] compared 
with 102cm and 88cm suggested for white people. [377] Individuals, who fall into 
the BMI range of 25 to 34.9 and have a waist size of over 40 inch for men and 35 
inch for women, are considered to be at especially high risk for health problems. 
Both BMI and WC can be useful measures of determining obesity and increased 
risk for various diseases. According to the National Institutes of Health, a high 
WC is associated with an increased risk for type 2 diabetes, dyslipidaemia, HT 
and CVD when BMI is between 25 and 34.9. 
 
 
Thus these predictive associations suggest the possibility of employing 1 
or more anthropometric measurements of central obesity as a first step in 
population screening for dyslipidaemia. [405,406] Using inexpensive and readily 
obtainable anthropometric measurements instead of more costly and time-
consuming wet-or even dry-chemistry laboratory cholesterol measurements is 
relevant in developing countries where an emerging epidemic of CVD is 
occurring amidst rising health care costs. 
 
 
 
 
2. Disease burden from excess weight in adults: 
 
 
 
 The prevalence of the high BMI according to age, and the proportion of 
the disease burden attributable to the excess weight are shown in the detailed 
estimates of the years of ill health and lives lost between the ages of 30 years 
and 75 years because of excess weight.  [395] CVD dominates, followed by 
diabetes, HT and some cancers, especially in women. Again, the burden of 
disease is high in Eastern Europe and Latin America, but the Asian countries 
have a surprisingly high burden in view of their lower obesity rates. This finding 
relates to the higher absolute risk of diabetes and probably CVD among Asian, 
[395] Hispanic, [412] and perhaps African populations, partly because they are more 
prone to abdominal obesity with its excess risks. 
 
 
Many of the comorbidities of obesity are reflected in the so-called 
metabolic syndrome, originally defined arbitrarily by WHO on the basis of insulin 
resistance with other features of obesity: [413] large WC, abnormal concentrations 
of TGs, HDL-C and fasting glucose and HT. The effects of obesity on 
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cardiovascular health and disease are many, one of the most profound of which 
is HT. 
 
 
 
 
3. Obesity and Hypertension: 
 
 
 
The risk of HT is up to 5 times higher among obese people than among those 
of normal weight, [414] the variability in response reflecting differential genetic 
susceptibility as well as dietary factors. Up to two-third of cases of HT are linked 
to excess weight, [415] and cross-sectional population surveys [416] suggest that 
more than 85% of HT arises in individuals with BMI values above 25kg/m2. 
 
 
In INTERSALT, an International study of electrolytes and BP, BMI was used 
to evaluate association with BP, [417] since BMI is highly correlated with weight or 
body fat while being independent of height [418] and was found to relate 
independently to BP. [419] Results from some studies on BP also suggest that 
BMI and other weight for height indices have stronger association with BP than 
does either weight alone or skinfold measurements. [420,421] Also in another study, 
when weight, directly adjusted for height was analyzed, it continued to be 
strongly related to systolic and diastolic pressures as was BMI. [419] The 
difference in systolic pressure associated with a 10 kg difference in weight was 
about 3.0 mm Hg. For DBP the difference in BP associated with a 10 kg 
difference in weight varied from 2.0 mmHg in women aged 40-59 years to 2.7 
mm Hg in men aged 20-39 years. [419] All the three measure of anthropometry i.e. 
BMI, WC, HC showed positive correlation with DBP while HC showed positive 
correlation with systolic as well as DBP. [423] Rabkin et al [424] also showed 
agreement with the above reports on the correlation of BP and the measures of 
anthropometry. 
 
 
Although different population studies have suggested HT to be directly 
attributed to obesity, the precise mechanism is not fully understood. 
Contemporary thinking concerning the link between obesity and subsequent 
renal failure has evolved from repeated observations of the relationship between 
body weight and BP. It is well documented that BP increases with weight gain 
and decreases with weight loss. In addition, there is increasing evidence that 
obesity may provide the impetus for sympathetic nervous system activation as 
well as for changes in renal structure and function. There is considerable 
evidence that renal dysfunction, characterized by increased tubular Na 
reabsorption and resetting of pressure natriuresis plays a key role in increasing 
BP in obese subjects. The increased tubular pressure reabsorbtion is closely 
related to the sympathetic nervous and renal angiotensin systems as are 
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structural changes that cause compression of the renal medulla. Renal 
vasodilation, glomerular hyperfilteration and increased arterial pressure are 
compensations that help overcome increased renal tabular reabsorbtion and 
maintain sodium balance in obesity. This also leads to increased glomerular 
capillary wall stress, which along with activation of the neurohumoral systems, 
increased lipids, and glucose intolerance, eventually causes glomerulosclerosis 
and loss of nephron function in obese subjects. [425] 
 
 
The increase in BP with excess weight gain arises partly because of the 
release from adipocytes of angiotensinogen (a precursor of angiotensin that has 
well known effects on BP), an increase in blood volume associated with the 
greater body mass and in response to a rise in blood viscosity. The change in 
blood viscosity is induced by the release of profibrinogen and plasminogen 
activator inhibitor-1 from adipocytes with a fall in plasminogen activator. [426] 
 
 
Diets conducive to weight gain independently amplify BP. Dietary fats, 
especially SFs; induce a rise in SBP and DBP as well as hypercholesterolemia, 
as shown in the Dietary Approaches to Stop HT (DASH) trials. [219] Energy dense 
diets rich in fats and refined sugars promote weight gain [427] and high sugar 
intakes also induces increases in BP of 6.9mm Hg (systolic) and 5.3 mmHg 
(diastolic). [428] Energy density is reduced by higher intake of fruit and veg, which 
the DASH trial also showed lowered BP. 
 
 
 
 
4. Obesity and Dyslipidaemia: 
 
 
 
Obesity has a strong effect on lipid metabolism, regardless of ethnic group. 
Dyslipidaemia progressively develops as BMI increases from 21 kg/m2 with a rise 
in proatheromatous, dense small particle sized LDL. Increased weight is a 
determinant of higher level of TGs, elevated LDL-C and low HDL-C. [429] This 
change increases the risk of CHD by 3-6 times. 
 
 
Hoffman et al [398] have reported a positive correlation of TC and TG with BMI. 
The association between obesity and LDL-C is more complex. LDL-C increases 
with BMI in men, but such increases are not as pronounced in women, the 
elderly and some ethnic groups. Increasing body mass is associated with small 
atherogenic LDL. Furthermore, central obesity in women is associated with 
elevated LDL-C conc. [425] 
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A negative correlation exists between HDL-C and BMI. [430] In the 
Framingham study [431] a clear correlation between BMI and lower HDL-C was 
shown with 25% men and  7% women with BMI > 30 having HDL-C < 35 mg/dl. 
A meta-analysis examining the effect of weight loss on HDL-C levels 
demonstrated that the levels increased by 0.35 mg/dl per kg of weight reduction 
in subjects who achieved a stabilized, reduced weight but increased by 0.27 
mg/dl in subjects during active weight loss. [158] In subjects who maintained a 
stable diet for six weeks after weight loss, HDL-C levels, LPL levels and LCAT 
activity increased, these increases may contribute to enhanced cholesterol 
esterification and reverse cholesterol transport. [432] 
 
 
Rabkin et al [426] in his study, has also observed a significant negative 
correlation between BMI and HDL-C in men and women aged 18-74 years. In 
another meta-analysis of 70 studies, the effect of weight loss on dieting showed a 
consistent linear association between weight loss and HDL-C, with an HDL-C 
increase of 2 mg/dl and LDL-C decrease of 4 mg/dl for every 4.5 kg weight loss 
maintained. [158] 
 
 
Left ventricular hypertrophy occurs in 70% of women with both obesity and 
HT and around 14% of cases of heart failure in women (11% in men) are 
attributable to obesity. [433] The effect of obesity on heart function is probably due 
to a combination of factors including HT, dyslipidemia, DM, increased fatness 
and left ventricular mass, endothelial dysfunction and atherosclerosis. Extensive 
Cochrane analysis [434] suggest that a weight loss of 10 kg will induce a reduction 
in TC concentration of about 0.25 mmol/L. These epidemiological inferences are 
paralleled by intervention studies, which have shown that weight loss improves 
the lipid profile as well as HT. 
 
 
 
5. Management of Obese  Patient: 
 
 
Various measures are used to grossly estimate the degree of obesity in large 
scale epidemioiological setting, including body weight, BMI, WC and the waist-to-
hip ratio. It is essential that valid and reliable measures of dietary intake be used 
in studies aimed at determining the links between dietary intake and obesity. 
Another factor to consider is diet composition. The recommendations for dietary 
intake for the prevention of CVD may require modification. 
 
 
Obesity is the normal physiological response to an environment in which 
energy intake exceeds energy output. It is an adaptive mechanism. Major 
environmental changes that support this adaptive mechanism are the greater 
                              
 87
availability of foods and the increase in sedentary lifestyle. Also obesity can 
develop when an imbalance exists between energy intake and energy 
expenditure. In the context of a 3000- calorie diet, typical energy expenditure can 
be anywhere from 450 to 1500 calories. There is little evidence that “defective” 
energy expenditure exists. Efforts to increase energy expenditure by increasing 
physical activity are considered an important treatment for obesity. Diet and 
exercise strategies provide relatively equal amount of weight loss in 
premenopausal and postmenopausal women. In men, this combination is also a 
very effective means of achieving weight loss. 
 
 
a) Physical inactivity: 
 
 Many studies have shown the relation between sedentary lifestyle and 
weight gain, but reliable direct measures of physical activity are only just 
emerging. [435]  Nevertheless, the secular decline in physical activity is obvious. 
Morris and colleagues showed more than 50 years ago [436] that vigorous 
exercise was crucial to cardiovascular health, but highly sedentary adults now 
derive benefit from even slight exertion. [437] Exercise has many benefits, from 
psychosocial to physical, independent of its contribution to weight stability. A 
report by the US Surgeon General on physical activity and health highlighted the 
significant health benefits which are associated with regular physical activity. [438] 
They include: 
 
1) lowered all cause mortality 
2) decreased risk of CVD mortality 
3) prevention or delayed development of HT 
4) reduced BP in those with HT 
5) decreased risk of colon cancer 
6) decreased risk of developing non-insulin dependent diabetes; and 
7) relief from symptoms of depression and anxiety. 
 
 
Regular aerobic exercise increases the HDL-C level by 3 to 9% in healthy 
sedentary persons [439] by stimulating the production of pre-β HDL-C and reverse 
cholesterol transport. [440] There is a dose response relationship between aerobic 
exercise (running) and HDL-C levels in middle aged men with a HDL-C increase 
of 0.2 mg/dl and LDL-C reduction of 0.1 mg/dl for every kilometre run per week. 
[441] Also regular exercise yields greater increases in HDL in men with low HDL-C 
levels, elevated TG levels and abdominal obesity than in those with isolated low 
HDL-C levels. [442]  Moderate exercise is also associated with reduction in TC, 
LDL-C and TG levels. [443] 
 
However, the recent emphasis on weight maintenance has highlighted the 
importance of total energy output - 60-90 minutes per day of walking, [444] 10,000 
steps monitored on a pedometer, or 15,000 steps in individuals attempting to 
maintain weight loss. Physical activity is helpful in weight loss, and essential for 
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limiting the progressive decline in lean tissues with age, but its main importance 
in body weight is in maintaining rather than increasing a 5-10% weight loss. In 
addition to the benefits of a lower weight, physically active obese subjects are at 
a lower risk of all cause and cardiovascular mortality compared to the sedentary 
obese independent of changes in weight. 
 
 
 
b) Dietary Management: 
 
 
 National studies of BMI of different groups [445] show that intake is now the 
dominant determinant with lower physical activity following, rather than 
preceding, weight gain in some cases. [446] Thus a decline in activity was 
probably a particular feature of the 1960s and 1980s, but the transformation of 
our food habits, industry competition is now the main amplifier of the epidemic. 
[447] 
 
 
Dietary quality is important; [448] about 20% proteins restrict the recognized 
inevitable loss of about 25% lean tissue that accompanies fat loss and helps in 
satiety. Dietary benefits are amplified by daily intake of 400-600 gm vegetable 
and fruits, with less than 20% fat; adequate n-3 fatty acids but the lowest 
possible amount of SFAs, less than 5% sugar and fiber-rich carbohydrates; such 
diets also have lower energy density and greater bulk, which further improves 
satiety. Explicit guidance on transferring to a low energy-density diet can double 
the quantity of food eaten and still achieve the energy deficits needed. 
 
 
Lately, very strict diets such as the low-carbohydrate Atkins diet have 
become popular. They have been shown to have good effects on blood lipid 
concentration, BP and glucose control. These effects are, however generally 
short lived and not superior to standard approaches over the longer term. [449] 
The degree of weight loss strongly depends on the ability of patient to adhere to 
their diets, [450] and the more restricted the regimen the greater the demand for 
intense discipline in the face of an intense physiological desire to eat. 
 
 
 The increasing epidemic of obesity in the world has stimulated interest in 
identifying or predicting individuals who are at greatest health risk at an early 
age. [451] This is particularly important to allow early implementation of preventive 
strategies. The scientific community has not yet reached consensus on viable 
ways to approach the problems associated with obesity. However, several lines 
of attack are being investigated. Because of the complexity of the obesity 
problem, a multifactorial approach will undoubtedly be required. 
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AIMS & OBJECTIVES: 
 
 
 
1) To study the effect of Age and Sex on BP, Serum lipids and 
Anthropometric Indices in normal healthy individuals. 
 
 
2) To explore the effect of Age and Sex on BP, Serum Lipids and 
Anthropometric Indices in hypertensive patients. 
 
 
3) To evaluate the Levels of  Serum Lipids and Anthropometric Indices with 
regard to levels of Hypertension 
 
 
4) To examine the effect of Diet on BP, Serum Lipids and Anthropometric 
Indices. 
 
 
5) To analyze the effect of Tobacco Consumption on BP, Serum Lipids and 
Anthropometric Indices. 
 
 
6) To scrutinize the effect of Heredity on BP, Serum Lipids and 
Anthropometric Indices. 
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    METHODOLOGY 
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? Study Population: 
 
 
 
The present study was conducted at Department of Biochemistry, M.P 
Shah Medical College, Jamnagar, Gujarat. The study population included 
subjects from Jamnagar with varied lifestyle based on their occupation. A 
total of 1146 person (593 women and 553 men) participated in the study. 
Individuals’ ≥ 30 years of age were included in the study. Random 
subjects free of not only HT but any disease and also who were not on 
any particular medication were included in the study as controls. The 
control group consisted of 400 healthy people (217 women and 183 men) 
between the age group of 30 to 80 years. 
 
 
 In the patient group, first time detected untreated hypertensive 
subjects of 30-80 years of age and a total of 746 (376 women and 370 
men) individuals were enrolled. HT was considered to be present if the 
SBP ≥ 140 mm Hg or the DBP ≥ 90 mm Hg [2] 
 
 
 Control and patient volunteers were interviewed according to a 
specifically designed questionnaire and were thereby noted in the record 
forms itself which is illustrated on the next page. 
 
 
 
 
? Methods: 
 
 
 
 ● Blood Pressure Measurement: 
 
 
 The BP was measured by a doctor using a mercury column 
sphygmomanometer by a standardized protocol in the sitting posture, with 
feet on the floor and arm supported at heart level. Following the 
standardized technique, the doctor made two separate measurements 
after making the patient take proper rest. In some cases, where high BP 
was recorded for the first time, the physicians checked the BP more than 
twice and took the average of the two close readings. 
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QUESTIONNAIRE 
 
Name of the Patient:- 
 
Address:- 
 
Age: -                                                                     Sex:- 
 
Occupation:- 
 
Family Income:- 
 
Members of the family: 
0-5 yrs _______                   5-10 yrs _______                     > 10 yrs______ 
 
BP: - Systolic: _______ mm Hg                           Diastolic: _______ mm Hg 
 
Weight: _______ (kg)          Height: ______ (m)          BMI ______kg/m2 
Waist:  ________ (cm)             Hip: ______ (cm)        WHR _____   
   
Whether diagnosed for any disease? If yes state: 
 
Family History:- 
 
DM HT Heart attack Paralysis 
    
 
Tobacco Consumption: - Y/N 
 
Smoking – No of Cigarettes/ Bidi per day: 
Chewing – Tobacco/ Gutkha per day: 
Pan with Tobacco per day: 
 
Dietary Intake:  
Cereals Pulses Sugar/Gur Oil/Ghee Milk Veg/Pot Fruits Non 
Veg. 
        
 
Physical activity: Sedentary / Mild / Moderate / Severe 
 
 
 
                              
 94
●   Anthropometric Measurements: 
 
 
 The height was measured barefoot with head in horizontal plane to 
the nearest 0.1 cm using a graduated tape attached to the wall. The 
weight was measured in light clothes using a weighing machine. BMI 
(weight in kg/ height in m2) was calculated. The waist and hip 
circumference was measured to the nearest 0.5 cm in the subjects 
standing barefoot and wearing light clothes. The waist circumference was 
measured at the level of the umbilicus and the hip at the level of the 
greater trochanter using a non-stretchable measuring tape. WHR was 
calculated from the above data. 
 
 
 
 
●   Nutritional Assessment: 
 
 
 The amount of an individuals daily food intake in relation to the 
cereals, pulses, sugars, oil, milk, vegetable, fruits, non veg, etc. were 
noted in the questionnaire. Through this information, an individual’s daily 
calorie and fat intake were calculated using the “Nutritive value of Indian 
foods” given by the Indian Council of Medical Research. [452] 
 
 
 
 
●   Collection of Samples: 
 
 
 5 ml of venous blood was withdrawn after an overnight fast of 12 
hrs and was allowed to clot for 25-30 minutes for proper serum extraction 
after centrifuging for 5 minutes. This serum was used to estimate the 
parameters within two hour of sample collection. 
 
 
 
●   Biochemical Markers: 
 
 
                The following biochemical markers were determined: 1) TC 
2) TG       3) HDL-C using “Accucare” manual kit. 
 
                              
 95
1. Total Cholesterol (TC): Allain et al [453] 
 
 
Principle: Cholesterol esterase hydrolyses cholesterol esters into free 
cholesterol and fatty acids. In the second reaction cholesterol oxidase 
converts cholesterol to cholest-4-en-3-one and hydrogen peroxide. In 
presence of peroxidase, hydrogen peroxide oxidatively couples with 4-
aminoantipyrine and phenol to produce red quinoneimine dye which has 
absorbance maximum at 510 nm. The intensity of the red colour is 
proportional to the amount of total cholesterol in the specimen. 
 
 
 
2. Triglyceride (TG): 
 
 
Principle: Glycerol released from hydrolysis of triglycerides by lipoprotein 
lipase is converted by glycerol kinase into glycerol-3-phosphate which is 
oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate 
and hydrogen peroxide. In presence of peroxidase, hydrogen peroxide 
oxidizes phenolic chromogen to a red coloured compound. 
 
 
 
3. High Density Lipoprotein Cholesterol (HDL-C): Burnstein 
et al [454] 
 
 
Principle: Phosphotungstate/Mg2+ precipitates chylomicrons, LDL and 
VLDL fractions. HDL fraction remains unaffected in supernatant. 
Cholesterol content of HDL fraction is assayed using the above stated 
principle of cholesterol. 
 
 
 
 
LDL-C concentration was calculated using Friedwalds and 
Fredricksons formula [216] which assumed that VLDL-C is present in a 
concentration equal to 1/5 of the TG concentration. Thus 
 
 
LDL-C = TC   -      TG   +   HDL-C 
           5
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? Statistical Analysis: 
 
 
 
                 Mean, standard deviation and standard error were calculated. 
Students ‘t’ test was applied. ‘p’ values were calculated to assess 
significance of the results. 
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RESULTS 
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1. Effect of Age on BP, Serum Lipids and 
Anthropometric indices in Normotensive subjects: 
 
 
 
     Systolic and diastolic blood pressures were 117.05/74.33 & 
119.22/78.58 in normal healthy male individuals and 116.23/72.60 & 
117.65/75.41 in normal healthy female individuals in the age groups 30-50 
and 51-80 years respectively. The BP increased with age in both sexes and 
this rise was extremely significant in DBP (P<0.001) while SBP showed a 
minor significance (P<0.05). Moreover in all age groups females were having 
lower SBP and DBP than those of males of corresponding age groups. The 
difference in SBP between the gender in the age group 51-80 was found to 
be highly significant (P<0.01) whereas DBP exhibited massive significance 
(P<0.001) in both the age groups.  
 
 
       Total Cholesterol concentrations were 176.0 & 186.5 mg/dl for males 
and 171.8 & 179.4 mg/dl for females in respective age groups. In male and 
female subjects, TC increased with age and this increase was tremendously 
significant (P<0.001). Both the age groups 30-50 and 51-80 years showed a 
difference in TC concentration between the genders and this difference was 
greatly significant (P<0.01).   
  
 
       The genderwise triglyceride concentrations in the aforesaid two age 
groups were 116.5 & 125.1 mg/dl for males and 93.9 & 97.6 mg/dl for females 
respectively. Even though an increase in TG concentration was seen with 
age, this rise remained insignificant in both the genders. The TG 
concentration of females in both the age groups were significantly (P<0.001) 
lower than those of the males in the respective age groups. 
 
 
       HDL-C concentration was 46.5 & 50.0 mg/dl for females whereas 
males illustrated a similar concentration in both the age groups (41.6 mg/dl). 
Thus an increase with age in the females were observed which was 
immensely significant (P<0.01). Moreover in both the age groups females 
were having higher HDL-C concentration than those of males of 
corresponding age groups and this difference was particularly significant 
(P<0.001). 
 
 
       LDL-C concentrations demonstrated an increase with age in both the 
gender with mean value being 111.2 &119.8 mg/dl in males and 106.5 &109.9 
in females respectively. In males this increase was found to be very 
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significant (P<0.01). In each age group the difference according to gender in 
LDL-C concentration was also somewhat significant (P<0.05).   
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Graph 1: Effect of age on BP, Serum Lipids and Anthropometric 
Indices in Normotensive cases:  
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       VLDL-C concentration exhibited an increase with advancement of age 
but with no significance in either of the gender, whereas the difference in the 
VLDL-C concentration according to gender in each age group was found to 
be enormously significant (P<0.001). 
 
 
       The atherogenic ratios TC/HDL-C & LDL-C/HDL-C demonstrated a 
similar trend of increase with age in only males with a significance of P<0.05, 
while the difference according to gender was found to be exceedingly 
significant (P<0.001) in both the corresponding age groups. Genderwise the 
mean values of TC/HDL-C & LDL-C/HDL-C were 4.5, 4.86, 2.9 & 3.18 in 
males and 3.88, 3.77, 2.45 & 2.35 in females respectively.  
 
 
       Among anthropometric indices the values of BMI were 25.07 & 24.19 
in males and 25.39 & 24.54 in females respectively. As can be observed a 
decrease with age is obvious but vague significance was seen in females 
only (P<0.05). Also the difference between the genders in each group was 
not found to be significant. WHR exhibited values like 0.93 & 0.95 in males 
and 0.82 & 0.83 in females. Here increase with age was observed and this 
rise was found to be slightly significant (P<0.05). Also the difference 
according to gender in WHR was seen to be extremely significant (P<0.001) 
in each of the age groups. 
 
 
 
 
2. Effect of Age on BP, Serum Lipids and 
Anthropometric indices in Hypertensive subjects: 
 
 
 
  In hypertensives, the SBP & DBP showed a specific pattern as 
observed for normal healthy individuals (Table 3). The SBPs & DBPs in 
hypertensive patients were 144.2/91.67 & 151.96/94.1 mmHg for males and 
142.22/89.93 & 149.36/92 mmHg for females in the age groups 30-50 and 51-
80 years in both genders respectively. In each age group female patients 
showed remarkably significant (P<0.001) lower BP values than the 
corresponding values of male hypertensive subjects. Also an increase with 
age was observed in both the genders and this rise was found to be incredibly 
significant (P<0.001). Moreover the BP values of the hypertensive subjects of 
both genders in both the age groups were much higher than those seen in 
control groups and were enormously significant (P<0.001).  
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  Total cholesterol values for male hypertensives subjects were 
236.7 & 245.6 mg/dl whereas for female hypertensive subjects the values 
were 230.7 & 238.2 mg/dl for the age groups 30-50 & 51-80 years 
respectively. Serum cholesterol concentration of male hypertensives was 
higher than those of female hypertensive in all age groups and this increase 
was outstandingly significant (P<0.001). Also the TC conc increased agewise 
in both sexes which were found to be exceedingly significant too (P<0.001). 
Moreover in both sexes, TC when compared with control group showed 
exceptionally significant difference (P<0.001), as hypertensives had higher 
cholesterol concentration in both the age groups.  
 
 
           A pattern analogous to the control group was seen in hypertensive 
patients also when TG conc were observed. TG conc values were 192.6 & 
207.4 for males and 160.3 & 170.9 for females respectively. There seemed to 
be a greatly significant (P<0.01) increase with age in both the genders and 
also the difference between the genders in both the age groups were 
incredibly significant (P<0.001). Male and female hypertensive volunteers in 
the age groups 30-50 & 51-80 years had higher TG conc than their normal 
counterparts in the respective age groups as shown in Table 3. This 
difference was tremendously significant (P<0.001). 
 
 
           The two age groups 30-50 & 51-80 years showed HDL-C conc 
38.75 & 39.48 mg/dl for males and 42.7 & 44.1 mg/dl for female hypertensive 
subjects respectively. All male hypertensive subjects had less HDL-C 
concentration than those of female hypertensive subjects and this difference 
in HDL-C concentration between two genders were exceedingly significant 
(P<0.001). Even though HDL-C concentration increased agewise in both 
genders, the trend was insignificant. The hypertensive patients of both 
genders had much lower HDL-C concentration than those of healthy 
individuals in both genders and their age groups. This decrease was found to 
be enormously significant (P<0.001). 
 
 
       LDL-C concentration in both male and female hypertensive 
subjects demonstrated an increase with age but among them only males 
exhibited any significance (P<0.01). In each age group females were having 
lower LDL-C than their male counterparts but the difference between the two 
genders were insignificant. Male and female hypertensive volunteers were 
also having higher LDL-C concentration than those found in normal healthy 
individuals in each age groups and their difference was incredibly significant 
(P<0.001).   
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       VLDL-C concentration of hypertensive subjects in both genders 
were in the same lines as hose of TGs. In both the genders, VLDL-C 
increased with the advancement of age and this rise was highly significant 
(P<0.01). Females in both age groups showed lower VLDL-C than their male 
counterparts and this difference was exceedingly significant (P<0.001). VLDL-
C of hypertensives in both sexes was higher as compared to the healthy 
individuals of both gender and it was remarkably significant (P<0.001).  
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The atherogenic ratio TC/HDL-C in hypertensives was above 4.5 and it 
was considered as a potent risk factor for CHD and atherosclerosis. In both 
genders TC/HDL-C values did not differ much with advancement of age and thus 
remained insignificant while the difference between genders in both age groups 
was outstandingly significant (P<0.001). All normal healthy individuals of both 
genders had TC/HDL-C values less than 4.5 and these differences in genders for 
both age groups were exceptionally significant (P<0.001). 
 
LDL-C/HDL-C ratio of hypertensives in both the genders showed a 
similar trend just like TC/HDL-C wherein no significance was observed with 
advancement of age while females displayed lower values than males and this 
difference observed in each age group was tremendously significant (P<0.001). 
Unlike healthy individuals these hypertensive patients had the ratio greater than 
3.0 which is also an important risk factor.  
 
Among the anthropometric indices BMI showed values greater than 
25kg/m2 in both genders of the two age groups in hypertensive patients. An 
extremely significant (P<0.001) decrease with age was identified in both the 
genders while the female hypertensives demonstrated a higher BMI than the 
males of the corresponding age group. This difference between the genders was 
also exceedingly significant (P<0.001). Also the difference observed between 
hypertensive and normotensive subjects was enormously significant (P<0.001).   
 
WHR also an anthropometric index did not show any significance with 
advancement of age in both the genders and female hypertensive subjects 
exhibited a lower ratio than males of corresponding age groups. This difference 
between the genders was remarkably significant (P<0.001). Apart from this the 
values of WHR of hypertensive patients were much higher than those observed 
in normotensive individuals and this rise was tremendously significant (P<0.001).  
 
 
 
 
3. Levels of Serum Lipids and Anthropometric indices 
with regard to Levels of HT: 
 
 
Hypertensive volunteers were regrouped according to the levels of  
hypertension into three subgroups viz prehypertension (80-89 mmHg), Stage-I 
(90-99 mm Hg) and Stage-II ( ≥ 100 mmHg) based on the two age groups as 
referred in the above instances (30-50 & 51-80 years) to study the effect of HT 
on serum lipids and anthropometric indices. As DBP in hypertensive subjects 
increased from prehypertension (80-89 mmHg) to Stage-II HT ( ≥ 100 mmHg), 
the SBP also increased from 132.49 to 164.4 mmHg in males and from 130.89 to 
162.3 mmHg in females respectively. DBP and SBP in females were lower than 
those of males of corresponding hypertensive groups. But these differences 
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according to the gender were insignificant except in the DBP of Stage-I and 
Stage-II hypertensive subjects. 
 
 
TC conc also increased with increase in DBP in hypertensive subjects. The 
TC conc in PreHT, Stage-I and Stage-II levels of 30-50 age group were 240.6, 
245.5 & 249.2 mg/dl and of 51-80 age group the values were 249.9, 250.4 & 
251.2 mg/dl. Thus increase with age in TC was observed in the corresponding 
hypertensive groups but it remained insignificant except in the PreHT level. In 
females also TC concentration increased from 230.5 mg/dl in preHT level to 
237.7 mg/dl in stage-II hypertensive group of 30-50 age group and in 51-80 age 
group it increased from 238.4 in preHT to 241.9 in stage-II HT group. Here also 
increase in TC concentration with the increase in DBP was outstandingly 
significant (P<0.001) in only preHT & control group in both the genders. In each 
levels of HT female TC concentration was less than that in male HT volunteers 
and this difference was vastly significant (P<0.01). 
 
 
The TG concentration in preHT, Stage-I and Stage-II HT increased 
but insignificantly with increase in BPs in both sexes. TG concentration were 
200.4, 172.1 & 208.1 in 30-50 years males while it was 213.5, 191.6 & 185.4 in 
51-80 years males respectively. The same in females were 159.8, 161.4 & 154.1 
in 30-50 age group and 177.9. 171.3 & 152.9 in 51-80 years age group. Thus an 
increase with age is observed but with no significance in both the genders. Also 
the female TG concentration was less than that in male HT volunteers and this 
difference were extremely significant (P<0.001). These conc were higher than 
those seen in normotensive males and females and the difference between 
control and preHT TG concentration is found to be incredibly significant 
(P<0.001). 
 
 
 HDL-C concentration were 41.6, 41.2, 39.07 & 37.1 in 30-50 years males 
and 41.6, 40.0, 37.0 & 40.4 in 51-80 years males while the same in females were 
46.5, 49.2, 35.6 & 39.4 in 30-50 years and 50.0, 44.4, 38.6 & 41.6 in 51-80 years 
of the control group and the various levels of HT respectively. The decrease in 
HDL-C concentration from control group to stage-I and an increase in the 
concentration from stage-I to stage-II was a little significant in females (P<0.05) 
but in male hypertensives this variation in the levels was insignificant in 51-80 
years when preHT to stage-I and stage-I to stage-II were compared. With 
advancement of age each level of HT showed a decrease in HDL-C 
concentration in male hypertensives whereas in females a significant increase 
(P<0.05) with age was observed. Also in each levels of HT female HDL-C 
concentration was more than that in male hypertensive subjects and this 
difference was somewhat significant (P<0.05) except in stage-II HT level. All 
male and female (except 30-50 years female of preHT group) hypertensive 
subjects had much lower HDL-C concentration in comparison to normotensive 
males and females as shown in Table 5.  
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LDL-C increased from 111.2 mg/dl in control group to 172.4 mg/dl in stage-
I and then decreased to stage-II with 170.4 mg/dl in 30-50 male hypertensives. 
Similar pattern was observed in 51-80 years male with 119.8, 167.1, 175.2 & 
173.7 mg/dl conc of LDL-C correspondingly. In females an increase with increase 
in DBP was observed in LDL-C concentration among both the age groups. This 
increase from normal to stage-I was enormously significant (P<0.001) in both the 
genders as well both the age groups. While the increase in females from stage-I 
to stage-II and the decrease in male within the same levels remained 
insignificant. Also an insignificant increase with age was obtained in each level of 
HT of LDL-C concentration. Moreover, female LDL-C concentration was less 
than that in male HT subjects in each level of HT but significance was proclaimed 
in only preHT level. LDL-C concentration in all three hypertensive subgroups of 
both sexes among the two age groups were considerably higher than their 
corresponding normotensive counterparts and tremendous significance 
(P<0.001) was observed with preHT level. 
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In hypertensive subjects of both genders within the two age groups, 
TC/HDL-C & LDL-C/HDL-C values were more than 4.5 & 3.0 respectively. These 
ratios increased with extreme significance (P<0.001) from normal to stage-I in 
both genders and age groups and decreased with a minor significance (P<0.05) 
from stage-I to stage-II level. Within each levels of HT an increase with age in 
males and a decrease with age in females were analyzed but slight significance 
was seen in only preHT level (P<0.05). The ratios in females were lower than 
those in male hypertensive subjects within the three subgroups of HT and this 
difference was immensely significant (P<0.01) in preHT and stage-II level.  
 
In all the three subgroups of HT, BMI was more than 25 in both the 
genders and age groups. In 30-50 years, with increase in DBP, BMI significantly 
increased (P<0.05) in both the genders while in 51-80 years BMI remained nearly 
alike in all the three subgroups of HT. The BMI values in each level of HT 
decreased with age in both genders but it was vastly significant (P<0.01) in only 
males. Also female BMI values was more than that of male hypertensive 
volunteers of corresponding groups and this difference was greatly significant 
(P<0.01) in only 51-80 age group. All values of BMI in each of the level of HT 
was considerably higher when compared to their normotensive counterparts and 
it was exceedingly significant (P<0.001) in preHT level.  
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Graph 3: Levels of Serum Lipids and Anthropometric Indices 
with regard to Levels of HT:  
 
         
0
50
100
150
200
250
300
TC 
M F M F M F M F
Control Pre HT Stage-I Stage-II
Levels of HT
30-50
51-80
0
50
100
150
200
250
TG
M F M F M F M F
Control Pre HT Stage-I Stage-II
Levels of HT
30-50
51-80
 
 
       
0
10
20
30
40
50
60
HD L- C
M F M F M F M F
Cont rol Pre HT St age-I St age- II
Le v e l s o f  HT
30-50
51-80
 
0
20
40
60
80
100
120
140
160
180
LD L- C
M F M F M F M F
Control Pre HT Stage-I Stage-II
Le v e ls of  H T
30-50
51-80
                 
 
                                   
0
1
2
3
4
5
6
7
TC/HDL-C
M F M F M F M F
Control Pre HT Stage-I Stage-II
Levels of HT
30-50
51-80
 
                              
 113
            
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
LDL-C/HDL-C 
M F M F M F M F
Control Pre HT Stage-I Stage-II
Levels of HT
30-50
51-80
 
 
           
0
5
10
15
20
25
30
35
BM I
M F M F M F M F
Cont rol Pre HT Stage-I St age- II
Le v e l s of  HT
30-50
51-80
 
 
           
0
0.2
0.4
0.6
0.8
1
1.2
WHR 
M F M F M F M F
Control Pre HT Stage-I Stage-II
Levles of HT
30-50
51-80
 
 
                              
 114
WHR remained similar to BMI with increase in level of HT. Both the gender 
of 30-50 years showed a highly significant (P<0.01) increase with level of HT 
while 51-80 year hypertensives remained nearly related through the levels of HT. 
All values of WHR were higher than their normotensive subjects in each level of 
HT in both the genders and age groups.  
 
 
 
 
4. Effect of Diet on BP, Serum Lipids and 
Anthropometric indices: 
 
 
(a) Calories: Normotensive individual and hypertensive patients were 
regrouped according to amount of calorie intake per day within the two age 
groups to see the effect of calories on BP, serum lipids and anthropometric 
indices. 
 
 
 Normotensive individuals consuming high calorie diet had significantly 
higher SBP & DBP (P<0.005)  in both genders within the two age groups 30-50 
years and 51-80 years when compared to low calorie diet consuming 
normotensive subjects. A parallel trend was observed in the hypertensive 
patients in relation to BP and the significance was found to be P<0.001. Also the 
BP values of the hypertensive patients consuming high calorie diet in the two age 
groups were much higher than those seen in normotensive subjects consuming 
low calorie diet and were tremendously significant (P<0.001). Thus the blood 
pressures in hypertensive subjects within the two age groups consuming high 
calorie diet were 152.1/96.1 & 156.1/101.7 in males and in females the values 
were 148.3/94.7 & 152.2/98.7 mmHg. While the blood pressures in normotensive 
subjects consuming low calorie diet were 116.2/93.49 & 119.0/75.3 mmHg in 
males and 115.7/70.67 & 118.0/74.48 in females respectively. 
 
 
TC & TG also showed a significant difference and positive correlation with 
the amount of calorie consumption in both genders as well as age groups in 
hypertensive and normotensive subjects. Normotensive subjects consuming high 
calorie diet within two age groups had 178.5 & 185.1 mg/dl TC and 121.9 & 
131.2 mg/dl TG concentration in males and the same in females were 174.8 & 
182.9 mg/dl TC concentration and 99.9 & 114.2 mg/dl TG concentration 
respectively. The values in hypertensive subjects consuming high calorie diet 
were 245.0 & 250.6 mg/dl TC and 207.7 & 210.3 mg/dl TG concentration in 
males and in females they were 232.4 & 241.5 mg/dl TC and 179.8 & 181.0 
mg/dl TG concentration respectively. Also both, TC & TG concentrations of the 
hypertensive patients consuming high calorie diet of both genders in the two age 
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groups were much higher than those seen in normotensive subjects consuming 
low calorie diet and enormously significant (P<0.001). 
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In normotensive subjects consuming high calorie diet, HDL-C was seen to 
increase in both sexes of 30-50 years while 51-80 years demonstrated a 
decrease when compared to subjects consuming low calorie diet. The 
hypertensive subjects on the contrary, illustrated an increase in females of both 
age groups while males did not show much change in relation to low calorie diet. 
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But in both normotensive and hypertensive subjects the rise or fall of HDL-C 
concentration with gender and age groups remained insignificant. In high calorie 
group, HDL-C concentration of hypertensive subjects in the two age groups were 
38.7 & 39.5 mg/dl in males and 42.9 & 43.2 in females while in low calorie group 
the HDL-C concentration of normotensive subjects were 40.49 & 41.5 mg/dl in 
males and 42.7 & 43.2 in females. The difference in HDL-C concentration 
between the high calorie and low calorie groups in both genders and age groups 
were not significant.   
 
 
The normotensive and hypertensive subjects consuming high calorie diet 
showed a related pattern in increase of LDL-C concentration in both genders and 
age groups when compared to their respective low calorie consuming subjects. 
But this increase in normotensive remained insignificant while hypertensive 
subjects showed a greatly significant increase (P<0.01). The values of LDL-C 
concentration of hypertensive subjects consuming high calorie diet in both the 
age groups were 164.8 & 169.0 mg% in males and 153.6 & 160.9 mg% in 
females while the control group consuming low calorie group had values like 
110.0 & 111.2 mg% in males and 108.4 & 112.7 mg% in females respectively. 
Thus the difference in LDL-C concentration between these diet groups in both 
the genders and age groups were remarkably significant (P<0.001). 
 
 
The atherogenic ratios TC/HDL-C & LDL-C/HDL-C did not show any 
significant rise in high calorie consuming subjects of normotensive and 
hypertensive group when compared to their respective low calorie consuming 
subjects in both the genders as well as age groups. While an extremely 
significant (P<0.001) difference was observed between high calorie hypertensive 
group and low calorie control group in both the genders and their age groups. In 
high calorie group the TC/HDL-C of hypertensive subjects in both age groups 
were 6.62 & 6.61 and the same in low calorie group were 4.44 & 4.50 in males 
while the same in females were 5.76 & 5.77 in high calorie group and 4.35 & 4.13 
in low calorie group correspondingly. 
 
 
The BMI of anthropometric indices exhibited an increase in normotensive 
and hypertensive subjects consuming high calorie diet when compared to their 
respective low calorie consuming subjects and the exceptionals in this case were 
females in the hypertensive group. This rise and fall of BMI values in both 
normotensive and hypertensive subjects were found to be vastly significant 
(P<0.001) in both age groups and genders. In high calorie group, BMI value of 
hypertensive subjects in the two age groups were 29.25 & 27.26 kg/m2 in males 
and 28.49 & 28.99 kg/m2 in females respectively. This difference in BMI between 
the two diet groups in both genders and age groups were enormously significant 
(P<0.001). 
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Graph 4.4: Effect of diet (fat) on BP, Serum Lipids and Anthropometric 
Indices in Hypertensive cases: 
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WHR also an anthropometric index did not increase but remained nearly 
alike in high calorie consuming normotensive and hypertensive subjects in both 
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the age groups and genders when compared to their individual low calorie 
consuming subjects. The values of WHR in hypertensive subjects consuming 
high calorie diet in the two age groups were 0.99 & 0.98 in males and 0.86 & 
0.86 in females while in low calorie consuming control group the WHR values 
remained 0.94 & 0.95 in males and 0.80 & 0.84 in females. These differences in 
WHR between the two diet groups in both genders were outstandingly significant 
(P<0.001) in 30-50 years age group while it was highly significant (P<0.01) in 51-
80 years age group.  
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An intragroup comparison of normotensive subjects and hypertensive 
patients consuming high calorie diet showed a similar trend of increase with age 
in all the parameters except HDL-C in normotensive subjects while atherogenic 
ratios and anthropometric indices in hypertensive patients in both the sexes. In 
normotensive subjects BP and TG exhibited significance while in hypertensive 
subjects, along with BP, TC also showed significance. In relation to male and 
female, the females pointed out a lower BP, serum lipids, atherogenic ratios and 
anthropometric indices excluding HDL-C and BMI in both the age groups of 
normotensive subjects as well as hypertensive patients consuming high calorie 
diet than those of males. In the hypertensive patients, all the parameters while in 
normotensive subjects only BP, TG and the anthropometric indices exhibited 
significance for the difference between male and female of the two age groups. 
 
 
(b) Fat: The normotensive and hypertensive subjects were also regrouped 
according to their amount of fat intake per day within the two age groups. In high 
fat consuming hypertensive and normotensive group the BPs exhibited an 
increase but huge significance (P<0.01) was seen in only hypertensive subjects. 
The BPs in the two age groups were 148.2/96.3 & 150.2/98.9 in males and 
143.5/94.7 & 147/96.4 mmHg in females of high fat consuming hypertensive 
group while the BPs in the low fat consuming control group were 116.3/73.33 & 
118.5/75.7 mmHg in males and 118.3/71.54 & 118.6 75.7 in females 
respectively. The difference in BPs between high fat and low fat groups were 
tremendously significant (P<0.001).  
 
 
TC & TG concentrations illustrated a significant increase in both 
hypertensive and normotensive high fat consuming group when compared to 
their relevant low fat consuming groups. In the two age groups of hypertensive 
subjects consuming high fat, TC concentration were 239.1 & 245.1 mg% in 
males and 232.8 & 240.4 mg% in females while in low fat consuming control 
group the same were 167.8 & 174.8 mg% and 167.2 & 167.2 mg% in females 
respectively. TG concentration in high fat consuming hypertensive subjects were 
196.8 & 200.9 mg% in males and 159.0 & 169.8 mg% in female while the same 
in low fat control group were 109.3 & 99.5 mg% in males and 76.8 & 70.9 mg% in 
females respectively. The differences in TC & TG concentrations in both groups 
were exceptionally significant in both the two genders and age groups (P<0.001).  
 
HDL-C concentration increased in high fat consuming hypertensive and 
normotensive subjects except in the males of hypertensive groups in both age 
groups when compared to their respective low fat consuming hypertensive and 
normotensive subjects. This rise and fall of HDL-C concentration was 
insignificant. In high fat consuming hypertensive subjects the HDL-C conc in both 
age group were 39.01 & 39.5 mg% in males and 42.7 & 44.5 mg% in females 
while HDL-C conc in low fat consuming normotensive subjects were 40.25 & 39.2 
mg% in males and 42.3 & 39.3 mg% in females respectively. This difference of 
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HDL-C conc between the two diet groups remained insignificant in both genders 
and age groups. 
 
      
   
 
 
 
 
 
              
 
 
 
 
                              
 134
Graph 4.5: Effect of diet (calorie) on BP, Serum Lipids, BMI and WHR 
in Normotensive and Hypertensive cases: 
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Graph 4.6: Effect of diet (fat) on BP, Serum Lipids, BMI and WHR in 
Normotensive and Hypertensive cases: 
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LDL-C concentration also showed an increase in both hypertensive and 
normotensive high fat consuming subjects but in hypertensive only this rise was 
highly significant (P<0.01) when comparison was done with reverence to their 
low fat consuming subjects. Also, the LDL-C concentration in high fat consuming 
hypertensive subjects was much higher than those observed in low fat 
consuming normotensive subjects and exceedingly significant (P<0.001). 
 
 
The atherogenic ratios exhibited a pattern similar to LDL-C concentration 
showing an increase in both hypertensive and normotensive high fat consuming 
subjects but no significance was seen in normotensive subjects. TC/HDL-C ratio 
in both age groups of hypertensive subjects with high fat diet were 6.41 & 6.48 in 
males and 5.76 & 5.73 in females while the low fat diet of normotensive subjects 
exhibited 4.38 & 4.63 in males and 4.01 & 4.32 in females respectively. Also the 
ratio of LDL-C/HDL-C in high fat diet of hypertensive subjects illustrated values 
likes 4.32 & 4.38 in males and 3.93 & 3.73 in females while the same in low fat 
diet of normotensive individuals were 2.83 & 3.13 in males and 2.64 & 2.95 in 
females respectively. This distinction of these atherogenic ratios in both high fat 
and low fat consuming hypertensive and normotensive volunteers were 
extremely significant (P<0.001) in the two age groups and genders.       
     
 
In the anthropometric indices, BMI demonstrated a trend like atherogenic 
ratios wherein increase in high fat consuming hypertensive as well as 
normotensive was noticed but highly significant (P<0.01) rise was seen in only 
hypertensive subjects. The value of BMI in high fat consuming hypertensive 
volunteers were 28.91 & 29.17 kg/m2 in males and 31.8 & 30.13 kg/m2 in females 
while the same in low fat consuming normotensive individuals were 24.25 & 2.75 
kg/m2 in males and 26.31 & 21.46 kg/m2 in females respectively. This diversity of 
BMI index in both diet groups was tremendously significant (P<0.001) in the age 
groups and genders. 
 
 
In case of WHR, also an anthropometric index, an insignificant decrease 
in high fat consuming normotensive subjects and an insignificant increase in 
hypertensive volunteers were observed when comparison was done with respect 
to their low fat groups. Also WHR values in high fat consuming hypertensive 
subjects were nearly alike in low fat consuming normotensive volunteers, thus no 
significance was observed. 
 
 
 An intragroup comparison of normotensive subjects and hypertensive 
patients consuming high fat diet illustrated a specific manner of increase with age 
in BP, serum lipids, atherogenic ratios and anthropometric indices in both the 
sexes except BMI in normotensive subjects while atherogenic ratios and 
anthropometric indices in hypertensive patients. A significant difference was seen 
with BP in normotensive subjects while in hypertensive patients, significance was 
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prevalent with BP, TC, HDL-C and the atherogenic ratios in the females. 
Furthermore, in male to female comparison, females demonstrated lower BP, 
serum lipids, atherogenic ratios and anthropometric indices excluding HDL-C and 
BMI in both the age groups of normotensive and hypertensive subjects 
consuming high fat diet than those of males. In the hypertensive patients, all the 
parameters excluding TC while in normotensive subjects only BP, TC, TG and 
WHR exhibited significance for the difference between male and female in the 
age groups. 
 
 
 
 
5. Effect of Tobacco Consumption on BP, Serum Lipids 
and Anthropometric indices: 
 
 
 
Smoking and tobacco habits play an important role in precipitation of HT 
and also have a more firmly established pernicious influence on cardiovascular 
mortality and morbidity. To understand the same, normotensive and hypertensive 
subjects were regrouped into two subgroups i.e. tobacco consumption and 
tobacco nonconsumption within the age groups: 30-50 years & 51-80 years. 
 
 
The tobacco consuming normotensive volunteers exhibited an increase in 
BP in both genders with regard to their age groups when compared to tobacco 
nonconsuming normotensive volunteers, while in hypertensive subjects 
consuming tobacco, an increase like normotensive volunteers was observed in 
BP in both genders in30-50 years age group while a decrease was seen in 51-80 
years age group in both genders. This rise and fall in BP values were extremely 
significant (P<0.001) in hypertensive subjects whereas normotensive volunteers 
showed significance in only 30-50 years age group in both genders. Tobacco 
consuming hypertensives demonstrated 147.4/96.1 & 144/92.1 BP values in 
males and 143.8/95.1 & 142.7/91.3 in females in both age groups while tobacco 
nonconsuming normotensive showed BP values like 115.8/74.7 & 118.6/78.0 in 
males and 112.4/72.4 & 117.1/75.6 in females correspondingly. This dissimilarity 
of BP values in both tobacco subgroups was exceedingly significant (P<0.001) in 
both genders with respect to their age groups. 
 
 
TC & TG concentration exhibited a similar trend in relation to tobacco. 
Tobacco consuming normotensive and hypertensive subjects showed a highly 
significant increase (P<0.01) of both TC & TG concentration in men and women 
of 30-50 years age group while an insignificant decrease was seen in case of 51-
80 years age group in both men and women when compared to their individual 
nonconsuming tobacco groups. TC concentration of tobacco consuming 
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hypertensive subjects in the two age groups were 248.9 & 243.1 mg% in males 
and 238.3 & 236.3 mg% in females while the same in non consuming  
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normotensive counterparts were 162.8 & 182.3 mg% in males and 159.4 & 171.1 
mg% in females respectively. The concentration exhibited by TG in tobacco 
consuming hypertensive were 206.7 & 156.2 mg% in men and 199.2 & 186.8 
mg% in women whereas the nonconsuming normotensive volunteers showed 
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values like 98.4 & 115.4 mg% in men and 93.6 & 95.1 mg% in women. These 
differences of TC & TG conc in the two subgroups of tobacco were found to be 
enormously significant (P<0.001) in both the genders and their age groups. 
 
 
HDL-C concentration illustrated an extremely significant (P<0.001) 
decrease in tobacco consuming hypertensives in male and female of both age 
groups while an insignificant increase in 30-50 years age group and a decrease 
in 51-80 years age group was observed in tobacco consuming normotensives 
when compared to their respective non consuming counterparts. HDL-C 
concentration in tobacco consuming hypertensives were 32.36 & 35.47 mg% in 
males and 36.11 & 39.9 mg% in females while the same in nonconsuming 
normotensives were 46.1 & 41.0 mg% in males and 49.2 & 48.3 mg% in females 
in the two age groups respectively. This divergence of HDL-C concentration in 
the two tobacco subgroups were outstandingly significant (P<0.001). 
 
  
LDL-C concentration of serum lipids demonstrated an increase in both 
normotensive and hypertensive tobacco consuming volunteers in either of the 
genders with relation to their age groups except in 51-80 years age group of 
normotensive subjects. But in these, only 30-50 year subjects in both 
normotensives and hypertensives displayed significance (P<0.01).  LDL-C 
concentration of tobacco consuming hypertensives in the two age groups were 
175.2 & 167.8 mg% in men and 164.9 & 165.1 mg% in women while their 
tobacco non consuming normotensive counterparts exhibited 97.0 & 118.1 mg% 
in men and 91.5 & 103.8 mg% in women respectively. This variation in LDL-C 
concentration among the two subgroups of tobacco was remarkably significant 
(P<0.001).  
 
 
The atherogenic ratios showed a pattern, alike LDL-C concentration 
wherein a highly significant increase was illustrated with tobacco consuming 
normotensives and hypertensives in both genders and their relevant age groups 
but an insignificant decrease was also observed in 51-80 years normotensives 
when compared to their respective tobacco nonconsuming counterparts. 
TC/HDL-C exhibited ratios like 8.07 & 7.1 in males and 6.87 & 6.43 in female 
tobacco consuming hypertensives whereas the same in non consuming 
normotensives were 3.79 & 4.85 in males and 3.42 & 3.73 in females 
respectively. Also LDL-C/HDL-C showed 5.75 & 4.93 in men and 4.79 & 4.60 in 
women hypertensives while non consuming normotensives illustrated 2.34 & 
3.22 in men and 2.01 & 2.30 in women correspondingly. The atherogenic ratios 
in hypertensives was considerably higher than the normotensives in the tobacco 
subgroups and was found to be exceptionally significant (P<0.001). 
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In the anthropometric indices, BMI in both normotensive and hypertensive 
tobacco consuming subjects showed an insignificant decrease in both genders 
and their age groups while WHR remained nearly alike in both tobacco 
consuming and nonconsuming groups of normotensive and hypertensive 
subjects. Both BMI & WHR values of hypertensive patients consuming tobacco 
were much higher than those observed in tobacco nonconsuming normotensives 
and were extremely significant (P<0.001).  
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Graph 5.3: Effect of tobacco consumption on BP, Serum Lipids and 
Anthropometric Indices in Normotensive and Hypertensive cases: 
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 An intragroup comparison of normotensive and hypertensive patients 
consuming tobacco displayed an analogous mode of decrease in all parameters 
except BP and HDL-C in normotensive subjects and only HDL-C in hypertensive 
patients. Significance was seen with only BP, TG, HDL-C and atherogenic ratios. 
Besides, in male and female assessment also, both the control and hypertensive 
gp illustrated similarity among them with decrease in females than those of males 
in all the parameters except HDL-C and BMI and significance being prevalent 
with TG, HDL-C, atherogenic ratios and WHR.  
 
 
 
 
6. Effect of  Heredity on BP, Serum Lipids and 
Anthropometric indices: 
  
 
Heredity has a positive correlation in the development of HT or cardiac 
events. To appreciate the same, normotensive and hypertensive individuals were 
regrouped into two subgroups explicitly, with and without family history. 
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The normotensives and hypertensives with positive family history showed 
significant rise (P<0.05) in BPs in both the age groups and their respective 
genders except the males in normotensives when compared to their concerned 
negative family history counterparts. The BPs exhibited by hypertensives with 
positive family history in the two age groups were 142.7/90.0 and 148.3/96.8 in 
males and 146.2/94.4 & 151.8/98.6 in females while the same in normotensives 
with negative family history were 127.5/83.1 & 130.5/85.9 in males and 
122.8/80.6 & 129.3/82.2 in females respectively. The divergence of BPs between 
these two groups of heredity were excessively significant (P<0.001). 
 
TC & LDL-C concentrations illustrated similar trends like an insignificant 
decrease in both normotensives and hypertensives with positive family history in 
both age groups and their genders except the females in normotensive cases. 
TC concentration in positive family history hypertensives in the two age groups 
were 224.6 & 239.3 mg% in men and 229.3 & 231.9 mg% in women while the 
same in negative family history normotensive were 180.9 & 187.9 mg% in men 
and 171.0 & 179.5 mg% in women respectively. Similarly, the concentration of 
LDL-C in hypertensives with positive family history were 148.4 & 159.6 mg% in 
males and 152.5 & 152.6 mg% in females where in normotensives with negative 
family history, the concentration were 116.5 & 125 mg% in males and 104.6 & 
107.7 mg% in females respectively. Thus the dissimilarity in TC & LDL-C concs 
between the heredity subgroups were exceedingly significant (P<0.001). 
 
TG concentration increased significantly (P<0.05) in normotensive with 
positive family history while the hypertensives exhibited nearly alike 
concentration when compared to their relevant negative family history 
counterparts. In hypertensive with positive family history the TG concentration in 
the two age groups were 192.7 & 201.2 mg% in men and 163.7 & 169.4 mg% in 
women whereas the normotensives with negative family history illustrated 108.3 
& 107.6 mg% in men and 91.4 & 114.9 mg% in women respectively. Thus the 
disparity of TG concentration in both the heredity groups were enormously 
significant (P<0.001).    
                              
 157
Graph 6.1: Effect of Heredity on BP, Serum Lipids and Anthropometric 
Indices in Normotensive cases: 
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Among the serum lipids, HDL-C concentration in normotensives with 
positive family history was nearly alike in males in both age groups while the 
females showed an insignificant decrease in 30-50 years and an increase in 51-
80 years. On the other hand, the hypertensives with positive family history 
illustrated a highly significant increase in both age groups and their genders 
except 30-50 years males wherein a significant decrease was observed. The 
concentration of HDL-C displayed in hypertensives with positive family history 
were 37.6 & 40.5 mg% in males and 44.2 & 45.4 mg% in females while the same 
in normotensives with negative family history were 42.74 & 41.4 mg% in males 
and 48.17 & 48.8 mg% in females respectively. These differences were found to 
be greatly significant (P<0.01) among the heredity subgroups.   
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Graph 6.2: Effect of Heredity on BP, Serum Lipids and Anthropometric 
Indices in Hypertensive cases: 
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The atherogenic ratios remained nearly similar in normotensives with and 
without family history whereas the hypertensives with family history 
demonstrated a vastly significant (P<0.01) decrease when compared to their 
negative family history counterparts. TC/HDL-C displayed values like 6.25 & 6.16 
in men and 5.53 & 5.38 in women of hypertensives with positive family history in 
both age groups whereas the same in normotensives with negative family history 
were 4.40 & 4.83 in men and 3.69 & 3.87 in women respectively. The same in 
LDL-C/HDL-C were 4.15 & 4.08 in males and 3.70 & 3.58 in females of 
hypertensives whereas the normotensives showed 2.85 & 3.26 in males and 2.28  
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Graph 6.3: Effect of Heredity on BP, Serum Lipids and Anthropometric 
Indices in Normotensive and Hypertensive cases: 
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& 2.37 in females correspondingly. The values of atherogenic ratios in the 
hypertensives with family history of both genders among the two age groups 
were much higher than those seen in normotensive with negative family history 
and these divergences were exceptionally significant (P<0.001). 
 
 
In the anthropometric indices both, BMI & WHR exhibited an increase in 
normotensives and hypertensives with positive family history when compared to 
their corresponding negative family history counterparts but highly significant rise 
(P<0.01) was observed in only BMI. Also, their values in both genders and their 
age groups of hypertensives with positive family history were considerably higher 
than those seen in normotensives with negative family history and were found to 
be outstandingly significant (P<0.001).  
 
 
An intragroup comparison of control and hypertensive cases with positive 
family history put forward a parallel manner of increase with age in all parameters 
except in control group of males in HDL-C. Significance was seen in only BP and 
anthropometric indices in hypertensive cases while in control group only BP 
showed significance. Moreover in male and female evaluation, normotensive 
subjects of both age groups and hypertensive patients of 30-50 age group, 
displayed  increase in BP, serum lipids and BMI and a decrease in TG, 
atherogenic ratios and WHR among the females than the males of the 
corresponding age groups. In hypertensive patients, the females in 51-80 age 
group had lower values in serum lipids, atherogenic ratios and WHR whereas 
higher BP, HDL-C and BMI were observed than those of males.  
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DISCUSSION 
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1. Effect of age on BP, Serum Lipids and 
Anthropometric indices in Normotensive subjects: 
 
 
 
Aging is the biological process common to all living organisms. It is 
a non-modifiable, but major risk factor in the anticipation of HT risk. 
Studies in humans have found that arterial wall thickening and dilatation 
are prominent structural changes that occur within large elastic arteries 
during aging. BP is determined by the interplay of peripheral vascular 
resistance and arterial stiffness. Peripheral vascular resistance raises 
both systolic and diastolic pressures to a similar degree whereas, arterial 
stiffness raises systolic but lowers diastolic pressure. 
 
 
In the present study, SBP and DBP have been found to increase 
with age in both sexes as shown in table 3 and graph 1. These findings 
were in agreement to those of Mathur, [455] Indrayan, [456] Boe [455] and 
others wherein an increasing tendency of both SBP and DBP; with 
advancement of age in both sexes were observed. Also the third 
NHANES and Framingham data have shown a rise in SBP with increase 
in age which also agrees to the results observed in this study. [21,22]  
 
 
Age related increase of BP is a common but not a universal 
phenomenon. This is predominantly influenced by environmental factors 
as certain non-migrant or tribal populations, who follow a primitive life 
style do not develop age related rise in BP. [457] But in most cases, BP 
rises with advancement of age. [458] Miall [459] opined that age, sex and 
race were the variables to which the BP was largely related. Boe [455] in 
Norway found that both SBP and DBP increased progressively with age 
in both sexes. 
 
In this study it was also found that SBP and DBP were higher in 
males than in females of the corresponding age group. There seems to 
be a positive correlation between BP and gender differences. It may be 
due to the protective effect of female sex hormones against stress. In 
agreement to this study, Shyamal Das et al also showed an influence of 
gender on BP among men. [13] The progressive urbanization, lifestyle 
modification and sedentary habits are probably some of the important 
factors considered to be responsible for increase in BP with 
advancement of age in Jamnagar. Also structural, functional and 
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biochemical changes occurring in the vascular system of human body 
due to aging process are some other factors which are again influenced 
by sex, race socioeconomic, etc. [13] 
 
Serum lipids (cholesterol, triglyceride) and lipoprotein levels (VLDL, 
LDL, HDL) do have immense importance in coronary artery disease 
patients because variation from normal levels can predict the cause of 
CAD to a great extent. [371] Thus increased level of serum lipids is 
considered to be one of the important factor for the development of 
atherosclerotic diseases. 
 
In the present study an increase in the serum lipids (TC &TG) and 
lipoproteins (VLDL, LDL) are observed with the advancement of age in 
both sexes. A similar observation was revealed by Ritu Sharma et al. 
[371] But Onitri and coworkers [460] showed that serum concentration of 
TG did not rise with age in adults but concentration of cholesterol did. 
Lipids Research Clinics (LCR) prevalence study carried out cross 
sectional age specific plasma lipid distribution in North American 
population. [461] This data also confirmed a rise in TC levels among male 
and female from teenage years to middle age. A substantial rise in TG 
levels between the late teens and middle age in males and a steady rise 
in women were also observed. B.M. Gandhi [462] also stated an increase 
in TC and TG with age in both the sexes. Reddy [463] for South Indian 
people of coastal Andhra Pradesh and Tirupati and Puri [464]  highlander 
community of Himalayan range showed an increase in TC concentration 
with advancement of age. However the rate of increase in total serum 
cholesterol was very high and highly significant in urban population. [463] 
TG showed a slight increase with increase in age, but females were 
possessing higher TG values than males. While  in this present study 
females always showed a value significantly lower to the males of the 
corresponding age groups of serum lipids (TC & TG) and lipoproteins 
(VLDL-C & LDL-C) which was in agreement with Chadha’s study [465] for 
Gujaratis, LRC data for North American population [466] and Reddy’s [463] 
findings for urbanization of Andhra Pradesh. 
 
HDL-C levels in the present study did not vary with increase in age 
in males while it increased in females. In females the elevated HDL-C 
maybe due to estrogens and thus they might have lower incidence of 
CAD before the age of 50. [160] Also a study by B.M. Gandhi [462] showed 
a marginal increase of HDL-C with age but the difference between the 
two sexes was insignificant. Abdul Rehman [466] showed an average 
serum HDL-C level of 58.4% with significant variation between age 
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groups 20 to 49 years in Kuwaiti males. Contrary to all these above 
findings, serum HDL-C was found to decrease with advancing age in 
normotensive people in Ritu Sharma et al study. [371] 
 
Factors associated with weight change during puberty due to 
differential effect by gonadal hormones, smoking and sucrose intake 
play a major role in the difference in HDL-C and TC concentration 
according to sex. [467] The sex difference in HDL-C is due to lower levels 
of HDL2-C subfractions in men. [468] Schaefer et al [469] concluded that 
higher apo A-I level normally found in women was associated with a 
greater synthetic rate of HDL-C. Thus the sex difference in lipoproteins 
may be resulted from difference in the effects of factors that influence 
lipoprotein levels between the two sexes. [469] In communities like 
Japanese, Greenland Eskimos [470] with little or no CHD had minimal sex 
difference in lipoprotein levels as compared with societies where CHD is 
a significant health problem as found in North West London. [471]  
 
Age and Sex related changes in LDL-C levels documented in this 
study closely resemble those for total plasma cholesterol. This is 
because 70% of TC is transported in this lipoprotein in the 
ultracentrifugal low density range. LDL-C in males and females increase 
with age which was in agreement with Heiss et al. [472] Also study by 
B.M.Gandhi [462] illustrated an increase of LDL-C with age in both sexes 
up to the age of 50 years. This increase in LDL-C with age has not been 
reported in older age groups. The change may be related to calorie 
intake in relation to requirements for growth and physical activity. VLDL-
C concentration demonstrated little but gradual change with age in 
males and females and resembles almost with respect to TG as VLDL-C 
was estimated with the use of Friedwald formula. 
 
Increased concentration of LDL-C in the plasma is the primary 
factor for increase in TC while a small part is due to an increase in 
VLDL-C with age which is also a form in which a little amount of 
cholesterol is transported. HDL-C hardly changes in men at this time and 
no increase in TC is related to HDL-C. In women LDL-C and VLDL-C 
increase more slowly, thus accounting for the major differences 
according to sexes [472] in plasma TC concentration. The presence of 
estrogen has a protective effect on the females from incidences of CAD 
but a shift in hormonal balance created with the deficiency of estrogen 
after 50 years, gradually increase the concentration of LDL-C in women 
and after 60 years LDL-C reaches its peak concentration. Miller [473] 
showed an inverse relationship between fractional catabolic rate (FCR) 
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of LDL-C and apo-B on one hand and age on the other. Brown and 
Goldstein [474] reported that increase in LDL-C with age is a 
consequence of a reduction in LDL-C receptors mediated catabolism 
due to decrease in numbers of LDL-C receptors with age. Angelin [475] 
also proposed that hepatic bile acid synthesis decreased with age, while 
biliary cholesterol increased which caused changes in intrahepatic 
cholesterol pool, down regulation of LDL-C receptors and a reduction in 
the LDL-C FCR. 
 
According to Simons [476] in an individual population TC and HDL-C 
estimations were enough to predict the risk for CHD. In a study by K.P. 
Misra et al [477] it  emphasizes the significance of HDL-C and more so of 
the ratios of TC/HDL-C and LDL-C/HDL-C as major lipid risk factors for 
CHD. This is understandable in view of the proposed hypothesis that 
HDL facilitates the uptake of cholesterol from peripheral tissues and 
helps in its transport to the liver for degradation and excretion. [139] 
Therefore for efficient transport of tissue cholesterol to the liver the 
proportion of HDL-C to TC and LDL-C is more important than the 
individual values of any of these. Also TC/HDL-C and LDL-C/HDL-C 
were used to compare and explain the international differences observed 
in the rate of development of CHD in various population studies. In this 
study the data confirmed the rise in these atherogenic ratios in the males 
with increase in age. 
 
Obesity predispose to many disease conditions like HT, diabetes, 
coronary and vascular disease. The percent of fat in a young individuals 
body weight is somewhere between 15 to 25% and this tends to 
increase to increase with age which may not be desirable. When the 
body fat content is greater than 25 to 30%, an individual is termed to be 
obese. Measuring the BMI and WHR in an individual is necessary to 
identify them as obese. In this study BMI decreased with age but 
showed no significance while WHR increased with age. Obesity has 
more recently been shown to decrease life expectancy by 7 years at the 
age of 40 years. [478] The increase in risk of death with each unit 
increase in BMI declines progressively with age but remains substantial 
until the age-group of 75 years and older. [479] Central adiposity is a 
predictor of CVD independently of major risk factors, including BMI. [402] 
Also dyslipidaemic individuals are more frequently “centrally obese”. [eg. 
with a high WHR] [404] 
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Thus the non-modifiable structural, metabolic and hormonal change in 
the body due to aging can be one of the factor which accounts for an 
increase in BP, dyslipidaemia and obesity. 
 
 
 
 
2. Effect of age on BP, Serum Lipids and 
Anthropometric indices in Hypertensive subjects: 
 
 
 
HT is becoming an important public health problem worldwide. It is 
the third leading killer in the world and responsible for one in every eight 
deaths. A recent report on the global burden of HT indicates that nearly 
1 billion adults ( more than a quarter of the world’s population ) had HT 
in 2000, and this is predicted to increase to 1.56 billion by 2025. [480]  HT 
is a precursor to major diseases like myocardial infarction, stroke, renal 
failure, etc. Also it has been identified as one of the leading risk factors 
for mortality and is ranked third as a cause of DALYs. [481] 
 
 
 
In this study hypertensive volunteers showed a similar pattern as 
observed for normotensive subjects in relation to age and gender. 
Hypertensive volunteers exhibited an increase in BP with age in both the 
genders and female values remained significantly lower to the males of 
the corresponding age groups. This result is in agreement with a study 
by Mohan et al wherein the prevalence of HT steadily increased with age 
in both sexes and was 3.5% in men and 3.1% in women at the age 
group of 20-29 years which increased rapidly and reached a prevalence 
of 50.8% in men and 51% in women at the age of 60years and above. 
Also in the same study it showed that compared to those below 35years, 
subjects between 35-49 years were at 3 times higher risk of HT; subjects 
between 50-64 years at >8 times higher risk while those above 65years 
were >13 times higher risk of HT. Thus an increase in prevalence of HT 
with aging has been observed in earlier studies also. [482] 
 
 
 
Several epidemiological studies have been carried out in the past in 
India and abroad to find out prevalence of HT and its relation with age. 
Age was related with HT in the urban population of Istanbul. [483] Age 
was also the key predictor of HT in Brazil [484] and Mexico. [485] Age is a 
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known risk factor for high BP. In general BP rises as people get older. 
Proof is in the numbers. Upto 80% of people over 65years old have 
measurable high BP. [486]  
 
 
 
Various studies in developing countries estimated a prevalence rate 
of HT among urban population ranging from 1.24% in 1949 to 36.4% in 
2003. [487] The difference in prevalence rates could be due to different 
cut points used in defining the level of HT and also differing age groups 
constituting the study population. The prevalence of HT in Jaipur 
representing an urban north Indian population aged 20years and above 
was 30% in men and 33% in women using JNC V criteria. [8] The 
prevalence of HT in the urban population of West Bengal representing 
eastern India as reported to be 24.9%, based on JNC VII criteria. [13] 
 
 
 
Another study showing the influence of age and sex on distribution 
of both systolic and diastolic HT among the sample population exhibited 
a higher prevalence of both systolic and diastolic HT in men below 
40years. After 40years systolic HT showed progressive age-dependent 
increase upto eighth decade in both sexes and only in women, the 
prevalence of diastolic HT remained higher upto eighth decade. [13] A 
study by Hazarika et al on HT in the native rural population of Assam 
established age as not only a factor among others associated with an 
increase in the risk of HT but also as a significant determinant of HT. [488] 
 
 
 
As seen in this study, influence of gender in HT prevalence has 
been observed among men by Shymal Kumar Das et al also. [13] A 
higher prevalence of both systolic and diastolic HT in young age among 
men, but higher prevalence of diastolic HT in women after 40years may 
be related to increasing family stress and obesity which is common in 
middle aged women. [489] 
 
 
 
The reasons why HT increases with age are still poorly understood 
but are a topic of intense research. Some known contributors include: 
[490] 
 
 
• Age related changes in hormone profiles. 
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• A tendency for older people to over salt their food because 
of decreased taste bud sensitivity. 
 
• Changes that happen in the walls of arteries and other blood 
vessels. 
 
• Decreased efficiency of the heart. 
 
 
 
 
HT is an important association of systemic atherosclerosis and is a 
strong risk factor for major cardiovascular and cerebrovascular events. 
These events are further increased in the presence of dyslipidaemia. [63] 
Both HT and dyslipidaemia coexist more often than by a chance alone. 
[66] A few studies in Western populations have established the 
relationship between hyperlipidemia and HT. [66,67] Also most studies on 
HT and dyslipidaemia in India so far have been confined to metropolitan 
cities. [491,492] Asian Indians have a high prevalence of CAD and the risk 
factors are still not clear. [493]  
 
 
In this study a strong correlation between age and serum lipids in 
hypertensive volunteers of both sexes was found. TC and TG values 
rose with the advancement of age in both sexes. In both gender LDL-C 
and VLDL-C concentrations remained parallel to that of TC and TG 
concentrations. Also HDL-C concentration increased in both sexes with 
increase in age but this rise was found to be insignificant. However in 
each age group of both genders the hypertensive patients showed an 
increase in TC, TG, LDL-C and VLD-C concentrations except HDL-C 
concentration as compared to normotensives. TC/HDL-C and LDL-
C/HDL-C values were also much above the normal upper limit (4.5 & 
3.0) in hypertensive volunteers as compared to normotensives. 
 
 
 
Various studies on lipids in Asian Indians have shown a mixed 
picture of dyslipidaemia. Studies among immigrant Indians have shown 
high TGs and low HDL-C as the common lipid abnormalities. [493] Studies 
from North West India have shown high TC, high TG and low HDL-C as 
the predominant abnormalities in normal as well as among hypertensive 
population. [494,495] Studies from Southern India have shown lipid 
abnormalities predominantly of TC, LDL-C and TG rather than low HDL-
C. [17,496] Also Zavaroni et al [497] have reported significantly raised 
systolic and diastolic pressures in subjects who have raised TGs and 
reduced HDL-C. In a retrospective study by Joglekar et al on the 
prevalence of lipid profile abnormalities in HT, it was found that 57% of 
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these subject had total cholesterol >200mg/dl. Also an elevated total to 
HDL-C >4.5 was found in 47% and 34% of subjects had serum TGs 
above 200mg/dl. [491] Thakur and Achari in their study on lipid level in 
uncomplicated HT found that with an increase in BP, the LDL-C was also 
elevated. [17] When these hypertensives were classified according to age 
the mean TC, HDL-C and TG levels were significantly different in 
hypertensives below 40 years of age as compared to controls. Within the 
hypertensive group, the mean HDL-C tended to rise and TG levels to fall 
with increasing age, when TC/HDL-C ratio were compared, a 
significantly higher proportion of hypertensives had an abnormal 
TC/HDL-C ratio (50.3% vs 44.4%) (p≤0.001); this applied to all the age 
groups and both the sexes. [17] Thomas and Mann [498] found 30% of 
patients seen in their lipid clinics to be hypertensive and many patients 
attending HT clinics had hyperlipidemia. In Bogalusa Heart Study, 
Newman [499] also found a strong and significant association between 
aortic fatty streaks and TC and LDL-C while an inverse association with 
HDL-C. SBP and DBP were also found to be related to coronary artery 
fatty streaks. Thus a positive correlation was established between 
atherosclerosis, BP and atherogenic index. Chadha et al [500] reported for 
Gujaratis settled in Delhi that 3.9% in control group with negative CAD 
were hypertensive and their lipid profile was quite high in both the 
genders.   
 
 
 
A slight tendency for HT in normal men with negative CHD was 
noticed by Albrink [501] along with higher serum lipid levels. He also 
observed an increase in lipid concentration with age and observed 
marked increase in concentration in older age group volunteers. Albrink 
found the increase in TG with age only in some persons rather than an 
obligatory change. Conway and Smith [502] in their study of aging and HT 
found lack of arterial elasticity in a group of older hypertensive people. 
He also found a negative correlation of atherosclerosis with 
chronological aging by the way of obtaining increased arterial rigidity 
index with increase in age and concluded that hardening of arteries may 
be the one cause of diastolic HT. 
 
 
 
The risk of HT is upto 5 times higher among obese people than 
among those of normal weight. [414] Upto two third of cases of HT are 
linked to excess weight [415] and cross sectional population surveys [416] 
suggest that more than 85% of HT arises in individuals with BMI values 
above 25kg/m2. The anthropometric indices in this study showed a 
negative correlation with the advancement of age but the BMI values 
were greater than 25kg/m2 in both genders of the two age groups in 
hypertensive patients. Females exhibited BMI values greater than males 
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of the corresponding age groups while an inverse was seen in case of 
WHR values. At all ages and throughout the world, women are generally 
found to have a higher mean BMI and higher rates of obesity than men 
for biological reasons. [395] Contrary to this study, the relation of HT with 
advancing of age and BMI has been documented in the past among 
Indian subjects. [4] In agreement to this finding an Indian study reported 
the occurrence of IHD even in patients with lower BMI. [503] According to 
the analysis by Brown et al; [504] the prevalence of HT as low at younger 
ages and high at older ages. At older ages, the prevalence is high even 
in normal weight individuals (BMI<25). Among men aged 60 to 79 years 
with BMI values <25, the prevalence of HT is 50%. Because the 
preponderance of cases of HT occur in the old age groups, even a 
considerable reduction in the prevalence of overweight and obesity as 
defined by BMI, might not necessarily lead to a large change in the 
population prevalence of HT. As stated earlier age, BMI and smoking 
were related with HT in the urban population of Istanbul [483] and also 
age and obesity were the key predictors of HT in Brazil [484] and Mexico. 
[485] Thus the possible explanations for the changes in BP, serum lipids 
and anthropometric indices with age in relation to hypertensive subjects 
might be same as those of normotensives as explained earlier. 
[18,160,474,475] 
 
 
 
 
 
 
 
3.   Levels of Serum Lipids and Anthropometric 
indices with regard to Levels of HT: 
 
 
 
HT is becoming an important public health problem worldwide. It is 
also an important direct cause of cardiovascular morbidity and mortality 
in general and CHD in particular. Elevated BP and hypercholesterolemia 
in a healthy person without CHD predicts an increase in future risks of 
CAD, where as in population with abnormal ECG or with symptoms of 
angina pectoris the presence of HT or high cholesterol, increase CHD 
development. 
 
 
 
According to the recommendations of JNC VII [2] an attempt had 
been made to find out a correlation between levels of HT (on basis of 
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DBP), serum lipids and anthropometric indices in comparison to 
normotensive subjects. Normal BP was defined as SBP <120mmHg and 
DBP <80mmHg. This classification includes preHT values from 80-
89mmHg; stage-I HT from 90-99 mmHg and stage-II HT ≥100mmHg.  
 
 
 
In this study the levels of HT from preHT to stage-II HT with respect 
to DBP was positively correlated with SBP in all three subgroups in both 
sexes as well as age groups. SBP in all three HT groups were 
significantly higher when compared to normotensives. DBP is the 
hallmark of essential HT and the CV sequelae of HT were derived 
entirely from diastolic component of BP. Kannel [505] specifically showed 
that SBP rises with age, while DBP tends to fall. This is true for people 
with high BP and those with no history of high BP. Goteborg multivariate 
analysis illustrated higher predictive capacity of SBP while DBP did not 
change the risk when SBP had been computed. [506] Also Anderson [507] 
pointed out that SBP, rather than DBP, was the most important indicator 
for overall CV mortality.  
 
 
 
In the Chennai Urban Rural Epidemiology Study (CURES), the 
overall prevalence of preHT, stage-I and stage-II HT were 36.01%, 
15.1% and 4.9% respectively. In addition, the prevalence of these levels 
of HT increased with increasing age. National health and nutritional 
survey of US obtained from 1976 to 1980, showed that, in adults (18-74 
years of age) about 7% had preHT, 15% had stage-I, about 2% had 
stage-II HT, about 8% had borderline systolic and 2% had ISH. [508] 
These data indicated that about 60% million Americans had abnormal 
levels of BP. Framingham Study [509] demonstrated that the risk of all 
major CV complications increased progressively with levels of DBP over 
82mmHg and of SBP over 130mmHg. The CURES study showed large 
proportion of sample population in the prehypertensive group. Even at 
the youngest age group studied (20-29years), the proportion of subjects 
with preHT was 33%, which was very high. In recognizing ‘preHT’ as 
clinical condition, JNC VII pointed out that BP related mortality is linear 
and that higher BP levels within what was earlier called ‘high normal’ or 
‘normal’ range is associated with increasing morbidity and mortality. The 
Trial of Preventing Hypertension (TROPHY) study [510] on individuals 
with high normal BP suggests clearly the risk of CVD begins to rise 
before the diagnosis of HT is evident.   
 
 
 
In the Framingham Heart study Castelli [511] found powerful 
interaction between HT and hypercholesterolemia. A few studies in 
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Western populations have established the relationship between 
hyperlipidaemia and HT. [66,67] Most studies in HT and hyperlipidaemia in 
India so far have been confined to metropolitan cities. [491,492]  A study 
from Assam showed the prevalence of lipid abnormalities among the 
hypertensive to be 54%. [512] 
 
 
 
In this study TC concentration showed significant rise with increase 
in DBP in both sexes as well as age groups. Moreover, in all three 
hypertensive groups as DBP increased from preHT to stage-II HT, 
cholesterol also elevated significantly. Males and females in this study 
also had increased LDL-C, TG and atherogenic ratios in comparison to 
normotensives. In addition, HDL-C decreased with each levels of HT and 
was lower to the normotensive values thus suggesting increased rise of 
CHD in hypertensive patients.  LDL-C increased with levels of HT just 
like TC as 70% of TC are transported in the plasma as LDL-C. 
 
 
 
Willum et al [513] had also shown that more than 25% of persons, 
60years or younger, in whom HT developed and who also had a sibling 
with early onset of HT, will have a major lipid abnormality as well. Study 
by Kotokey et al [512] reported TC, TG and LDL-C cholesterol values to 
be significantly higher, whereas HDL-C value was lower among the 
hypertensive than the normotensives. The findings of this study were 
similar to those of Shankar Shiv et al on essential HT. [514] These 
findings suggest the coexistence of HT and hyperlipidaemia in a 
hypertensive population. The atherogenic ratios in hypertensive 
volunteers was not only significantly higher than that in normotensives of 
sexes but also significantly increased with the increase in DBP from 
preHT to stage-II HT. These ratios can be the best predictors to the risk 
of CHD in hypertensive subjects as higher the values greater is the risk 
and thus it is advisable to keep the ratio below 4.5 and 3.0. 
 
 
 
Obesity being one of the risk factors for HT was correlated with 
levels of HT. The anthropometric indices, BMI and WHR exhibited 
similar pattern in relation to levels of HT. Both demonstrated an increase 
with increase in DBP among individuals with less than 50years in both 
gender while above 50years no change in these indices were illustrated. 
Compared to the normotensive the values of these indices were 
significantly high in each levels of HT. A study by Hazarika et al [488] is in 
agreement with this finding where in HT was associated with increased 
values of BMI and WHR. 
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Thus from this study the coexistence of HT, hyperlipidaemia and 
obesity can be well established. Moreover, the occurrence of coronary 
events is exaggerated with the presence of BMI and central obesity 
along with HT and dyslipidemia. 
 
 
 
 
 
4. Effect of Diet on BP, Serum Lipids and 
Anthropometric indices: 
 
 
 
Many risk factors for CVD, including high blood cholesterol, HT, 
obesity and diabetes are substantially influenced by dietary factors. 
Several population studies [167,168] correlated severity of atherosclerosis, 
serum cholesterol level and dietary fats. The Seven Countries study by 
Keys et al in the 1960s showed a relation between saturated fat intake, 
fasting blood cholesterol concentration and CHD mortality in various 
populations, [175] which suggests the protective effect of traditional 
Mediterranean-type diets. The diet in the high-risk group usually is high 
in animal foodstuffs, total calories, saturated fat cholesterol and refined 
carbohydrate. This does not imply that diet is the sole cause of HT and 
CHD. Nevertheless, diet must be considered as a major factor in the 
widespread occurrence of these clinical diseases since the disease 
occurs only rarely in the absence of diets habitually high in total calories, 
total and saturated fats, cholesterol and refined sugar.  
 
  
 
 
Calorie: In this part of the study, the effects of high calorie consumption 
on the parameters were positively correlated. The BPs, SBP and DBP 
exhibited an increase in relation to age groups and genders in the 
hypertensive subjects consuming high calorie when compared to the 
hypertensive low calorie consuming subjects. A similar significant 
increase was prevalent among the serum lipids TC, TG and LDL-C 
concentration. HDL-C illustrated an increase in females of both age 
groups while males did not show much change in relation to low calorie 
diet consuming hypertensive patients. The atherogenic ratios also 
demonstrated an increase with high calorie consuming hypertensive 
subjects but this rise was not significant. The anthropometric indices, 
BMI increased in males but not females; in hypertensive, high calorie  
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consuming subjects while WHR remained nearly alike when comparison 
was done with low calorie consuming hypertensive subjects. However, in 
relation to normotensive individuals consuming low calorie diet all 
parameters demonstrated a tremendously significant increase except 
HDL-C concentration when compared to hypertensive patients 
consuming high calorie diet.   
 
  
 
Several short-term laboratory studies have demonstrated that very 
low carbohydrate diets can have substantial effects on metabolism 
including weight loss and ketonemia. [515] Seven Countries study [296] 
and International atherosclerotic project [164] demonstrated a positive 
relationship between the saturation of dietary fat, serum cholesterol 
levels and CHD. In relation to BP, SBP did not change significantly in 
either low-carbohydrate diet (Atkins Diet) or high carbohydrate diet 
(conventional diet) during a study [213] but DBP decreased in both 
groups. Regarding lipids, HDL-C increased and TG concentration 
decreased in the group on low-carbohydrate diet. [213] The mechanism 
responsible for the decreased energy intake induced by a low 
carbohydrate diet with unrestricted protein and fat intake is not known, 
but may be related to the monotony of simplicity of the diet, alterations in 
plasma or central satiety factors, or other factors that affect appetite and 
dietary adherence. [213] Excessive caloric intake from sources like fats, 
carbohydrates, proteins or alcohol promotes hyperlipidaemia. A 
carbohydrate rich diet increases serum lipids in persons having higher 
baseline serum lipid levels than in those with low or normal serum lipids. 
[213]  
 
 
 
 Several epidemiological studies have reported reduced BP linked to 
Mediterranean dietary pattern (α linolenic acid rich diet ). [209,210] The 
DASH trial has shown that a dietary pattern rich in fruit vegetables and 
low fat dairy products and with reduced total and saturated fat can be 
effective in the prevention of HT. [52,219] Also fruit and vegetable intake 
may reduce CVD risk through the beneficial combination of 
micronutrients, AOs, phytochemicals and fiber in these food. Several 
prospective studies have directly related fruit and vegetable intake with 
CVD. [516] Findings from ecologic studies show that populations with 
lower intake of animal products and higher intakes of fruit and 
vegetables have lower prevalence of CVD than do populations with 
higher intakes of animal products. [517] Also in a recent study the co-
administration of garlic pearls with fish oil was found to be more effective 
than placebo in the management of dyslipidemia. [240] Walker et al [518] 
demonstrated in two men that an excess of calories over a short period 
of time caused striking increases in serum cholesterol and lipoprotein 
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levels even though the diet was low in fat. Anderson et al [519] found that 
a daily excess of 600 calorie cause a significant elevation in the total 
serum cholesterol of 20mg/100ml. 
 
 
 
 Obesity is common in patients who have essential HT although 
there is no direct relationship. For this reason, the total calorie intake 
should be restricted in such patients. Thus the low-carbohyrate, high 
protein, high-fat Atkins diet produces greater weight loss (an absolute 
difference of approximately 4%) than a conventional high-carbohyrate, 
low fat diet. Christakis et al [520] reported the effect of a cholesterol 
lowering diet on hypercholesterolemia in obese and normal weight 
subjects in experimental and control groups. In the experimental group 
42% of the normal weight subjects were hypercholesterolemic. In the 
control group, 44% of the normal weight men were 
hypercholesterolemic. After 4years of observation, the proportion of 
hypercholesterolemic men in the experimental group was significantly 
lower than that in the control group, thus suggesting that the dietary 
protocol of the study was effective in lowering serum cholesterol levels 
without regard to initial or final weight status or change in weight status. 
 
 
 
  
Fat: The intake of total fat exerts a strong influence on the BP and 
serum lipid levels. In this study it was evident that in hypertensive 
volunteers fat played a significant and positive role. Subjects taking high 
fat diet showed increased BP,  serum lipid levels, atherogenic ratios and 
anthropometric indices. In normotensive subjects, all these parameters 
demonstrated a decreased value with low fat diet when compared to 
their high fat consuming hypertensive subjects. 
 
 
 
Populations with diets high in total fat usually have high SBP, DBP 
and serum cholesterol levels. Dodson and Paul [521] separately were able 
to get the findings that a combination of dietary interventions with a low 
sodium, low fat and high fibre diet caused a greater fall in both SBP and 
DBP ( 11.6 and 7.6mmHg ) than any of those interventions alone in 
treated hypertensive patients. In hypertensive North Karelian volunteers, 
Pekka and James [522] were able to reduce BP from 138.9/88.9 to 
129.5/81.3 mmHg on low fat (23% energy) diet.   
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 Food consumption patterns in a particular study [523] showed that 
important difference in relation to CAD were higher intake of total visible 
fat, milk and milk products, meat, eggs, sugar and jaggery in urban 
compared to rural subjects. Prevalence of CAD in relation to visible fat 
intake showed a higher prevalence rate with higher visible fat intake in 
both sexes and the trend was significant for total prevalence rates both 
for rural and urban men and women. Another study [524] reported that 
urban subjects had three times better socioeconomic status than rural 
subjects and were thus eating higher total and saturated fat, cholesterol 
and refined carbohydrates and lower total and complex carbohydrates 
compared to rural men and women. Also energy expenditure during 
routine and spare time physical activity was significantly higher in rural 
compared to urban subjects. Those patients who had risk factors, 
showed lesser physical activity and had greater adverse factors in the 
diet compared to subjects without risk factors. Thus, this finding 
suggested that decreased consumption of total and SF and increased 
physical activity may be useful for prevention of HT and CAD among 
urban as well as immigrants. [524] 
 
 
 
 The dietary intake of cholesterol in human adults varies between 
200 and 800 mg/day and is highest in those with a high intake of SF. 
The body synthesizes approximately 2000mg daily from various sources. 
Wilson [525] noted that 60 to 80% of serum cholesterol was derived from 
endogenous source when a diet high in cholesterol is fed. Taylor et al 
[526] reported that subjects of cholesterol free and cholesterol rich diets 
showed essentially the same rates of daily endogenous cholesterol 
synthesis. Thus restriction of exogenous cholesterol has; been 
recommended as helpful in reducing serum cholesterol. In relation to 
TGs, elevations of serum TGs have been reported with diets low in total 
fat and high in carbohydrates. This hypertriglyceridemia is transient, 
however as shown by Antonis and Bersohm, in a carefully controlled 
study on South African white Bantu prisoners. [527]  They showed that a 
diet low in total fat (15%) and high in carbohydrate (70% of total 
calories), when followed for a period of 39 weeks caused a lowering of 
all serum lipids, including cholesterol and TGs in both groups (European 
and Bantu) to the usual low levels found in Bantu natives. [527] 
 
 
 
 Also it has become apparent that changes in serum lipids and 
cholesterol are dependent on the degree of saturation or unsaturation of 
the fats, rather than on their source. [528] The highly SFs such as butter, 
coconut oil and cocoa butter produce high levels of serum cholesterol, 
while iso-caloric amounts of highly unsaturated oils such a safflower oil, 
corn and cotton seed oil, produce lower levels of cholesterol. Contrary to 
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the above statement, in 1957, Ahrens et al [192] reported that cocoa 
butter does not raise the plasma cholesterol level in humans as much as 
butter fat since cocoa butter is rich in stearic acid. Thus results 
suggested that this fatty acid is not “hypercholesterolemic” in humans. 
Also a study by Bronte-Steward et al [529] exhibited that the essential 
unsaturated fatty acids, linoleic acid, linolenic acid and arachidonic acid, 
which are present in most oils but not butter, exert a lowering effect in 
the serum cholesterol. Further  they went on to show that when these 
polyunsaturated fatty acids were hydrogenated their favorable effect on 
serum cholesterol was lost and they acted to elevate it just as did certain 
highly SFs such as butter and coconut oil. [529] Some metabolic studies 
suggest that fatty acids containing at least one double bond in the 
transconfiguration, which are found in hydrogenated fat, have a 
detrimental effect on serum lipoprotein cholesterol levels as compared 
with unsaturated fatty acids containing double bonds only in the cis 
configuration. Also considerable attention has been focused on the 
effects of trans FAs on HDL-C levels after initial reports suggested not 
only a LDL-C raising effect but also an HDL-C lowering effect. [262] 
Similarly FAs have been reported to increase serum Lp(a) levels in 
some, but not all, studies. [530,531] 
 
 
 
 
 In relation to anthropometric indices, an analysis of potential 
anthropometric predictors of the risk factor response to diet showed 
significant correlations between the indices of adiposity and changes in 
LDL-C  concentration, but not with change in HDL-C or TG 
concentration. [264] In this above study the men with a BMI ≥25.3 had 
30% smaller reductions in LDL-C concentration than did the men with a 
BMI <25.3. This effect of BMI on the LDL-C response is consistent with 
data from dietary intervention and epidemiologic studies. Katan and 
Beynen [532] first reported that TC response to increases in dietary 
cholesterol was negatively correlated with BMI in women but not in men. 
In studies conducted in premenopausal women, Cole et al [533]  found 
that women with a BMI between 24.8 and 30 had smaller reductions in 
LDL-C concentration than did women with BMI <24 when switched from 
a typical American diet to one lower in total fat, SF and cholesterol. 
Additionally TGs increased the most in women with a BMI >30. 
Additional studies conducted in both men and women and with diets of 
varying FA composition have shown a positive correlation between BMI 
and LDL-C in response to reduction in dietary SF. [210,221-224] Thus these 
data suggest that  weight reduction may be required to fully derive the 
benefit of dietary changes on CVD risk.    
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5. Effect of tobacco consumption on BP, Serum 
Lipids and Anthropometric indices: 
 
 
 
   Smoking is a major risk factor for CVD. Cigarette smoking 
contributes to heart disease through induction of a hypercoagulable 
state, reduced oxygen delivery, coronary vasoconstriction and nicotine-
induced hemodynamic effects. The epidemiological studies have 
mounted ample evidences of a strong positive association between 
cigarette smoking and the risk of CVD morbidity and mortality in men 
and women under 65years. [296,534,535] MRFIT, MRC and prospective 
cardiovascular studies found 35%, 34% and 20% hypertensive 
volunteers having smoking habits in USA, UK and North Europe 
respectively. [536] More than 1.1 million individuals are affected by MI 
each year in North America and >20% of these individuals are habitual 
smokers. [288] Cigarette smoking is associated with an increased risk of 
sudden death, angina, MI, peripheral vascular disease and stroke. 
[289,290] 
 
 
 
  The effect of tobacco consumption on BP and serum lipids was 
seen in hypertensive subjects. The risk of smoking is dependent on the 
presence of HT and concomitant hyperlipidaemia. The landmark 
Framingham study have not only established smoking as cardiovascular 
risk factor, but also revealed a synergetic effect with the risk factors, 
such as HT, hypercholesterolemia, glucose intolerance and DM. [537] 
 
 
 
  Hypertensive tobacco consumers in this study showed a age 
dependent variation in BP. An increase in BP in both genders in 30-50 
years age group but yet both these values in the two age groups were 
considerably higher to normotensive cases. This finding was in 
agreement with the epidemiological finding of Israel population [538] in 
which nonsmokers had lower BP. Also other epidemiological studies had 
shown a sudden rise in BP of 10/8mmHg or 11/9mmHg in hypertensive 
volunteers after smoking two cigarettes and this happened as a result of 
increase in nicotine content which caused rise in epinephrine and 
norepinephrine concentrations in blood. [539] Also the nicotine mediated 
hemodynamic effects of smoking include an increase in heart rate and 
BP, which increases myocardial risk. [301] Also in another study by 
Sharma et al pan masala intake causing acute increase in PP and BP 
was reported. [540]  
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  In seven countries study Keys [296] could not find an association 
between smoking and CHD in population with low plasma cholesterol 
levels and low risk of CHD. On the contrary, a study by Pais et al reports 
smoking 10 cigarettes or beedies/day carries an independent four-fold 
increased risk of AMI. [541] Khurana et al showed that though different 
mode of addictions, smoking and tobacco chewing have an equal and 
comparable effects on lipid profile and therefore raising cardiovascular 
risk in same proportion. [542] Cigarette smoking is associated with 
reduced HDL-C, [128] lecithin cholesterylacyl transferase (LCAT)activity 
[306] and cholesteryl ester transfer protein (CETP) activity. [307] In chain 
smokers there was increased risk of CHD with high levels of TC, TG, 
LDL-C and low levels of HDL-C and also decreased capacity of liver and 
kidney functions. In this study TC and TG concentration of tobacco 
consumers in hypertensive volunteers showed a increase in 30-50 years 
age group while a decrease in 51-80 years age group when compared to 
hypertensive tobacco nonconsuming counterparts. This study showed a 
consistent positive association between tobacco consumption and LDL-
C values, while an inverse relation between tobacco consumption and 
HDL-C. The atherogenic ratios were also positively associated with 
tobacco consumption. Thus variations at hypertensive level of tobacco 
consumers might occur but when compared to their normotensive 
counterparts a significantly positive correlation was exhibited between 
serum lipids, atherogenic ratios and tobacco consumption. 
 
 
 
  The Framingham Offspring Study showed that smoking was 
significantly associated with lower HDL-C levels of 4mg/dl in men and 
6mg/dl in women. [293] Also there is a linear dose dependent effect 
between the number of cigarettes smoked per year and HDL-C level. 
Nesje [543] showed that in Northern Norway HDL-C levels were more 
pronounced between heavy smokers (≥20 cigarettes) and nonsmokers 
particularly for HDL2-C levels. Cigarette smoking habit interfering with 
LCAT activity causes decrease in esterification of free cholesterol and 
results in the rise of free cholesterol in the plasma and this in turn is 
related to decreased levels of HDL-C concentration [544] Thus tobacco 
consumption increase atherogenic lipids in blood and decrease the 
protective effect of HDL-C by decreasing HDL2-C fraction. Nicotine in 
the cigarette smoke increases oxygen demand and causes arterial 
constriction, which impairs blood flow to the heart. [301] Also smoking 
further accelerates endothelial atherosclerosis through damage to the 
endothelium and increased fibrinogen levels. [303,330] In these ways 
tobacco consumption impairs the lipid metabolism and promotes the 
development of CHD and atherosclerosis. Thus there is a synergistic 
interaction of tobacco smoking with HT and high blood cholesterol which 
greatly increase CHD risk as well as sudden death and stroke. [545]  
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Among the anthropometric indices, BMI showed a decrease in 
hypertensive tobacco consumer while WHR did not vary much when 
compared to hypertensive tobacco nonconsumers. But yet these indices 
were significantly higher compared to their normotensive counterparts. In 
agreement to this finding a study shows that the factor for pathogenesis 
of obesity is addiction to smoking among others. [546] Also an inverse 
relationship between cigarette smoking and weight is well documented 
[547] which again is in agreement to part of this study. 
 
 
 
Thus in hypertensive tobacco consumers, HT itself being a risk 
factor for CHD, the possibility is enhanced by additive effect of 
hyperlipidaemia, smoking and obesity. 
  
 
 
 
6. Effect of heredity on BP, Serum Lipids and 
Anthropometric indices: 
 
 
 
There are several challenges in the prevention and management of 
atherosclerotic heart disease. The principal challenge is to identify 
susceptible individuals before they develop the disease. Knowledge of 
genetic risk factors will help define the mechanisms of the disease and 
could ultimately assist in the rational design of selective prophylaxis or 
therapy. Many single genes have been identified as the basis for 
different CVDs. Family history as an isolated event for genetic 
implications of recurrence of disease is more suggestive when the illness 
occurs early. 
 
 
 
In 2004, the Journal of American Medical Association published a 
study entitled, “Parental CVD as a Risk Factor for CVD in Middle-aged 
Adults.” The study found that a parental history of CVD is an 
independent predictor of cardiovascular events in middle aged men and 
women. After adjustment for other risk factors, premature CVD in atleast 
1 parent was associated with a significant doubling (100% increase) in 
cardiovascular risk for men and a 70% increase in risk for women over 
8years. Some workers have observed positive family history as an 
independent predictive factor for CHD in men aged less than 50years. 
[335] In a study by Trivedi et al CHD was significantly associated with 
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increased BP, family history and smoking.[548] Also in an 
epidemiological study to find the influence of risk factors on the 
prevalence of CHD in a total rural community of Punjab, it was found that 
of the various risk factors tested, HT, hypercholesterolemia and a 
positive family history showed an association with CHD. [549]   
 
 
 
In this part of the study an effort was made to study the effect of 
heredity and its relation to BP, serum lipids and anthropometric indices 
in hypertensive volunteers. There was a significant increase in BP in the 
hypertensives with positive family history in both genders along with their 
corresponding age groups. HT is a serious disease that can result in 
heart attack, strokes or kidney failure and scientists have known for 
some time that HT is a heritable condition that runs in families. Elizabeth 
et al [550] showed significantly higher BP and TC in men less than 
60years of age with positive history of heart attack and thus was found to 
be independent of all other risk factors studied. She also showed a five 
fold excess risk of cardiovascular death in younger men with positive 
family history of heart attack. Heller [551] also found on an average the 
first degree relatives of hypertensive patients to have higher BP than 
those relatives of normotensive controls. Some studies have suggested 
that high blood pressure may be associated with the presence of E4 
allele, when studies aimed to find out the association of apo E genotypes 
with HT were carried out. [351,552] The genetic variations at apo E have 
also been shown to affect lipid and lipoprotein levels in the general 
population. [553] 
 
 
 
With regard to lipids in this study, TC and LDL-C concentrations 
showed an insignificant decrease in hypertensive with positive family 
history while TG concentration did not vary in both age groups and their 
genders when compared to hypertensives with negative family history. 
But yet, when compared to the normotensive negative family history all 
serum lipids demonstrated tremendous significant increase among the 
hypertensives with positive family history except HDL-C concentration. 
One of the best understood inborn error of metabolism determining 
elevated levels of plasma cholesterol and LDL-C is the autosomal 
dominant disorder of familial hypercholesterolemia (FH). Studies indicate 
that 5-10% of individuals with premature MI may have FH. [114] A study 
on FH indicated that there exist mutational heterogeneity if the LDL 
receptor gene among the Indians, wherein, none of the mutation were 
reported to be common among Indian immigrants. [554] In recent times 
new markers like the apo E gene polymorphism stated earlier have been 
found associated with CHD and are being extensively studied. [347] A 
small study from the Southern parts of rural India on tribal communities 
                              
 190
suggested that the low frequency of the apo E4 allele was a contributing 
factor for the low prevalence of CHD in this community. [363] A significant 
relation was found between cholesterol levels and the family history of 
CAD. Persons with high family history scores were found to have 
cholesterol values of 213mg% while those with intermediate or low 
scores had average cholesterol values of 192 and 189mg% respectively. 
[555] Mowar et al [556] also studied coronary risk factors in family 
members, close or distant relatives of patients having MI. He observed 
highly significant TC and TG concentrations in brothers and sisters of the 
patients having MI in comparison to those without having MI or positive 
history of CHD. 
 
 
 
A genetic predisposition to CAD is suggested by high levels of 
lipoprotein in Asian Indians. [557] Pometta et al [558]  found lower HDL-C 
and did not find any significant differences in TC or LDL-C in young 
males with family history of AMI in comparison with control group. Kukita 
[558] also found significantly lower apo A and higher apo B in first 
degree relative of CHD patients. Backer [558] observed (LDL-C+VLDL-
C)/apo B and HDL-C/apoA-1 values to be very high in offspring group in 
comparison to the control group. These ratios of serum lipids and apo 
proteins reflected internal composition of LDL-C and HDL-C. HDL-C 
concentration also was less and TC/HDL-C ratio was high in those with 
positive family history which suggested that the protective role of HDL-C 
against atherosclerosis was very much reduced. Widhalm et al [559] 
showed that the progeny of families with manifestation of CHD could be 
distinguished from children with negative family history with the help of 
HDL-C, TC/HDL-C and LDL-C/HDL-C, where as apoA-1/apo B was the 
strongest discriminator. 
 
 
 
Lp(a) level is an important determinant if CHD among patients with 
FH and non FH. [560] Higher Lp(a) levels were reported in individuals as a 
strong family history of CHD than in those without such history. [561] A 
study by Rajashekhar et al found higher Lp(a) levels in patients with 
hypercholesterolemia than normocholesterolemia but not significant. [563] 
The pathogenecity of Lp(a) is increased with high LDL-C and vice-versa. 
[562] In 1958, research conducted in Singapore first established that 
Indians have thicker blood and more of Lp(a) than the Chinese. The 
significance was not well understood, till 1990 when a subsequent 
10year study conducted by Enas confirmed that one of four Indian-
American had high levels of Lp(a) as compared to the Japanese, 
Chinese, Caucasians and Hispanics. Recently, a study in Singapore 
which took blood from the natal chord of 5000 babies of Indian origin, 
found extraordinarily high contents of Lp(a) present, indicating that 
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genetics, not lifestyle or diet, was the major cause of such abnormal 
levels of  Lp(a). Thus Lp(a) levels correlate with both early and advanced 
atherosclerosis, severity, extent and progression of atherosclerosis and 
all complication of CHD. [564] 
 
 
 
The causes of obesity are many, but there is little doubt that genetic 
factors play an important role in its etiology. Humans carry probably 
dozens of genes that are directly related to body size. In this study the 
anthropometric indices, BMI and WHR showed a positive correlation with 
hypertensive positive family history patients. Statistical analyses suggest 
that 50% or more of the variation between individuals in BMI has a 
genetic basis [565] but these effects are dominated by polygenic 
environmental interactions that reflect many genetic influences affecting 
spontaneous physical activity, twitchiness, BMR, propensity to 
synthesize diurnally lean rather than fat tissues and appetitive behavior. 
The increasing epidemic of obesity in the world has stimulated interest in 
identifying or predicting individuals who are at greatest health risk at an 
early age. [378] This is particularly important to allow early implementation 
of preventive strategies. 
 
 
 
The role of apoE polymorphism in causing atherosclerotic events 
have been reported. [345,346] ApoE is an exchangeable protein which acts 
as an ligand for LDL receptors. It plays an essential role in lipid 
metabolism specially in the removal of atherogenic remnants of TG-rich 
lipoproteins [347] and by reversing cholesterol transport in plasma and 
intercellular lipid transport within tissues. These common isoforms of apo 
E including E2, E3, E4 [348] have been identified. It is well known that the 
E4 isoform is associated with increased levels of TC and β-lipoprotein 
[349] and increased susceptibility to CVD. [350] Some studies have 
suggested that high BP may be associated with the presence of the E4 
allele [351,352] while others have found its association with E2 allele [353]. 
Mechanisms of apoE such as increased rigidity and decreased elasticity 
of the aorta and other large vessels [354] may contribute to the 
development of HBP and thus explain the lack of association in the 
elderly subject. Thus significant association of E4 allele is observed with 
HT in addition to other well known risk factors and positive family history. 
These observations emphasize the need to monitor HT and lipid 
metabolism especially in middle aged males and those with a positive 
family history to reduce the susceptibility to CAD. 
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However genes alone don’t explain the spurt in HT and heart 
diseases among the young. The answer, in a word, is lifestyle. While 
over 10% of urban Indians succumb to HT and heart diseases, the figure 
is only 3-5% in rural areas. Thus lifestyle changes due to rapid 
urbanization are the precipitating cause of these diseases in India. The 
solution to these, sky-rocketing figures are – Simply tweaking our 
lifestyles a little.  
 
 
 
 
 
 
 
 
 
 
 
                              
 193
 
 
 
 
 
 
 
SUMMARY 
AND 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              
 194
          Summary and Conclusion: 
 
 
HT occupies the no.1 position as a major public health problem in 
most industrialized countries of the world. Existing data suggests that the 
prevalence of HT has remained stable or has decreased in economically 
developed countries during the past decade, while it has increased in 
developing countries. [4] (ht32) However, the increase in the prevalence 
rates of HT needs to be quantified to plan for effective prevention 
strategies, which are urgently needed in developing countries. Given the 
rising prevalence of HT in developing countries undergoing 
epidemiological transition like India, increased awareness treatment and 
control of high BP are critical to the reduction of CVD risk and prevention 
of the associated burden of illness. This study was undertaken with the 
objective to gather the effect of diet, tobacco and heredity on lipid 
metabolism and HT.  
 
 
 
In normotensive and hypertensive subjects a positive correlation 
with BP and serum lipids were observed while HDL-C showed a 
negative correlation with the advancement of age in both sexes. Thus, 
age was an important atherogenic factor, which indicated that with 
increase in age, the older individuals are more susceptible to the 
development of HT and CVDs. 
 
 
 
In relation to gender, males had values higher to females in all the 
parameters but still both are prone to develop HT and atherosclerotic 
disease as the values were above normal in both the genders. Thus 
gender specific increase of development of HT in both men and women 
indicate significant role of environmental factors. This suggests public 
health remedial measures to address growing HT in the community. 
Thus health education about lifestyle changes, dietary modification and 
avoidance of urban stress are required to be taught. 
 
 
 
In hypertensives with respect to age in both genders, the levels of 
HT from preHT to stage-II illustrated an increase in serum lipids and 
anthropometric indices. As lipid levels increased and HDL-C decreased 
with increase in DBP, the risk of development of CAD increased from 
preHT to stage-II HT (severe HT). Thus, the levels of HT show an 
increase in levels of serum lipids and anthropometric indices, which may 
be major contributors to increased risk of CAD in patients of HT. Patients 
                              
 195
with preHT, are at increased risk for progression to HT as they usually 
remain unnoticed with their asymptomatic behavior and thus become 
easy targets to develop severe HT. Therefore subjects with preHT 
should be monitored regularly and life style altered to curb them from 
progressing to stage-I or stage-II level of HT. 
 
 
 
Diet plays a positive and significant role in hypertensive patients. 
The increased consumption of both calorie and fat exhibited an 
increased BP, serum lipids and anthropometric indices when comparison 
to their low consuming calorie and fat in normotensive counterparts were 
conducted. Thus, the patient who has essential HT should eat as much 
as is necessary to maintain strength and nutrition but should avoid 
excesses. This restriction of the quantity and quality of the diet should be 
extended to total calories, total volume of fluids protein and salt. Special 
modification of the diet for the patient with hypertensive vascular disease 
may be indicated because of coincidental or associated disturbances in 
lipid and carbohydrate metabolism. Moderation as a watchword should 
apply to the diet as well as to all other aspects of treatment. 
 
 
 
This study showed a consistent positive association between 
tobacco consumption, BP, serum lipids and anthropometric indices, 
while an inverse relation was established between HDL-C and tobacco 
consumption among hypertensive individuals. Several smoking related 
mechanism are responsible for the development of atherosclerosis and 
the induction of cardiac events. Benefits from quitting are seen in former 
smokers even after many years of heavy smoking. Investigations also 
have demonstrated benefits from cessation for smokers who have 
already developed smoking related diseases or symptoms. Persons with 
diagnosed CHD experience as much as 50% reduction in risk of 
reinfarction, sudden cardiac death and total mortality if they quit smoking 
after the initial infarction. Thus, there is overwhelming evidence 
demonstrating both the cardiovascular hazards of smoking and the 
prompt benefit that occurs with smoking cessation. Therefore, tobacco 
consumption is the single most alterable risk factor contributing to 
premature morbidity and mortality that can be reversed by quitting 
consumption of tobacco. 
 
 
 
Heredity also among the above parameters demonstrated a 
positive relation with BP, serum lipids and anthropometric indices except 
HDL-C in the hypertensive subjects. Nothing can be done about ones’ 
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family history, but if a strong family history of CHD or HT is present one 
must: 
 
 
• Change lifestyle 
• Lose weight  
• Stop smoking 
• Lower cholesterol levels 
• Eat more fiber, more vegetables and fruits 
 
 
 
Furthermore, the principal challenge is to identify susceptible 
individuals before they develop the disease. Advance in the field of 
genomics and proteomics will help in preventing and treating this 
multifactorial disease. 
 
 
 
However, several potential limitations should be considered while 
interpreting the results of this study. First, the dietary data were obtained 
from a structured questionnaire and therefore underestimation or 
overestimation of calorie and fat intake cannot be ruled out. In addition, 
the correlation of socio-economic status with HT was not analyzed, as 
participants did not want to reveal their actual income status. Lastly, the 
lipid parameters analyzed are not enough to come to a particular 
conclusion due to limitations in the infrastructure. Thus, further studies on 
apolipoproteins and other risk factors are required to be conducted to find 
out the effect of these observations stated in this study.  
 
 
 
 The results of the present study show, there is a long way to go to 
accomplish the goal of optimal control among the Saurashtrian population. 
Undoubtedly, a similar situation exists in other parts of the country as well. 
It took 30 to 40years of sustained effort to substantially improve HT, 
detection and control in western countries and the rates are still far from 
optimal. HT itself being a risk factor for CAD, further deteriorates the 
patients with presence of all atherogenic parameters. Thus, screening of 
the population for detecting HT at the earliest and timely intervention could 
curb the sequel events to a certain extent. Therefore hypertensive patient 
can more appropriated be targeted for, therapy for risk factor clusters 
rather than HT alone. Thus, it is obvious that considerable effort is needed 
to prevent or reduce the increasingly large burden of disease related to 
increasing rates of HT in countries in epidemiological transition, such as 
India. 
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